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ABSTRACT 
NOVEL MONOCLONAL ANTIBODIES TARGETING 
CONFORMATIONAL ERBB2 EPITOPES 
1.4ABSTRACT 
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Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
October 2012, 233 pages 
 
ERBB2 is a tyrosine kinase receptor which can act as homodimers or 
heterodimers with other members of the ERBB family. Nearly 30% of breast cancers 
overexpress ERBB2, which can be effectively targeted by anti-ERBB2 monoclonal 
antibodies. Trastuzumab directed against an epitope on subdomain IV of the 
extracellular domain (ECD) of ERBB2 is a clinically used therapeutics but the 
response rate is poor and acquired resistance is frequent. Pertuzumab that binds to 
subdomain II and inhibits receptor dimerization is another promising therapeutics 
under clinical trials. Anti-ERBB2 antibodies directed to novel epitopes are 
potentially useful tools for replacement and combinatorial therapies. We produced 
five new anti-ERBB2 antibodies, all directed against epitope(s) present only on the 
native ECD.  They performed selective growth inhibitory effects depending on the 
level of ERBB2 expression and cellular background. When used alone, novel anti-
ERBB2 antibodies displayed modest but significant growth inhibition on SK-BR-3, 
BT-474 and MDA-MB-361 cells with ERBB2 overexpression; while no detectable 
inhibition was observed on MCF-7 and T47D cells lacking ERBB2 amplification. 
When the antibodies were tested in combination with TNF-α, they acted 
synergistically on SK-BR-3 cells, producing upto 80% growth inhibition; but 
performed antagonistically on BT-474 cells. Detailed investigation of a 
representative antibody indicated G1-arrest as the main mechanism of the anti-
proliferative effects exerted on SK-BR-3 cells. Antibody treatment induced 
permanent inhibition of DNA synthesis, leading to accumulation of cells at G1-
phase; an effect which was accelerated in the presence of TNF-α. In addition, treated 
SK-BR-3 cells displayed inhibition of Akt and ERK1/2 phosphorylation leading to 
cyclin D1 accumulation and growth arrest, independently from TNF-α. Novel 
antibodies against conformational epitopes present on the extracellular domain of 
ERBB2 receptor may serve as new analytical and diagnostic tools, in addition to 
being potent anti-cancer bioactive molecules. Cell-dependent synergy and 
antagonism between anti-ERBB2 antibodies and TNF-α provide evidence for a 
complex interplay between ERBB2 and TNF-α signaling pathways. Such complexity 
may drastically affect the outcome of ERBB2-directed therapeutic interventions. 
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ÖZET 
KONFORMASYONAL ERBB2 EPİTOPLARINI HEDEF ALAN 
ÖZGÜN MONOKLONAL ANTİKORLAR 
1.5 ÖZET 
Ceyhan Ceran 
Moleküler Biyoloji ve Genetik Doktora Tezi 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ekim 2012, 233 sayfa 
 
Bir tirozin kinaz almacı olan ERBB2, gerek homodimer yapıda, gerekse ERBB 
ailesinin diğer üyeleriyle heterodimer oluşturarak etki gösterir. Meme kanserlerinin 
% 30’unu oluşturan ve ERBB2 almaç ifadesi yüksek olan vakalar, hedefe yönelik 
tedavi kapsamında anti-ERBB2 antikorlarıyla başarılı bir şekilde tedavi 
edilebilmektedir. ERBB2’nin hücredışı bölgesindeki IV. alt-bölgeye karşı 
geliştirilmiş Trastuzumab klinikte kullanılan bir terapötik olmasına karşın, elde 
edilen başarılı yanıt oranı zayıftır ve hastalarda sıklıkla tedaviye karşı bağışıklık 
gelişir. II. alt-bölgeye bağlanarak almaç dimerizasyonunu engelleyen Pertuzumab, 
klinik çalışmaları yürütülmekte olan diğer bir ümit verici terapötiktir. Yeni epitoplara 
karşı geliştirilen anti-ERBB2 antikorları, replasman ve kombine tedavilerde 
kullanılabilecek etkin araçlardır. ERBB2 almaçının yalnızca doğal haldeki hücredışı 
bölgesine bağlanan beş adet özgün anti-ERBB2 antikoru ürettik. Bunlar, hücredeki 
ERBB2 ifade düzeyine ve hücrenin yapısal özelliklerine bağlı olmak üzere değişik 
oranda çoğalmayı baskılayıcı özellik gösterdiler. Tek başlarına kullanıldıklarında, 
SK-BR-3, BT-474 ve MDA-MB-361 gibi ERBB2 ifadesi yüksek hücrelerin 
çoğalmasını mütevazi ancak anlamlı ölçüde baskılarken, MCF-7 ve T47D gibi 
normal ifade düzeyine sahip hücrelerde belirgin etki göstermediler. Antikorlar TNF-
α ile birlikte kullanıldıklarında, SK-BR-3 hücrelerinde sinerjik bir etki göstererek 
hücre çoğalmasını % 80’e varan oranlarda baskılarken, BT-474 hücrelerinde 
antagonistic etki gösterdiler. Antikorlardan seçilen bir tanesiyle yapılan detaylı 
inceleme, SK-BR-3 hücrelerinde görülen çoğalma baskılayıcı etkinin ana 
mekanizmasının hücre döngüsünün G1-evresinde durma ile ilintili olduğunu ortaya 
koymuştur. TNF-α ile birlikte kullanıldığında artan antikor etkisi, DNA sentezini 
kalıcı olarak engelleyerek hücrelerin G1-evresinde birikmesini sağlamıştır. Buna ek 
olarak, antikor tedavisine tâbi tutulan SK-BR-3 hücrelerinde TNF-α’dan bağımsız 
olarak Akt ve Erk1/2 proteinlerinin fosforlanmasındaki azalmayı takiben Cyclin D1 
birikmesi gözlenmiş ve hücre çoğalması engellenmiştir. ERBB2 almacının hücredışı 
bölgesindeki üç boyutlu yapıya bağlı oluşan epitoplara karşı geliştirilen özgün 
antikorlar, anti-kanser özellik taşıyan biyoaktif ajan olma potansiyellerinin yanı sıra, 
yeni analitik ve tanısal araçlar olarak da kullanılabilir. Anti-ERBB2 antikorları ve 
TNF-α arasında hücre yapısına bağlı olarak görülen sinerji ve antagonism, ERBB2 
ve TNF-α arasında karmaşık bir etkileşim olduğunu göstermektedir. Böyle karmaşık 
etkileşimlerin, ERBB2 hedefli tedavilere gösterilen yanıtı ciddi ölçüde etkilemesi 
mümkündür. 
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1 INTRODUCTION 
 
1.1 Breast Cancer 
With a lifetime risk of ~12%, breast cancer is the most common cancer in 
women worldwide [1], ranking second overall. Although the survival rates were 
increased due to the recent developments in breast cancer therapy, it is still the most 
frequent cause of cancer-related death in women worldwide (with 458,000 estimated 
deaths in 2008), and fifth overall [2]. More than 225,000 new cases of female-breast 
cancer are estimated to occur in 2012, in the United States alone, and 40,000 female 
deaths are expected as a result [3]. 
Breast cancers can be divided into two main subtypes according to their 
estrogen dependency. Estrogen-dependent breast cancers can further be divided into 
Luminal A and Luminal B types. Luminal A type represents 58% of all breast cancer 
cases [4]. Luminal B type which accounts for 16% of all breast cancer cases, 
overexpresses ERBB2 in addition to the common hormone receptors, shows greater 
proliferative potential and lower frequency of relapse-free survival [5]. Estrogen-
independent breast cancers which account for ~26-30% of all breast cancer cases, are 
more aggressive than estrogen-dependent cases, tend to have poorly differentiated 
phenotypes, higher recurrence rate and decreased overall survival and can be further 
divided into basal-like and ERBB2-positive subtypes [5]. Of all breast cancer cases, 
~16% are basal-like mostly with a triple-negative phenotype, where the expression of 
Estrogen Receptor (ER), Progesterone Receptor (PR) and ERBB2 is either low or 
absent. The rest, which comprise ~6% of all breast cancer cases have an estrogen-
independent, ERBB2-positive phenotype [4]. Therefore ~25-30% of all breast cancer 
cases are associated with ERBB2 overexpression. [6, 7] 
 
1.2 ERBB2 
 
ERBB2 (also known as HER2) is a Receptor Tyrosine Kinase (RTK) identified 
in the early 1980s which is shown to be amplified in breast cancer cells [8]. The gene 
contains 27 exons spanning 38 kilobases and is located on chromosome 17q21 [9]. 
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The 4.8 kb mRNA product is translated into a polypeptide of 1255 amino acids [10] 
and through extensive glycosylation, the precursor protein of 170 kDa is further 
processed and matured into 185 kDa glycoprotein [11]. In addition to the 185 kDa 
holoreceptor, breast cancer cell lines were documented to express two ERBB2 
peptides of lower molecular mass [12]. The presence of the 68 kDa and 95 kDa 
peptides were very significant in the ERBB2-overexpressing cell line SK-BR-3 [12]. 
Being the human ortholog of the rat Neu protooncogene [10, 13], ERBB2 
belongs to the ERBB transmembrane receptor family together with EGFR (HER1 or 
ERBB1), ERBB3 (HER3) and ERBB4 (HER4) [14]. Each family member contains 
four extracellular subdomains at their N-terminal, a transmembrane domain and an 
intracellular domain containing tyrosine residues that are used for signal transduction 
(Figure 1.1 A). In addition, except for ERRB3, all ERRB receptors have intracellular 
tyrosine kinase domains and intrinsic kinase activity. Extracellular subdomain I and 
III were documented to take role in the establishment of receptor conformations that 
allow dimerization through subdomain II [15] (Figure 1.1 B). In the absence of the 
ligand, the receptor is found on a closed-conformation, where subdomain II makes an 
intramolecular contact with subdomain IV and is not available for dimerization [16, 
17]. Upon ligand binding by subdomains I and III, conformation of the receptor is 
changed exposing the dimerization domain [18, 19] and allowing dimerization of two 
receptors present in this open-conformation (Figure 1.1 B). ERBB2 is unique in the 
family in two ways; first it has no identified ligands upto date [20]. Second, the 
structure of its extracellular region is radically different from other family members; 
resembling the ligand-activated state of other ERRB receptors, it provides the 
receptor with a fixed open-conformation [17, 18], negating the requirement of 
ligand-induced activation. Due to its constitutive open-conformation, ERBB2 is 
permanently available for heterodimerization with other ligand-activated ERRB-
family receptors and is frequently documented as their preferred partner [14] (Figure 
1.1 B). Since their dimerization arm is permanently exposed, ERBB2 receptors 
readily homodimerize and activate each-other when they are overexpressed. This is a 
key mechanism in cell proliferation observed both in ERBB2 overexpressing cells in 
vitro [21] and ERBB2-positive breast cancers [6, 22]. Recently, an autoinhibition 
mechanism was revealed, where the αC helix and β4 sheet in its kinase domain form 
a loop inactivating ERBB2 kinase. Since many kinase domain mutations observed on 
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human cancers were localized on this loop, the loss of this autoinhibition was 
suggested to cause oncogenic ERBB2 activation [23]. 
Upon dimerization, ERRB receptors cross-phosphorylate one another on 
multiple intracellular tyrosine residues and provide docking sites for adaptor proteins 
(Figure 1.1 C). In adition, via phosphorylating the adaptor proteins, they create 
additional docking sites available for the down-stream signalling transduction 
pathway and alter the activity of intracellular signalling proteins by phosphorylating 
them (Figure 1.2). Main auto- and trans-phosphorylation residues present on the 
intracellular region of ERRB receptors, and the adaptor molecules that interact with 
these docking sites are summarized on Figure 1.1 C [14]. Being the main 
autophosphorylation sites on ERBB2; Tyr-1221/1222 and Tyr-1248 interact with Shc 
through Src homology 2 (SH2) domain and participate in Ras-Raf-MAPK signal 
transduction pathway [24–26]. In addition, phosphorylated Tyr-1196 and Tyr-1248 
interact with Shc through a phosphotyrosine binding (PTB) domain [24]. Also 
associated with ERBB2 overexpression, phosphorylation of Tyr-1139 induces GRB2 
and GRB7 interaction through SH2 domain contributing to a subset of breast tumors 
[27]. Phosphorylation of Tyr-877 is performed by Src family kinases and was 
initially suggested to influence the intrinsic kinase activity of ERBB2 [28], however, 
Tyr-877Phe substitution of ERRB2 did not alter its biological and/or biochemical 
properties [25], refuting its role in ERBB2 activation [23]. Tyr-1028 on rat 
NEU corresponding to Tyr-1023 on human ERBB2, was shown to be a negative 
regulator of NEU-mediated transformation [29]. Upon EGF stimulation, EGFR 
heterodimerizes with ERBB2; PI3K interacts with phosphorylated Tyr-1196 on 
ERBB2 [30] and Ser-1113 is phosphorylated by CaMK II which serves as an 
indicator of poor prognosis [31]. In addition, neuregulin mediated heterodimerization 
of ERBB2 and ERBB3 induces phosphorylation of Thr-686 on ERBB2 by PKA; and 
in turn stimulates the crosstalk between PKA and cAMP leading to activation of 
PI3K-Akt and MEK-Erk pathways [32]. c-Cbl ubiquitin ligase is recruited to the 
phosphorylated Tyr-1112 on ERBB2 and induces poly-ubiquitination and proteolytic 
degradation of ERBB2 [33]. 
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Figure 1.1 ERRB family of tyrosine kinase receptors. A) ERRB family of tyrosine 
kinase receptors are shown in their ligand-free conformation; while ERRB1, ERRB3 and 
ERRB4 are found in closed-conformation without a bound ligand, ERBB2 is constitutively 
present in the open-conformation. Each receptor contains four extracellular subdomains, a 
transmembrane domain and an intracellular C-terminal tail. All except ERRB3 also have an 
intracellular tyrosine kinase domain. Identified ligands of the receptors are listed above each 
receptor. B) Proposed mechanism of receptor dimerization is illustrated. Upon ligand 
binding (dark blue arrow), a conformational change occurring at the extracellular 
subdomains of EGFR exposes the previously buried subdomain II. ERBB2 and ligand-
activated EGFR interact through their exposed subdomain II, and heterodimerize. C) Main 
auto- and trans-phosphorylation sites on the intracellular C-terminal tail of each ERRB 
receptor and the adaptor molecules interacting with the respective phosphorylated tyrosine 
residues are shown. 
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Figure 1.2 ERBB2 signaling. Upon homodimerization, tyrosine residues (in addition to 
few threonine and serine residues) on the cytosolic tail of ERBB2 are phosphorylated 
activating the downstream effectors mainly on PI3K-Akt, Ras-Raf-MAPK and JAK/STAT 
pathways. As a result, proliferative signals are received, pro-apoptotic signals are blocked 
and cell cycle arrest is inhibited leading to to cell survival and proliferation. Effectors shown 
in dark blue are the molecular forms induced upon ERBB2-dimerization and participate in 
proliferation. Effectors shown in pale purple are the molecular forms which participate in 
cell cycle arrest and apoptosis that are decreased upon ERBB2-dimerization. /: 
molecular transitions/signal transductions in action. : inhibited signal transductions. : 
phosphorylated residues. TK: Tyrosine kinase domain. TF: Transcription factor. 
 
 
Upon dimerization, receptors transphosphorylate each other and recruit 
downstream effectors such as PI3K, Src, Grb2 [29, 34–36]. When Src is recruited to 
intracellular phospho-tyrosine residues on activated ERBB2, it phosphorylates PTEN 
downregulating its activity. Therefore PTEN can no longer antagonise PI3K 
pathway. Activated ERBB2 further recruits and activates PI3K, facilitating Akt 
activation through PI3K-mediated phosphorylation. Activated Akt further 
phosphorylates pro-apoptotic proteins Bad, Bim and MDM2, leading to cell-survival 
[37]. It also phosphorylates p27 leading its ubiquitinilation and degradation. Since 
p27 is no longer active to block CDK2, CDK2 interacts with CyclinE, leading to cell 
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proliferation [38, 39] (Figure 1.2). As an additional mechanism for silencing tumor 
suppression, ERBB2 was shown to interfere with TGFβ-induced cytostasis and 
oncogene-induced senescence by deregulating C/EBPβ isoform translation [40]. Cell 
culture conditions were reported to induce a switch between the two main signalling 
pathways downstream of ERBB2; PI3K and MAPK pathways [41]. 
It was shown that ERBB2-overexpression in NIH3T3 cells leads to malignant 
cellular transformation and tumorigenesis [21, 42]. Numerous reports have 
demonstrated that ERBB2 amplification and receptor overexpression was observed 
in several human cancers including breast [6, 22], ovarian [43], endometrial [44], 
gastric [45], lung [46], esophageal [47], oropharyngeal [48], bladder [49]. Relation 
between ERBB2 status and breast pathology is described by Ross et. al. and shown 
on Table 1.1 [50].  
 
 
 
Table 1.1 Relationship between ERBB2 status and breast pathology. Reprinted 
with permission from "Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, 
Hortobagyi GN: The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-
2 Therapy and Personalized Medicine. The Oncologist 2009, 14:320–68." [50]. Copyright  
AlphaMed Press 2009. 
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A Val664Glu point mutation found on the transmembrane domain of rat 
ERBB2/NEU (corresponding to Val659Glu in humans) was shown to be sufficient 
to transform cells [51, 52], where the glutamic acid variant was suggested to stabilize 
dimerization leading to conversion of pro-oncogenic NEU to an oncogenic protein 
[53]. Through examination of transgenic mice overexpressing ERBB2/NEU, single 
point missense mutations and in-frame deletions were detected at the juxtamembrane 
domain; and the cysteine-rich juxtamembrane region was suggested to have an 
important role in regulation of NEU catalytic activity [54, 55]. While the human 
equivalent Val659Glu has been shown to constitutively activate ERBB2 in vitro 
[56], up to date it has never been observed in human breast cancers [57]. Through the 
computational analysis of the transmembrane regions of the ERBB2-homodimer, it 
was shown that Val664Glu mutation stabilizes the active conformation of the 
dimeric RTK, whereas Ile-655Val destabilizes the active conformation [58].  
ERBB2 polymorphisms/mutations found on human tumors are summarized on 
Figure 1.3. The common Ile655Val polymorphism that is suggested as a risk 
factor for breast cancer development is studied by various groups. While some 
groups reported increased risk of predisposition with Val-allele [59–63], many others 
observed no-association [64–68] or even decreased risk [69].  
Screening kinase domain of ERBB2 in metastatic breast cancer patients, Gori 
et. al. have detected one insertion in exon 20 (ins780 (C)) and a missense mutation in 
exon 21 (Ser856Pro) [70]. Through the investigation of breast, gastric and 
colorectal tumors, missense mutations in exon 18 (Lys724Asn, Thr733Ile), exon 
19 (Leu755Ser, Asp769His) and exon 20 (Val777Leu, Val777Met, 
Glu799Pro), exon 21 (Val842Ile, Leu869Glu), exon 22 (Arg896Cys) and 
one in-frame deletion on exon 19 (Leu755-Thr759del) was detected on ERBB2-
kinase domain [71]. Another study analysing exon 18-24 of ERBB2 on non-small 
cell lung cancers (NSCLC) identified four main types of insertion at exon 20 
(ins776(TyrValMetAla), ins781(GlySerPro), Gly-776Val + ins777(C), Gly-
776Leu + ins777(C)) [72].  
Screening ERBB2 in various tumour types, Stephens et. al. detected further 
somatic mutations and in frame insertions in NSCLC, glioblastoma, gastic and 
ovarian tumours. These ERBB2 mutations which were located on exon 19 
(Leu755Pro), exon 20 (ins774(AlaTyrValMet), Gly776Ser, ins779(ValGlySer)), 
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exon 21 (Asn857Ser) and exon 23 (Glu914Lys) of the kinase domain were not 
associated with ERBB2 overexpression in these tumours [73]. Kinetic analysis 
demonstrated that, the catalytic activity of ERBB2 dramatically increases when 
Gly776 and Gly778 are mutated [23]. 
 Point mutations at the transmembrane domain of ERBB2 was detected in 
malignant central nervous system (CNS) tumors [74]. As a rare event, His559Ala 
point-mutation located on the Trastuzumab-binding site was detected on the 
juxtamembrane domain of ERBB2 in invasive human breast cancers overexpressing 
ERBB2 [75].  
In a recent study, Zito el. al. resequenced every individual amplicon in human 
breast cells with ERBB2 amplification; the high-resolution analysis of the total 
ERRB2 coding sequence on five cell lines and two breast tumors did not reveal any 
activating mutations on ERBB2 [76]. This suggests that, receptor overexpression and 
ERBB2 activating mutations may have mutually exclusive roles in breast cancer 
development.  
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ERBB2 amplification and overexpression is tested either at gene level by 
fluorescence in-situ hybridization (FISH) or at protein level by 
immunohistochemistry (IHC) respectively. While IHC is easier to perform, faster 
and less expensive; lack of standardization in fixation and paraffin-embedding 
protocols, sensitivity of the antigen epitope, and the subjectivity in measurement of 
staining intensity may cause variation, leading to false-positive and false-negative 
results. On the contrary, FISH is a standardized procedure providing quantitative 
more reliable and reproducible results but more expensive, complex and slower than 
IHC. IHC based HercepTest (DakoCytomation Denmark A/S, Glostrup, Denmark), 
and FISH based PathVysion (Vysis Inc., Downers Grove, IL) kits are approved by 
FDA for the verification of HER2 status of breast tumors. Although there is strong 
correlation (upto 90%) between IHC and FISH results for strong positive cases (IHC 
+3), tumors with IHC scores of +2 are recommended to be confirmed by FISH 
analysis [45, 48, 77, 78].  
While normal breast cells express ~20,000 ERBB2 receptors on their 
membrane (IHC score: 0), the protein expression in tumor cells was documented to 
reach as high as 2,000,000 ERBB2 molecules per cell (IHC score: +3) [79]. ERBB2 
levels which were selectively much higher in cancer cells than the normal tissues 
were shown to strongly correlate with breast cancer prognosis and pathogenesis [22]. 
ERBB2 gene amplification is observed in 20–25% of invasive breast cancers and is 
highly correlated with protein expression [6, 22, 78, 80]. ERBB2 overexpression 
which was detected both in primary lesions and metastatic sites was found to be 
relatively homogeneous among ERBB2 overexpressing tumor cells [81]. In addition 
to above, being a cell surface receptor, ERBB2 was an ideal candidate target for 
monoclonal antibody (MAb) based breast cancer therapy [82] 
 
1.3 Anti-ERBB2 Antibody Based Targeted Therapy of ERBB2 
Overexpressing Breast Cancers 
ERBB2 amplification alone was shown to cause cell transformation [21] and 
was linked to TNF-α/macrophage resistance in vitro which was reversed upon 
treatment by monoclonal antibodies (MAbs) targeting extracellular domain (ECD) of 
ERBB2 [83, 84]. In addition, 25% of all breast cancers have ERBB2 overexpression 
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which was linked with a more aggressive type of breast cancer [6, 22], therefore 
ERBB2 was acknowledged as a significant therapeutic target in breast cancer 
treatment. A large panel of MAbs targeting ERBB2-ECD was developed [85] and 
shown to inhibit monolayer proliferation and revert anchorage independent 
phenotype [86]. In vivo data also supported the findings that indicate anti-ERBB2 
antibody therapy as a treatment regime for ERBB2-overexpressing tumors. 
Radiolabeled antibodies against ERBB2-ECD were localised to ERBB2-
overexpressing mammary tumors in NEU-transgenic mice; suggesting a potential for 
a successful therapeutics [87]. 
More than 100 monoclonal antibodies were developed against extracellular 
region of human ERBB2 by various groups [88]. Among this wide panel of anti-
ERBB2 antibodies, mouse monoclonal 4D5 was shown to have anti-tumor effects 
both in vitro and in vivo [84, 89–91]. 
In order to overcome the human anti-mouse antibody response that limits the 
therapeutic efficiency of murine monoclonal 4D5 (MuMAb4D5), the heavy and light 
chain variable regions (VH and VL) of the antibody are humanized by gene 
conversion mutagenesis. In addition, 5 aminoacids on framework region 3 (FR3) 
were changed by site-directed mutagenesis to increase the affinity and the therapeutic 
efficiency of the humanized antibody named as Trastuzumab (Herceptin
®
) [92]. 
Trastuzumab is the first FDA approved humanized MAb therapeutics targeting 
ERBB2. Having received first FDA approval in 1998, Trastuzumab is now used both 
for metastatic and for early-breast cancer treatment mostly in adjuvant settings [93]. 
When Trastuzumab was used as a single agent therapy for ERBB2-overexpressing, 
metastatic breast cancer (MBC), ~66-88% of the patients showed primary resistance 
[94–96]. While combined therapy was better than Trastuzumab monotherapy for 
MBCs, the majority of patients developed resistance within one year even if they had 
an initial response [82]. In addition, although Trastuzumab led to promising results in 
the treatment of ERBB2-overexpressing early-stage breast cancers, ~15% of the 
patients still developed metastasis [97], demonstrating the clinical limitations caused 
by the development of Trastuzumab-resistance in the long run. 
Recently another monoclonal antibody (2C4) developed at the same time with 
4D5 is being investigated as an alternative therapeutics for the treatment of ERBB2-
overexpressing breast tumors. 2C4 which initially displayed growth inhibitory 
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activity weaker than 4D5 was later found promising due to its inhibitory effects on 
ERBB2 dimerization. The therapeutic activity of Pertuzumab, the humanized form of 
2C4 is being tested in clinical trials [98].  
Although numerous additional anti-ERBB2 antibodies were developed up to 
date, Trastuzumab and Pertuzumab are the two main antibodies extensively studied 
so far.  
Through crystal structure analysis, Trastuzumab was found to interact with 
ERBB2 through three regions (557–561, 570–573, 593–603) on the ERBB2 
extracellular domain IV, located juxtamembrane of the receptor [17]. The 
dimerization inhibitory antibody Pertuzumab binds to the dimerization domain on 
ECD-II [99].  
 
1.3.1 Mechanism of Action of anti-ERBB2 Antibody Treatment 
Being the first monoclonal antibody developed for selective targeting of 
ERBB2 overexpressing tumors, Trastuzumab provided most of the information 
gathered on the mechanism of anti-ERBB2 treatment. As summarized on Figure 1.4, 
anti-ERBB2 treatment acts mainly by inhibiting growth inducing signals transduced 
through MAPK and PI3K pathways. Antibody treatment stimulates tumor cell 
elimination by further activating antibody dependent cellular cytotoxicity (ADCC) 
mechanism and apoptotic pathway. In addition, it was suggested that antibody 
interaction with ERBB2 receptor may decrease receptor shedding, influence 
endocytic receptor downregulation and enhance the chemotherapeutic response. 
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Figure 1.4 Mechanism of Action of anti-ERBB2 treatment. Molecular responses of 
ERBB2 overexpressing cells following anti-ERBB2 antibody treatment are shown. PI3K and 
MAPK pathways are downregulated. Effectors shown in dark purple are the molecular forms 
induced upon Trastuzumab treatment which participate in anti-proliferative pathways.  
Effectors shown in pale blue are the molecular forms which participate in proliferation and 
survival pathways and are decreased upon ERBB2-dimerization. /: molecular 
transitions/signal transductions in action. /: inhibited molecular transitions/signal 
transductions. : upregulation, activation or stabilization. : downregulation, inactivation or 
degradation. : inhibition. ?: conflicting results : phosphorylated residues. TK: Tyrosine 
kinase domain. 
 
 
1.3.1.1 Increased Autophosphorylation, Internalization, Degradation and 
Down-regulation of ERBB2 
Contradictory observations are documented regarding the effect of anti-ERBB2 
treatment on ERBB2 phosphorylation. While some groups showed decrease of 
ERBB2 phosphorylation [100], others demonstrated induction of tyrosine 
phosphorylation of the receptor upon antibody treatment [33, 101, 102]. 
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Phosphorylation of Tyr-1112 of ERBB2 induces recruitment of c-Cbl to the receptor 
[33]. Binding of anti-ERBB2 antibodies were shown to stimulate ubiquitinylation of 
the receptor by activating E3 ubiquitin ligase c-Cbl, leading to ERBB2 degradation 
[103]. While receptor internalization and degradation upon anti-ERBB2 treatment 
(mostly by Trastuzumab) is demonstrated by several groups as a means to explain the 
inhibition of ERBB2 kinase activity and downstream pathways [84, 101, 102, 104–
106], others failed to show a decrease in ERBB2 levels [107–110]. 
 
1.3.1.2 Growth Inhibition Modulated Through PI3K and MAPK 
Pathways 
ERBB2 overexpressing cells induce Src which phosphorylates and deactivates 
PTEN. Following Trastuzumab treatment of ERBB2-overexpressing cells, Src is 
dissociated from ERBB2; PTEN which is left active upon Src-inhibition is 
translocated to the plasma membrane [111], where it dephosphorylates and 
deactivates Akt [108]. Since phosphorylation of the internal tyrosine residues on 
ERBB2 is reduced by anti-ERBB2 treatment [100], anti-ERBB2 treatment blocked 
PI3K-docking necessary to activate the kinase. Through inhibition of PI3K, the 
membrane localization of PTEN is increased and phosphorylation level of Akt is 
decreased leading to increased GSK3β stability, decreased Cyclin D1 expression and 
G1-arrest [111–114]. Inducing the association between p27 and CDK2, anti-ERBB2 
treatment decreases CDK2/Cyclin E mediated cell cycle progression. The decrease in 
CDK2/Cylin E mediated phosphorylation and degradation of p27 further stabilizes 
p27 and leads to a negative feedback resulting in G1-arrest [39, 115, 116]. Cyclin G2 
which belongs to the G-cyclins that are upregulated during cell cycle arrest and 
apoptosis is also induced by Trastuzumab [117]. Decreasing the phophorylated 
MAPK levels, the treatment also inhibited the MAPK pathway [113, 118].  
 
 
1.3.1.3 Inhibition of ERBB2 Shedding 
Truncated ERBB2 receptors lacking extracellular N-terminal region were 
detected in human breast tumors. Through cleavage by matrix metalloproteases, the 
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wild type 185kDa ERBB2 was reported to be cleaved into two fragments; 110 kDa 
ERBB2-ECD circulates in the blood [119, 120], while the 95 kDa C-terminal 
fragment (CTF) is left attached to the cell membrane being constitutively activated 
[56, 121–124]. Elevated levels of p110 circulating in the serum was shown to be 
associated with poor prognosis in advanced breast cancer patients [125–128]. CTFs 
are also detected in a subset of breast cancer patients that developed nodal 
metastasis, leading to worse prognosis and poor clinical outcome [129, 130].  
Trastuzumab decreased ERBB2 shedding by inhibiting ADAM 
metalloproteinase activity; an effect which is not shared by Pertuzumab [119, 120]. 
Trastuzumab not only decreased serum ERBB2-ECD levels, but also the intact 
ERBB2 levels; suggesting the presence of another mechanism in addition to 
sheddase inhibition [131]. At least ~20% reduction in serum ERBB2 (p110) levels 
has been proposed as a marker of better prognosis upon Trastuzumab therapy 
(patients with elevated pre-treatment ECD levels had higher response rates to 
Trastuzumab) [132–134]. 
 
1.3.1.4 ADCC 
Antibody dependent cellular cytotoxicity (ADCC) is one of the mechanisms of 
tumor elimination induced by antibody binding and conducted by natural killer (NK) 
cells, macrophages and monocytes expressing Fc receptors that recognize IgG 
molecules bound to target cells. Anti-ERBB2 antibodies were shown to elicit 
apoptosis in breast cancer cell lines through ADCC [86, 92] and significant lymphoid 
infiltration was observed in Trastuzumab treated patients [107]. Kute et. al. 
demonstrated that ERBB2 overexpressing breast cancer cells that developed 
resistance to anti-proliferative effects of anti-ERBB2 treatment in vitro were still 
sensitive to ADCC response and were successfully eliminated by the effector-
mediated cytotoxicity; emphasizing the importance of ADCC mechanism on anti-
ERBB2 dependent tumor elimination [135].  
FcRIII receptor activates effector-mediated target cell lysis whilst FcRIIB 
performs as an ADCC inhibitory receptor. While mice engineered to express only the 
activating FcRIII receptors were capable of a successful cytotoxic response, those 
lacking the activating receptors were insufficient to arrest tumor growth in vivo. In 
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addition, anti-ERBB2 antibodies lacking the Fc region (Fab molecules) were unable 
to trigger significant anti-tumorigenic response; indicating ADCC as one of the main 
mechanism of anti-ERBB2 treatment in vivo [136, 137].  
Antibody molecules were modified to enhance the ADCC response; non-
fucosylated oligosaccharide chains on Fc region dramatically enhanced apoptosis 
both in vitro and in vivo [138, 139]. In addition, Fc regions engineered for higher 
FcR affinity enhanced the in vitro effector functions and cytotoxicity [140].  
Bispecific antibodies targeting both the ERBB2 receptors present on cancer cells and 
the immuno-effector cells were shown to significantly induce the apoptotic response 
[137, 141]. In addition to their ERBB2 specificities, Ertumaxomab target CD3 [142], 
2B1 target FcRIII [143], MDX-H210 target FcRI [144] (Figure 1.6). Adjuvant 
lymphokines such as interleukin-2 (IL-2) intensified NK-induced ADCC upon anti-
ERBB2 treatment both in vitro and in vivo [145, 146]. 
 
1.3.1.5 Inhibition of DNA Repair (after chemotherapy or radiation) 
In order to overcome the tumor relapse occuring after the cessation of anti-
ERBB2 treatment, the antibody therapy was combined with chemotherapeutics 
inducing DNA damage such as doxorubicin and cisplatin or with radiotherapy. DNA 
damage and DNA adducts induced by the chemotherapeutics and radiotherapy 
stimulates repair pathways. Addition of anti-ERBB2 antibody to the therapeutic 
cocktail inhibited p21 expression that participates in DNA repair, blocked 
unscheduled DNA synthesis and DNA-adduct repair leading to enhanced tumor 
elimination [147, 148].   
 
1.3.1.6 Inhibition of Angiogenesis 
Since tumor cell survival partly depends on angiogenesis that provide nutrients, 
growth factors and oxygen to the tumor microenvironment; cancer cells secrete 
factors to induce angiogenesis. ERBB2 overexpression was shown to stimulate 
angiogenesis through PI3K-Akt mediated induction of pro-angiogenic factors like 
vascular endothelial cell growth factor (VEGF) and interleukin-8 (IL-8) while 
decreasing the levels of anti-angiogenic factor thrombospondin-1 (TSP-1) [149–151]. 
17 
 
Downregulating the PI3K-Akt pathway, anti-ERBB2 treatment counteracted 
ERBB2-mediated regulation of angiogenic factors, decreased vascular permeability 
and inhibited angiogenesis [151, 152]. Combination of Trastuzumab treatment with a 
microtube-inhibitor (paclitaxel) further enhanced the dephosphorylation of Akt, 
downregulation of VEGF secretion, reduced endothelial cell migration and decreased 
the tumor microvessel density (MVD) [153]. 
  
1.3.2 Response to Trastuzumab 
In phase II clinical trials where Trastuzumab was used as a single agent therapy 
for ERBB2-overexpressing, metastatic breast cancer, ~66-88% of the patients 
developed primary resistance to Trastuzumab monotherapy [94–96]. 
Later on in phase III trials, trastuzumab was combined with paclitaxel or 
docataxel for treatment of ERBB2-overexpressing metastatic breast cancers (MBCs) 
[154]. The response rates, time-to-disease progression and overall survival of the 
combined therapy were superior to Trastuzumab monotherapy, leading to FDA 
approval of Trastuzumab-based combined treatment regime in 1998 for ERBB2-
overexpressing metastatic breast cancers. MBC patients receiving first-line treatment 
with chemotherapy in combination with Trastuzumab had ~20% lower risk of death 
than patients treated with chemotherapy alone [155]. Median time-to-diease-
progression was 4.9 months for patients that received trastuzumab monotherapy 
without any prior chemotherapy [95]; however, it was 7.4 months for patients that 
received Trastuzumab in combination with chemotherapy [155]. While combined 
therapy was better than monotherapy for MBCs, the majority of patients still 
developed resistance within one year even if they had an initial response [82].  
Afterwards, other clinical trials were established where Trastuzumab was 
tested for the treatment of early stage breast cancers with ERBB2-overexpression. 
Disease-free and over-all survival rates were found to be improved by Trastuzumab 
therapy either in combination with or following chemotherapy [156–158]. These 
results brought about FDA approval of Trastuzumab in 2006 as part of a treatment 
regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant 
treatment of patients with early-stage ERBB2-positive, node-positive breast cancer. 
In 2008, Trastuzumab received further FDA approvals to be used in early stage 
ERBB2-positive settings. Multiple reports suggest that, a trastuzumab-containing 
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treatment regime should be recommended to early-stage breast cancer patients 
carrying ERBB2-amplification and/or overexpression [159–162]. Although 
Trastuzumab led to promising results in the treatment of ERBB2-overexpressing 
early-stage breast cancers, ~15% of the patients still developed metastasis [97], 
demonstrating the clinical limitations caused by the development of trastuzumab-
resistance in the long run.  
Trastuzumab treatment was most beneficial for ERBB2-positive patients whose 
tumors displayed gene amplification by FISH or intensive membrane staining (3+) as 
detected by IHC [95, 155, 156, 158, 163, 164]. 
 
1.3.3 Mechanisms of Trastuzumab Resistance 
In order to tackle with these limitations faced in clinic, numerous groups have 
endeavoured to elucidate the mechanisms of trastuzumab resistance in vitro, ex-vivo 
and in-vivo.  
Mechanisms of Trastuzumab-resistance are being studied and reviewed 
extensively by various groups [82, 97, 165, 166]. Overexpression of other ERBB 
receptors (i.e. EGFR) and/or their ligands (i.e. EGF, TGF-α, heregulins) and 
heterodimerization with other receptors types (i.e. IGF-1R) were reported to increase 
downstream signalling through heterodimerization with ERBB2. Activating PI3K 
mutations, PTEN deletion, p27 downregulation and increased Akt activity also 
induce constant activation of donstream pathways stimulating cell proliferation and 
survival, and lead to Trastuzumab resistance. MUC4-ERBB2 interaction and 
circulating ERBB2-ECD (p110) in serum was shown to block Trastuzumab binding. 
Mutations on Fc-receptors were identified as the possible reason of hampered 
ADCC-response. 
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Figure 1.5 Mechanisms of Trastuzumab Resistance. Potential culprits of anti-
ERBB2 resistance are shown. Mutations on intracellular region of ERRB2 receptor (mainly 
at Tytosine Kinase region), activating PI3K mutations and PTEN deletion is shown to cause 
constitutive activation of Akt induced signaling, leading to p27 degradation (A). Mutations 
on antibody-binding epitope (A), receptor shedding by ADAM proteases (B) and receptor 
masking through ERBB2-MUC4 interaction (E) prevents antibody binding. Mutations on Fc 
receptor hamper the ADCC response (A). In addition cross-talk between ERBB2 and other 
growth factor receptors (C and D) activate the downstream proliferative pathways. Effectors 
shown in dark blue are the molecular forms demonstrated or suggested to be active in 
Trastuzumab resistance, participating in proliferation and survival pathways. Effectors 
shown in pale purple are the molecular forms demonstrated or suggested to be decreased in 
Trastuzumab resistance, participate in anti-proliferative pathways. /: molecular 
transitions/signal transductions in action. : inhibited signal transductions. : 
upregulation, activation or stabilization. : downregulation, inactivation or degradation. X: 
inhibition of receptor binding.     : mutation or polymorphisms. : phosphorylated residues. 
TK: Tyrosine kinase domain. 
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1.3.3.1 Variations in ERBB2-ECD 
Since Trastuzumab binds to a juxtamembrane position on the extracellular 
domain of ERBB2 receptor tyrosine kinase, any variation in that region will interfere 
with Trastuzumab-response. Missense mutations and in-frame deletions at the 
juxtamembrane domain of ERBB2 were found in transgenic mice overexpressing 
ERBB2/NEU and shown to be capable to oncogenic transformation when introduced 
into wild type ERBB2/NEU [55]. Yet, common point mutations in ERBB2-ECD 
have not been documented in human breast tumors (Nahta et al. 2006). A rare His-
559-Ala point-mutation identified on the Trastuzumab-binding site on the 
juxtamembrane domain of ERBB2 might account for some resistance observed in 
ERBB2-overexpressing invasive human breast cancers, but far from explaining the 
high frequency of Trastuzumab-resistance observed in clinic [75].  
Truncated ERBB2 receptors lacking extracellular N-terminal region were 
detected in human breast tumors. Since they lack the Trastuzumab binding 
extracellular domain IV, it is not surprising that they are irresponsive to Trastuzumab 
treatment. ERBB2 Carboxy-Terminal-Fragments (CTFs) were suggested to be 
produced either through proteolytic receptor shedding (as in the case of p95) [121–
124] or by alternative ERBB2 translation (either starting from methionine-611 
located upstream of the transmembrane domain as in the case of 611-CTF, or from 
methionine-687 downstream of the transmembrane domain) [167, 168]. CTFs were 
detected in a subset of breast cancer patients that developed nodal metastasis, leading 
to worse prognosis and poor clinical outcome [129, 130]. In addition, ERBB2-
overexpressing patients were shown to be less responsive to Trastuzumab if they 
expressed p95; the response rate was 51.4% for tumors expressing full-length 
ERBB2, while it was 11.1% for patients expressing p95 [169]. HSP90 inhibitors 
which block downstream signalling induced by p95-ERBB2, were suggested as a 
therapeutic option for p95-overexpressing, Trastuzumab resistant breast cancer types 
[170]. 
ERBB2 N-terminal fragments (p100 and p110) circulating in the serum that are 
produced either through the cleavage of matrix metalloproteases [119, 120] or by 
alternative splicing also participate in Trastuzumab resistance [171, 172]. Identical to 
full-length ERBB2 sequence at its 5’ end, the alternative transcript diverged from the 
wild type sequence due to an in frame stop codon 61 nucleotides upstream of the 
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transmembrane domain. The truncated ERBB2 of 100 kDa is found both 
intracellularly at the perinuclear cytoplasm and secreted into the conditioned media 
[171]. It has been reported that, p110 competed with full-length ERBB2 present on 
cell surface for binding to anti-ERBB2 antibodies [123, 173], and elevated levels of 
p110 circulating in the serum was shown to be associated with poor prognosis in 
advanced breast cancer patients [125–128].  
Another alternative splicing event deleted the entire exon 16 which is coding 
for amino acids immediately preceding the transmembrane domain of the receptor on 
ERBB2 ECD-IV. Associated with constitutive ERBB2 activation [174] and stronger 
transformation capacity [175], this ERBB2 variant (16ERBB2) with a 16 amino 
acid in-frame deletion (C634-S649del) was detected in human breast tumors [174, 
176]. A later report indicated that, the oncogenic ERBB2Δ16 was found in 89% of 
the lymph-node positive breast tumors with ERBB2-overexpression [177]. Although 
C634-S649 is not involved in Trastuzumab-ERBB2 interaction [17], tumor cell lines 
with this variant were found to be resistant to Trastuzumab [174, 177]. 
One other alternative splicing event produces a 68 kDa Herstatin which only 
retains the total extracellular domain I (ECD-I) and most of extracellular domain II 
(ECD-II); replacing the remaining sequence [178]. Through its unique C-terminal tail 
which substitutes the extracellular domain III (ECD-III) of the wild type ERBB2, 
Herstatin was shown to bind ERBB2 ECD-II [179], EGFR, Her4, IGF-IR [180], 
prevent ERBB2 dimerization with Her3 and EGFR [181] and inhibit TGF-α, EGF 
and heregulin mediated growth of breast cancer cells [182, 183] similar to the 
dimerization inhibitor antibody Pertuzumab [99, 184]. On the contrary to other 
alternative splicing products of ERBB2 which are suggested to be associated with 
worse prognosis, Herstatin which acts as an endogenous pan-HER inhibitor was 
suggested as a therapeutic regimen to prevent ERBB2 mediated growth [185] 
 
1.3.3.2 Activating Mutations on ERBB2 Transmembrane and Kinase 
Domain 
Being the earliest detected mutation on NEU; Val664Glu was commonly 
observed in Neu transgenic mice and was shown to constitutively activate NEU 
favouring its homo- and hetero-dimerization [51–53, 186]. While the human 
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equivalent Val659Glu has been shown to constitutively activate ERBB2 in vitro 
[56], up to date it has never been observed in human breast cancers [57]. However, 
point mutations at the transmembrane domain was detected in malignant central 
nervous system (CNS) tumors [74]. Although rarely detected in invasive human 
breast cancers with ERBB2 overexpression, His559Ala point-mutation located on 
the Trastuzumab-binding site may lead to Trastuzumab resistance [75]. In addition, 
kinase domain mutations mentioned above may cause constant activation of the 
downstream effectors, decreasing the response to Trastuzumab treatment.  
 
1.3.3.3 Inhibition of Receptor Downregulation  
Since downregulation of the ERBB2 receptor is one of the mechanisms 
suggested for the action mechanism of anti-ERBB2 treatment, it is not suprising to 
observe antibody resistance upon blockage of receptor downregulation.  
During endocytosis, the endocytic vesicle is known to rapidly acidify following 
the internalization of the receptor. Since TGF-α is more basic than EGF, it quickly 
dissociates from the receptor, allowing EGFR to recycle to the cell surface instead of 
being degraded. This leads to the prolonged stimulation of both EGFR, and its 
partners in heterodimerization [187]. Since TGF-α did not interfere with 
Trastuzumab binding to ERBB2 receptor, Valagebra et. al. have suggested that, 
TGF-α may induce Trastuzumab-resistance by hampering the endocytic pathway 
through uncoupling ERBB2 from the Cbl ubiquitin ligase. They demonstrated that, 
exogenous TGF-α expression in breast cancer cells reduced Trastuzumab-mediated 
ERBB2 endocytosis, receptor downregulation and cell growth inhibition [188]. In 
addition they also observed TGF-α induction in-vivo following Trastuzumab therapy. 
Through the action of fatty acid synthase (FAS), ERBB2 was shown to 
colocalize with lipid rafts in breast cancer cells, inhibiting antibody internalization 
[189]. Pharmacological or RNAi-mediated FAS blockage was demonstrated to 
sensitize ERBB2 overexpressing breast cancer cells to the Trastuzumab induced 
growth inhibition and apoptosis [190].  
Rac-1, a Ras-like small GTPase was also demonstrated to cause Trastuzumab 
resistance by inducing cytoskeletal disorganization and impairing anti-ERBB2 
mediated endocytic down-regulation of the receptor [191]. 
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1.3.3.4 Receptor Masking 
Through heterodimerization with ERBB2 receptor, the sialomucin complex 
MUC4 was shown to block interaction of anti-ERBB2 antibody Trastuzumab with 
the receptor; leading to therapeutic resistance [192]. Interestingly, anti-MUC4 
antibodies decreased the anti-ERBB2 binding instead of restoring the interaction; 
substantiating the role of steric hindrance [193].  
ERBB2 receptor in Trastuzumab resistant JIMT-1 cells [192, 194] were found 
to physically interact with the overexpressed CD44 receptor [195]. CD44 which is 
also accepted as a breast cancer stem cell marker [196] was shown to aid in 
internalization and downregulation of ERBB2 upon anti-ERBB2 treatment. The 
authors suggested that 6 months after the cessation of Trastuzumab treatment, anti-
ERBB2 antibodies will be cleared from the circulation and CD44 cells which have 
downregulated their ERBB2 will re-express the receptor, displaying lower 
Trastuzumab/ERBB2 ratio on their membrane, leading to relapse [195]. They also 
recommended that screening for CD44 positivity will be useful when ERBB2 
overexpressing cells are to be targeted with radioactive isotopes or 
chemotherapeutics that need to be internalised. Apart from its role in ERBB2 
downregulation, CD44 pathway leads to anti-ERBB2 resistance through a totally 
different mechanism. When CD44 was bound by its bulky ligand hyaluronan, access 
of Trastuzumab to its epitope on ERBB2 was blocked due to steric hindrance; an 
effect similar to MUC4 [195]. 
 
1.3.3.5 Crosstalk Among Other ERBB Family Members 
While ERBB2 is a ligand-less receptor, other ERBB family members are 
stimulated by a number of ligands, which induce their homo/heterodimerization with 
ERBB family members, preferentially with ERBB2 [197]. Several groups have 
indicated that activation of the downstream pathways through these ligands is one of 
the mechanisms responsible for Trastuzumab resistance. 
Investigating Trastuzumab resistant cell lines that were established by 
continuous Trastuzumab treatment of BT-474 xenografts, Ritter et. al. detected 
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EGFR dependent phosphorylation of ERBB2. Trastuzumab resistance was shown to 
be correlated with overexpression of HER ligands (TGF-α, EGF, heregulins, 
betacellulin and heparin-binding EGF) in addition to increased levels of EGFR, 
phosphorylated EGFR and EGFR/ERBB2 heterodimers; suggesting EGFR and its 
ligands as potential inducers of Trastuzumab resistance [198–200]. In addition, as 
discussed in section 1.3.3.3, TGF-α was suggested to decrease Trastuzumab 
sensitivity by interfering with receptor degradation and downregulation [188]. TGF-β 
receptor stimulation by TGF-β binding was demonstrated to activate 
TACE/ADAM17 which in turn induce the secretion of TGF-α, amphiregulin, and 
heregulin secretion stimulating anti-ERBB2 resistance [201]. An independent study 
demonstrated that Trastuzumab-mediated deactivation of Akt further stimulated 
TACE/ADAM17-induced release of ERBB ligands such as heregulin and β-cellulin 
creating a negative feedback loop and resulting in anti-ERBB2 resistance [202].  
Lacking a tyrosine kinase domain itself, once stimulated by its ligand, HER3 
heterodimerizes with EGFR or ERBB2 and activates the downstream effectors 
through the tyrosine kinase of its partners [203, 204]. Trastuzumab was shown to be 
inefficient in preventing heregulin mediated ERBB2/HER3 heterodimerization, 
ERBB2 phosphorylation and Akt activation, suggesting HER3 receptor and its 
ligands as potential inducers of Trastuzumab resistance [184, 198]. Prevention of 
ERBB2 heterodimerization by Pertuzumab or inactivation of downstream effectors 
by adjuvant tyrosine kinase inhibitors were shown to inhibit growth of Trastuzumab-
resistant cancer cells [184, 199, 205, 206]. Another study demonstrates that, 
interacting with ERBB2/ERBB3 heterodimer, IGF1-R induces the formation of 
heterotrimeric ERBB2/ERRB3/IGF1-R complex which activates downstream 
effectors in Trastuzumab resistant cells [207]. 
 
1.3.3.6 Constitutive Activation of Effector Proteins in PI3K Pathway 
Since PI3K pathway was known to be effective in ERBB2-mediated signalling, 
and Trastuzumab was shown to exert its action through blockage of the signal-
transducers in this pathway, it was not surprising that PTEN was one of the suspects 
of Trastuzumab resistance. In addition, it has long been known that, almost half of all 
breast cancers carried PTEN mutations, PTEN happloinsufficiency (LOH) or 
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epigenetic downregulation [208–210]. In order to demonstrate the effect of PTEN 
loss in Trastuzumab resistance, Nagata et. al. induced Trastuzumab resistance by 
anti-sense-oligonucleotides against PTEN [111]. In addition, to prove the necessity 
of Akt inhibition in overcoming Trastuzumab resistance, they have rescued the 
resistant phenotype (induced by PTEN anti-sense oligonucleotides) by using PI3K 
inhibitors. PI3K inhibitors were also proven useful to treat ERBB2-overexpressing 
cells which developed resistance following continuous exposure to Trastuzumab and 
had elevated levels of phosphorylated Akt [211]. Furthermore, breast cancer patients 
with PTEN-deficiency were reported to respond poorer to Trastuzumab therapy [111, 
212]. On the contrary, patients having elevated levels of PTEN were reported to have 
better Trastuzumab responses [213, 214]. 
PI3K gene amplification and gain-of-function mutations on its catalytic subunit 
(p110) rendering the kinase constitutively active are commonly found in many types 
of human cancers [215–218]. These PI3K mutations disabled the modulation of the 
proliferative pathway causing resistance to anti-ERBB2 therapies [212, 214, 219]. 
Constitutive Akt activation was also shown to rescue proliferative loss of ERBB2 
signaling [220]; causing resistance to anti-ERBB2 treatment [114, 211, 221]. 
Decreased p27 levels and elevated CDK2 activity were observed in 
Trastuzumab resistant cells that also displayed higher S-phase fraction and increased 
doubling speed. Induction of p27 expression by transfection or inhibition of the 
proteasome complex restored anti-ERBB2 sensitivity [222]. Inhibition of nuclear 
localization of p27 induced a similar resistance [223]. Downregulation of p27 was 
also shown in Trastuzumab-resistance caused by the heterodimerization of ERBB2 
and IGF1R [222, 224, 225]. Consequently, p27 was suggested as a therapeutic target 
in treating anti-ERBB2 resistance caused by aberrant signalling upstream [82]. 
Recently, Scaltriti et. al have demonstrated the role of abnormal Cyclin E level 
in Trastuzumab-resistance. A genomewide copy-number variation analysis on the 
Trastuzumab-resistant cells has revealed cyclin E gene-amplification. In addition, 
comparing Trastuzumab-treated breast cancer patients according to the level of 
Cyclin E expression on their tumors, the group has shown an association between 
Cyclin E amplification/overexpression and worse clinical outcome. To confirm their 
hypothesis, they have further demonstrated decreased tumor growth of Trastuzumab-
resistant xenografts upon CDK2 inhibition [226]. 
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1.3.3.7 Increasing Signalling From Other Receptors 
In addition to heterodimerization with other ERBB receptors, ERBB2 was 
found to interact with other receptors leading to activation of oncogenic pathways 
and anti-ERBB2 resistance. 
IGF-1 mediated IGF-1R induction and subsequent IGF-1R/ERBB2 
heterodimerization was demonstrated to decrease p27 levels and p27/CDK2 
association leading to attenuation of anti-ERBB2 mediated G1-arrest in Trastuzumab 
resistant breast cancer cells [224, 225]. Clinical data indicate that, membrane IGF-1R 
expression was associated with a lower response to Trastuzumab/vinolrelbine 
therapy [227]. While the dimerization inhibitory anti-ERBB2 antibody Pertuzumab 
was inefficient in preventing the interaction between ERBB2 and IGF-1R, anti-IGF-
1R antibody α-1R3 sensitized the cells to anti-proliferative effects of Trastuzumab 
[228]. In addition, as mentioned in section 1.3.3.5, IGF1-R was shown to be present 
in a heterotrimeric ERBB2/ERRB3/IGF1-R complex in Trastuzumab resistant cells 
[207]. 
Met receptor that is induced by its ligand hepatocyte growth factor (HGF) was 
also shown to trigger Trastuzumab resistance in ERBB2 overexpressing breast 
cancer cells by inhibiting upregulation of p27. Similar to IGF signalling, both Met 
receptor and HGF was found to be upregulated in patients resistant to 
Trastuzumab/vinolrelbine therapy [229]. 
Elevated levels of the receptor tyrosine kinase EphA2 and cleaved form of 
MUC1 (MUC1*) were also detected in Trastuzumab resistant breast cancer cell 
lines. Trastuzumab-induced EphA2 phosphorylation was shown to cause Src-
meadited activation of PI3K-Akt and MAPK pathways, leading to anti-ERBB2 
resistance. EphA2 overexpression was correlated with worse prognosis and lower 
survival of ERBB2-overexpressing breast cancer patients [230]. Sublethal doses of 
Trastuzumab exposure induced overexpression of MUC1*; a growth factor receptor 
that is also elevated on embryonic stem cells and correlated with drug resistance 
[231]. 
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1.3.3.8 Fc Receptor Status 
ADCC was suggested as one of the main anti-oncogenic mechanisms of anti-
ERBB2 treatment. The antibody bound to the target tumor cells engage with IgG 
receptors present on the effector cells and induce effector-mediated cytotoxicity. As 
explained above, strong antibody-effector cell interaction is necessary for a 
successful cytotoxic response. There are three groups of Fc receptors found on 
human leukocytes; FcRI, FcRII and FcRIII. While FcRIIa and FcRIIIa are 
activating receptors, FcRIIb and FcRIIIb have inhibitory effects on ADCC. 
Analyses of the correlation between Fc receptor polymorphisms and clinical 
response to Trastuzumab treatment indicated that FcRIIIa 158V/V and FcRIIa 
131H/H phenotypes either alone or in combination significantly enhanced the 
effector response both in vitro and in vivo, leading to stronger ADCC response and 
better clinical outcome [232, 233].  
 
1.3.3.9 DNA Methylations 
Microarray analysis of paired breast cancer samples indicated significant 
epigenetic regulations in breast cancer etiology and prognosis which can be used as 
biomarkers and therapeutic targets [234]. Although anti-ERBB2 resistant and 
sensitive subtypes are not selectively compared in this study, it suggests that, not 
only genetic but also epigenetic regulations might have a role in drug responses of 
certain tumor types. 
 
1.3.3.10 Other Factors 
Microarray analysis of Trastuzumab resistant cells revealed protein kinase A 
(PKA) network as one of the signalling mechanisms responsible for the constant 
activation of PI3K/Akt signalling. Darrp-32, suppressor of both PKA and protein 
phosphatase-1 (PP-1) was elevated in Trastuzumab resistant cells [235, 236].  
Heat shock proteins (HSPs) were shown to be important in Trastuzumab 
response. When upregulated, HSP27 was shown to increase ERBB2 protein stability 
and induce Trastuzumab resistance [237]. HSP90 level was inversely correlated with 
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survival rates of breast cancer patients and HSP90 inhibitors were shown to reduce 
Trastuzumab resistance in vitro [170, 238]. 
 
1.3.3.11 Complexity Accompanying ERBB2 gene amplifications 
As reviewed by Vanden Bempt et. al., the genes co-amplified with ERBB2 
depends on the amplicon size, in turn influencing the clinical outcome of 
Trastuzumab therapy [239]. In addition, as reviewed above, there are other genes 
whose expression and activity critically affect the ERBB2 pathway, although they 
are not located on the same amplicon with ERBB2. It appears that resolving the 
aberrant expression pattern of each patient is key to designing a tailored therapeutic 
cocktail. In the near future, progressions in personal genomics technology would 
allow clinicians unveil genomic signature of every individual patient and offer 
personalized therapy [240–243] 
 
1.4 Alternative Therapeutics for Treatment of ERBB2 
Overexpressing Breast Cancer 
A subset of ERBB2 positive tumors was inherently resistant to Trastuzumab 
treatment due to the constitutive activation of the proliferative pathways regardless of 
ERBB2 activation status. Others were shown to develop Trastuzumab resistance after 
prolonged treatment. Since cytostatic growth inhibition was suggested as the main 
effect of Trastuzumab treatment [39, 116, 244, 245], the clonal selection and 
proliferation of once dormant cells that are activated by other genetic or epigenetic 
factors appears to be one of the main reasons of the acquired clinical resistance 
[246]. Whether anti-ERBB2 resistance is inherent or de novo, there are two main 
approaches to revert this phenotype; a) blocking the initial activation of additional 
proliferative pathways by targeting their receptors, b) preventing the final message 
by targeting the molecular effectors down the signal transduction pathways. While 
former includes MAbs targeting ERBB2 dimerization domain (Pertuzumab) or other 
growth factor receptors such as EGFR (Cetuximab), IGF-1R (α-IR3), VEGF 
(Bevacizumab); the latter mainly includes kinase inhibitors targeting either the 
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receptor tyrosine kinases such as ERBB2 and VEGF (Lapatinib, Erlotinib, Neratinib, 
Sunitinib, etc) or intracellular kinases such as PI3K and mTOR (Dasatinib, 
Perifosine, Everolismus etc) [50, 247–250] (Figure 1.6).  
 
 
 
Figure 1.6 Alternative Therapeutics Agents targeting the molecular effectors on 
ERBB2 signaling pathway are shown. Effectors shown in dark blue are the molecular forms 
demonstrated or suggested to be active in Trastuzumab resistance, participating in 
proliferation and survival pathways. Effectors shown in pale purple are the molecular forms 
which participate in anti-proliferative pathways and are demonstrated or suggested to be 
decreased in Trastuzumab resistance. /: molecular transitions/signal transductions in 
action. /: inhibited molecular transitions/signal transductions. : phosphorylated 
residues. TK: Tyrosine kinase domain. : inhibition. 
 
Alternative therapeutics developed for the treatment of ERBB2-overexpressing 
breast cancers are summarized on Figure 1.6. Besides growth factor receptors and 
intracellular kinases, the molecular chaperon HSP90 which participates in the 
stabilization of survival mediators such as ERBB2, PDGF, Akt and p53; and histone 
deacetylases (HDACs) that activate HSP90 are also accepted as therapeutic targets 
and tested in clinical trials together with Trastuzumab [251, 252]. 
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In addition, monoclonal antibody Pertuzumab (originally 2C4) developed 
simultaneously with Trastuzumab (originally 4D5) as a weaker growth inhibitor was 
later discovered to prevent heterodimerization between ERBB2 and other growth 
factor receptors such as EGFR, ERBB3 [184], IGF-1R [228]. Clinical trials suggest 
that Pertuzumab may be used to overcome Trastuzumab resistance induced by the 
crosstalk between ERBB2 and other growth factor receptors [228, 253]. 
Recently, therapeutic agents are being developed that target more than one 
signalling molecule at the same time. These include dual specificity kinase inhibitors 
such as Lapatinib, Neratinib and some modified anti-ERBB2 antibodies that interact 
with the receptors on immunoeffector cells in addition to ERBB2 on target cells. 
Bispecific antibodies Ertumaxomab (targeting ERBB2 and CD3) [142], 2B1 
(targeting ERBB2 and FcRIII) [143] and MDX-H210 (target FcRI in addition to 
ERBB2) [144] are currently being tested in clinical trials. In addition, anti-ERBB2 
antibodies fused to chemotherapeutics (T-DM1) are developed to specifically target 
ERBB2-overexpressing cells, limiting the overall toxicity of chemotherapy [254]. 
Although promising anti-oncogenic activities were demonstrated, each of the 
alternative therapeutics mentioned above has a limited selectivity, targeting only a 
small subset of Trastuzumab resistant conditions. In fact, most of the preclinical and 
clinical trials are performed with combinational regimens containing at least two 
agents with distinct target specificities in order to increase the application range and 
therapeutic efficacy [50, 247, 255].  
It should also be noted that, even antibody combinations targeting distinct 
epitopes of the same receptor provide significantly stronger anti-oncogenic effect 
than either of the individual agents both in vitro and in vivo [253, 256]. Aiming to 
generate antibodies targeting unique epitopes with better therapeutic outcome, a 
number of groups developed novel anti-ERBB2 antibodies whose therapeutic 
efficiencies as single agent and/or in multidrug combinations are still being examined 
in preclinical and clinical studies [257–271]. 
In the very near future, with the developments in personalised medicine, it will 
be possible to unveil molecular signature of every single patient, and to offer the 
correct therapeutic combination individually. In order for this to come true, it is 
critically important to have a wide variety of therapeutics available in market 
offering different target selectivity and therapeutic efficacy. 
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1.5 TNF-α and ERBB2 
TNF-α can act either as a pro-apoptotic and an anti-apoptotic agent depending 
on the receptor type, adaptor proteins and cellular context [272]. TNF-α-induced 
caspase-8 activation (mostly through TNF-R1) leads to apoptosis, whereas NFB 
activation causes downstream activation of Bcl-xL and caspase inhibitors such as c-
FLIP, c-IAP1 and c-IAP2, counteracting TNF-α-induced apoptotic pathway and 
leading to proliferation [273–276]. 
As an indication of its anti-apoptotic effect, TNF-α was shown to induce breast 
cancer growth through p42/44, JNK, Akt and NFB pathways [277]. Studying 
ERBB2-overexpressing breast cancer cells, the same group later demonstrated that 
TNF-α transactivates ERBB2 by inducing its autophosphorylation and c-Src 
mediated ERBB2-Tyr877 phosphorylation, leading to cell proliferation through 
NFB activation, and suggested that the presence of TNF-α in tumor environment is 
a factor in development of trastuzumab resistance [278].  
On the other hand, TNF-α was best known for its pro-apoptotic effect. 
Therefore it had been striking when it was first shown that tumor cells developed 
TNF-α-resistant phenotype due to increased signalling through growth factor 
receptors [279], and overexpression of ERBB2 was demonstrated to render NIH3T3 
cells resistant to cytotoxic effects of TNF-α treatment [83]. The TNF-α-resistant 
phenotype of ERBB2-overexpressing NIH3T3 cells was reversed by the help of 
monoclonal antibodies targeting the extracellular domain of ERBB2 [84]. The 
mechanism of the additive effect seen between TNF-α and anti-ERBB2 therapy was 
studied by a number of groups and illustrated on Figure 1.7. Zhou et. al. have shown 
that TNF-α-induced apoptosis was blocked by ERBB2 overexpression through Akt 
and NFB [280]. ERBB2-mediated PI3K-induction of Akt was demonstrated to 
activate IKKα/IKKβ and in turn NFB, leading to TNF-α-resistance. Therefore 
equilibrium between pro-apoptotic/anti-apoptotic pathways downstream of TNF-α 
was suggested to shift towards anti-apoptosis upon ERBB2-overexpression. Later, 
Trastuzumab was demonstrated to inhibit PI3K and Akt in order to exert anti-tumoral 
activity on ERBB2-overexpressing cells [113], therefore Trastuzumab may be 
suggested to sensitize ERBB2-overexpressing cells to TNF-α-induced apoptosis 
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through deactivation of Akt/NFB pathway. PI3K-mediated activation of ILK was 
further suggested as an alternative pathway causing activation of Akt and 
IKKα/IKKβ conferring resistance to TNF-α-induced apoptosis upon ERBB2-
overexpression [281]. Trastuzumab treatment of ERBB2 overexpressing cells BT-
474 and SK-BR-3 demonstrated induction of TNF-α-mediated NF-B activity and 
IBα phosphorylation only in BT-474; emphasizing the role of cell-specific 
responses [278]. On the other hand, IB phosphorylation which was associated with 
increased NFB activity was observed in Trastuzumab resistant clones of both SK-
BR-3 and BT-474 [243].  
A direct effect of Trastuzumab in enhancing TRAIL-mediated apoptosis was 
demonstrated in ERBB2-overexpressing ovarian and breast cancer cell lines upon 
downregulation of ERBB2 [104]. Blocking Akt pathway by dominant negative Akt 
or PI3K-inhibitors were shown to sensitize ERBB2-overexpressing cells to TNF-α-
mediated [280] and TRAIL-mediated [104] apoptosis respectively. In addition, 
PARP-inhibitors were shown to be effective in triggering TNF-α-sensitivity in 
ERBB2-overexpressing cells [282], and interestingly, while PARP inhibitors 
reversed the TNF-α-resistant phenotype in ERBB2-overxpressing cells, they 
inhibited TNF-α-response in TNF-α-sensitive cells that has lower ERBB2 
expression. 
While these studies help to unveil the potential mechanisms by which the anti-
ERBB2 antibody Trastuzumab enhanced the effect of TNF-α, the mechanism of the 
opposite route was to be answered. Although TNF-α treatment was suggested to 
decrease ERBB2 mRNA synthesis [283] and ERBB2 protein expression [284], the 
effect on transcriptional level was controversial [272] and the exact mechanism by 
which TNF-α increased the anti-oncogenic potential of anti-ERBB2 therapy 
remained unclear until TNF-α was shown to stimulate caspase-8 mediated ERBB2 
cleavage which is counteracted by NFB [272].  
TNF-α pro-apoptotic pathway acts through caspase-8, which was further 
shown to be active in ERBB2 cleavage. On the contrary, TNF-α anti-apoptotic 
pathway acts through NFB which in turn increases c-FLIP expression leading to 
inhibition of caspase-8 [272]. Upon ERBB2 overexpression, NFB is activated 
through either a PI3KAkt activation, or through ILKAkt activation [281], which 
might lead to caspase-8 inhibition and further stabilization of ERBB2. Therefore, 
33 
 
ERBB2 might produce a positive-feedback deactivating its own cleavage and 
increasing cellular ERBB2 protein level. However, it can be argued that, when 
ERBB2 is deactivated either by Trastuzumab, ERBB2 kinase inhibitors or anti-sense 
oligonucleotides, NFB is no-more activated [278, 280], rendering caspase-8 free to 
cleave ERBB2, adding up to the pro-apoptotic effect of TNF-α-stimulated caspases 
[272]. On the other hand, NFB-negative background is prone to TNF-α mediated 
caspase-8 dependent ERBB2 cleavage even in the absence of Trastuzumab, such as 
observed in NFB defective MCF-7 A/Z cells [272]. 
On its own, Trastuzumab was able only to block downstream signalling of 
wild-type full-length ERBB2, however signalling could continue through mutant or 
ECD-shed ERBB2. On the other hand, dependent on Trastuzumab-mediated NFB 
deactivation, TNF-α may lead to downregulation of total ERBB2-tyrosine kinase 
activity through induction of ERBB2 cleavage on 6 different intracellular sites, in 
turn causing a stronger anti-proliferative and apoptotic result. Although weak, a 
positive correlation was later shown between serum ERBB2 and pro-apoptotic TNF-
R1 and TNF-R2 cytokines in patients with heart-failure, suggesting a clinical 
indication of association between TNF-α and ERBB2-cleavage [285]. 
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Figure 1.7 Interaction between TNF-α and ERBB2 TNF-α can act as a pro-apoptotic 
or anti-apoptotic agent. Through activation of NFβ pathway, TNF-α transactivates Cyclin 
D1 and FLIP, leading to cell proliferation. Through activation of Caspase8 cascade, TNF-α 
induces apoptosis. TNF-α and ERBB2 pathways interact through Src and Akt; both inducing 
anti-apoptotic pathways. On the other hand TNF-α induced Caspase8 induces ERBB2 
degradation, counteracting with the ERBB2 pathway. Through deactivation of Akt/NFβ 
pathway, anti-ERBB2 treatment may sensitize ERBB2-overexpressing cells to TNF-α-
induced apoptosis. 
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2 OBJECTIVES AND RATIONALE 
 
2.1 Aim of the Study 
As described above, there is no single therapeutics available to efficiently treat 
all the ERBB2 positive breast cancers. In addition, drug resistance against 
Trastuzumab (the anti-ERBB2 therapeutics widely used in clinics) stands in the way 
of long-term clinical success during prolonged treatment. In order to provide 
alternative therapeutics selectively targeting ERBB2-overexpressing cancer cells, we 
wanted to develop novel anti-ERBB2 antibodies having different epitope preferences 
and anti-proliferative efficiencies than the antibodies already used or being tested in 
the clinic. Since anti-ERBB2 treatment was previously suggested to increase TNF-α 
sensitivity of ERBB2-overexpressing cancer cells, we also intended to analyse the 
drug interactions between novel anti-ERBB2 antibodies and TNF-α. 
 
2.2 Rationale 
Immunizing BALB/c mice with recombinant “human ERBB2 ECD/Fc” fusion 
protein, we have developed five hybridoma clones producing novel anti-ERBB2 
antibodies (BH-antibodies). Biochemical properties and biological activities of the 
antibodies were extensively analysed.  
The affinities of the novel antibodies for recombinant and cellular ERBB2 
were examined by ELISA, flow cytometry and indirect immunofluorescence assays. 
While all novel antibodies successfully detected native ERBB2, they failed to 
interact with ERBB2 proteins denatured during SDS-PAGE. Immunofluorescence 
and immunoprecipitation/western analyses of various ERBB2 deletion constructs 
revealed that all novel antibodies reacted with conformational ERBB2 epitopes. 
Biological activities of novel anti-ERBB2 antibodies were tested ex-vivo on 
breast cancer cell lines having different ERBB2 expression levels. Effect of BH-
antibodies on breast cancer cell growth either alone, in pairs or in combination with 
TNF-α was tested by Sulforhodamine B (SRB) based proliferation assay. BH-
antibodies displayed anti-proliferative effects on tested cell lines with ERBB2 
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amplification. Drug interactions between anti-ERBB2 antibodies and TNF-α are 
analysed by two distinct methods; Bliss model of independence and Loewe model of 
additivity. While BH-antibodies and TNF-α had synergistic effects on SK-BR-3 
background, they were antagonistic on BT-474 cells. 
In order to reveal the mechanism of the growth inhibition observed by BH-
antibodies in the presence or absence of TNF-α, BrdU-incorporation, SAβ-gal 
positivity and cell-cycle distribution of the treated SK-BR-3 cells were analysed. In 
addition, molecular changes induced on PI3K and MAPK pathways were also 
examined. 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 General Chemicals  
General chemicals and reagents (i.e. NaCl, glycine, trisma-base, ethanol, bacto-
tryptone) were purchased from Sigma-Aldrich (St. Louis, USA) or Calbiochem 
Merck Millipore (Darmstadt, Germany). Specific reagents are listed on Table 3.1 
and Table 3.2. 
All tissue culture flasks, tissue culture plates, cryotubes, serological pipettes,  
bacterial petri-dishes, fiter tips, and  other general plastic-ware that were used 
throughout the project were purchased from Costar Corp. (Cambridge, England) or 
Greiner Bio-one (Austria). 
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Reagent Name Catalogue Number
Trichloroacetic acid 1008100250 Merck (Schucdarf, Germany)
Bovine serum albumin (BSA) A7906 Sigma-Aldrich (St. Louis, USA)
Sulforhodamine B (SRB) sodium salt 341738 Sigma-Aldrich (St. Louis, USA)
p -Nitrophenyl Phosphate Disodium Salt (PNPP Tablet Set) N2770 Sigma-Aldrich (St. Louis, USA)
4',6-diamidino-2-phenylindole (DAPI) D8417 Sigma-Aldrich (St. Louis, USA)
insulin Sigma-Aldrich (St. Louis, USA)
5-Bromo-2'-deoxyuridine (BrdU) B5002 Sigma-Aldrich (St. Louis, USA)
Propidium Iodide (PI) P4864 Sigma-Aldrich (St. Louis, USA)
Protease inhibitor cocktail tablet (complete EDTA free) 11873580001 Roche Ltd (Basel, Switzerland)
PhosSTOP 4906837001 Roche Ltd (Basel, Switzerland)
Rnase A EN0531 Thermo Scientific Inc. (IL, USA)
PageRuler Prestained Protein Ladder SM0671 Thermo Scientific Inc. (IL, USA)
PageRuler Plus Prestained Protein Ladder SM1811 Thermo Scientific Inc. (IL, USA)
NotI ER0592 Thermo Scientific Inc. (IL, USA)
XhoI ER0691 Thermo Scientific Inc. (IL, USA)
SacI ER1135 Thermo Scientific Inc. (IL, USA)
EcoRI ER0275 Thermo Scientific Inc. (IL, USA)
XmnI ER1532 Thermo Scientific Inc. (IL, USA)
T4 DNA Ligase EL0014 Thermo Scientific Inc. (IL, USA)
Taq DNA polymerase EP0402 Thermo Scientific Inc. (IL, USA)
Phusion® High-Fidelity DNA Polymerase F-530L Finnzymes (Espoo, Finland)
DyNAzyme™ II DNA Polymerase F-501L Finnzymes (Espoo, Finland)
SYBR Green I nucleic acid gel stain 50513 FMC BioProducts (ME, USA)
QIAquick Gel Extraction Kit 28706 QIAgen (CA,USA)
QIAquick PCR Purification Kit 28106 QIAgen (CA,USA)
QIAprep Spin Miniprep Kit 27106 QIAgen (CA,USA)
QIAGEN Plasmid Midi Kit 12145 QIAgen (CA,USA)
BCA Protein Assay Kit 23227 Thermo Scientific Inc. (IL, USA)
ECL Plus Western Blotting Detection System RPN2132 GE Healthcare (WI, USA)
Monoclonal Antibody Isotyping Kit 37502 Thermo Scientific Inc. (IL, USA)
SuperSignal West Dura Extended Duration Substrate 34075 Thermo Scientific Inc. (IL, USA)
SuperSignal West Femto Maximum Sensitivity Substrate 34095 Thermo Scientific Inc. (IL, USA)
SuperSignal West Pico Trial Kit 34079 Thermo Scientific Inc. (IL, USA)
ProLong Gold Antifade Reagent with DAPI P36935 Invitrogen (CA, USA)
GeneRuler™ DNA Ladder Mix, 100-10,000 bp SM0331 Thermo Scientific Inc. (IL, USA)
GeneRuler™ 1 kb DNA Ladder, 250-10,000 bp SM0311 Thermo Scientific Inc. (IL, USA)
PageRuler™ Prestained Protein Ladder SM0671 Thermo Scientific Inc. (IL, USA)
PageRuler™ Plus Prestained Protein Ladder SM1811 Thermo Scientific Inc. (IL, USA)
Ampicillin A9393 Sigma-Aldrich (St. Louis, USA)
96-well polysorb ELISA plates 475094 NUNC (Roskilde, Denmark) 
Immobilon-P transfer (PVDF) membrane IPVH00010 Millipore (MA, USA)
3MM Cellulose Chromatography Papers (Filter Paper) 3030-917 Whatman International Ltd. (Madison, USA)
Kodak medical x-ray film general purpose blue/E  7710783 Kodak
Company
 
Table 3.1 List of specific chemicals, enzymes and commercial kits used during 
the project. 
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Reagent Name Catalogue Number
Constructs, Recombinant Proteins, Antibodies
Full length human ErbB2 plasmid
OCABo5050G0219D-
pDEST26
Source BioScience 
LifeSciences 
(Nottingham, UK)
Recombinant Human ErbB2/Fc Chimera 1129-ER R&D Systems (MN, USA)
Recombinant Human EGF R/Fc Chimera 344-ER R&D Systems (MN, USA)
Recombinant human tumor necrosis factor-alpha (TNF-α) 300-01A PeproTech (NJ, USA)
Trastuzumab (Herceptin) Roche Ltd (Basel, Switzerland)
anti-ErbB2 (CB11) antibody ab8054 Abcam (MA, USA)
anti-phospho ErbB2 antibody sc-1011694 Santa Cruz (California, USA)
anti-Akt antibody 9272 Cell Signaling (MA, USA)
anti-phospho Akt antibody 9271 Cell Signaling (MA, USA)
anti-Erk1/2 antibody 9107 Cell Signaling (MA, USA)
anti-phospho Erk1/2 antibody 9106 Cell Signaling (MA, USA)
anti-CyclinD1 antibody sc-246 Santa Cruz (California, USA)
IgG1 isotype control antibody MAB002 R&D Systems (MN, USA)
anti-mouse IgG (H+L) Alexa Fluor® 488 A11029 Invitrogen (CA, USA)
anti-human IgG Alexa Fluor® 488 A11013 Invitrogen (CA, USA)
anti-mouse IgG (H+L) Alexa Fluor® 568 A11031 Invitrogen (CA, USA)
anti-BrdU (Bu20a) antibody M0744 Dako (Glostrup, Denmark)
anti-mouse Immunoglobulins/AP D0314 Dako (Glostrup, Denmark)
anti-Calnexin antibody C4731 Sigma-Aldrich (St. Louis, USA)
anti-human IgG (Fc specific)?Peroxidase antibody A0170 Sigma-Aldrich (St. Louis, USA)
anti-human IgG (Fc specific)?Alkaline Phosphatase antibody A9544 Sigma-Aldrich (St. Louis, USA)
anti-mouse IgG (Fc specific)–Peroxidase antibody A0168 Sigma-Aldrich (St. Louis, USA)
anti-rabbit IgG (whole molecule)–Peroxidase antibody A6154 Sigma-Aldrich (St. Louis, USA)
FPLC Columns and Protein Purification Material
Protein G coupled sepharose gel slurry R801-H226 East Coast Biologics (ME, USA)
Hi-Trap rProtein A FF (1 ml) 17-5079-01 GE Healthcare (WI, USA)
Hi-Trap Protein A HP (5 ml) 17-0403-01 GE Healthcare (WI, USA)
Hi-Trap Protein G HP (1 ml) 17-0404-01 GE Healthcare (WI, USA)
Hi-Trap Protein G HP (5 ml) 17-0405-01 GE Healthcare (WI, USA)
Amicon Ultra-15 Ultracel-10k concentrators UFC901024 Millipore (MA, USA)
Polyacrylamide Electrophoresis Ready Gels and Reagents
NuPAGE 10% Bis-Tris Gel 1.5mm x 10 well NP0315BOX Invitrogen (CA, USA)
NuPAGE 4-12% Bis-Tris Gel 1.5mm x 10 wel NP0335BOX Invitrogen (CA, USA)
NuPAGE® MOPS SDS Running Buffer (for Bis-Tris Gels only) 
(20X) 
NP0001 Invitrogen (CA, USA)
NuPAGE® Transfer Buffer (20X) NP0006 Invitrogen (CA, USA)
NuPAGE® LDS Sample Buffer (4X) NP0007 Invitrogen (CA, USA)
Company
 
Table 3.2 List of constructs, recombinant proteins, protein purification and 
analysis reagents used during the project. 
 
 
3.1.2 Instruments 
Instruments used throughout the project and their application fields are listed 
on Table 3.3. 
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Instument Name Application
XCell SureLock® Mini-Cell 
Poly Acrylamide Gel Electrophoresis 
(PAGE) Invitrogen (CA, USA)
XCell II™ Blot Module Wet Transfer following PAGE Invitrogen (CA, USA)
Mini-PROTEAN® 3 Cell 
Poly Acrylamide Gel Electrophoresis 
(PAGE) BioRad (CA, USA) 
Mini Trans-Blot Cell Wet Transfer following PAGE BioRad (CA, USA) 
Sub-Cell GT System Agarose Gel Electrophoresis BioRad (CA, USA) 
Power-PAC300 Power Supply BioRad (CA, USA) 
Power-PAC200 Power Supply BioRad (CA, USA) 
ÄKTAexplorer™ FPLC system 
Fast Protein Liquid Chromatography 
(FPLC) for antibody purification GE Healthcare (WI, USA)
Beckman Spectrophotometer Du640 Spectrophotometry Beckman Instruments Inc. (CA, USA) 
Nanodrop ND-1000 Full-spectrum 
UV/Vis Spectrophotometer Spectrophotometry Thermo Fisher Scientific Inc. (IL, USA)
BioTek mQuant Microplate Reader BioTek (VT, USA)
FACSCalibur Flow Cytometer and 
CellQuest Software Flow Cytometry Becton Dickinson (NJ, USA)
Chemi-Smart 2026WL Imaging System Vilber Lourmat France
Hyperprocessor
Development of films used for 
autoradiography GE Healthcare (WI, USA)
Axio Imager.A1 Fluorescent Microscopy Zeiss (Jena, Germany)
Company
 
Table 3.3 List of instruments used during the project. 
 
 
3.1.3 Cell Lines and Tissue Culture Reagents 
Human breast cancer cell lines SK-BR-3, MDA-MB-361, T-47D, MCF-7, 
human hepatocellular carcinoma cell line Huh7 and mouse myeloma cell line SP2/0 
was obtained from Bilkent University Molecular Biology and Genetics department 
cell line stocks. Human breast cancer cell line BT-474 was a kind gift of Assoc. Prof. 
Dr. Elif Erson (Middle East Technical University). Authenticity of all mentioned cell 
lines was checked periodically by STR-analysis. The most recent analysis was 
performed on 09.02.12 and all cell lines were STR-proven to be authentic. 
Expression profiles of the breast cancer cell lines used throughout the project were 
examined by a number of groups [286–289] and the genomic amplifications and 
deletions they contain are listed on Table 3.4. 
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Table 3.4 High-amplitude amplifications and deletions of breast cell lines. 
Reprinted with permission from "Kao J, Salari K, Bocanegra M, Choi Y-L, Girard L, Gandhi 
J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR: Molecular 
profiling of breast cancer cell lines defines relevant tumor models and provides a resource 
for cancer gene discovery. PloS one 2009, 4:e6146" [289]. Copyright  Plos 2009. 
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Tissue culture media and reagents used throughout the project were purchased 
from GIBCO (CA, USA), Sigma-Aldrich (St. Louis, MO) or HyClone (IL, USA) and 
are listed on Table 3.5.  
 
 
Reagent Name Catalogue Number
Incomplete Freund’s Adjuvant F5506 Sigma-Aldrich (St. Louis, USA)
Complete Freund’s Adjuvant F5881 Sigma-Aldrich (St. Louis, USA)
HAT Media Supplement (50×) Hybri-Max H0262 Sigma-Aldrich (St. Louis, USA)
HT Media Supplement (50×) Hybri-Max™ H0137 Sigma-Aldrich (St. Louis, USA)
Polyethylene glycol solution - Hybri-Max™ P7181 Sigma-Aldrich (St. Louis, USA)
G7513 Sigma-Aldrich (St. Louis, USA)
25030024 Invitrogen/GIBCO (CA, USA)
P4333 Sigma-Aldrich (St. Louis, USA)
PST999 Invitrogen/GIBCO (CA, USA)
F7524 Sigma-Aldrich (St. Louis, USA)
10270106 Invitrogen/GIBCO (CA, USA)
M7145 Sigma-Aldrich (St. Louis, USA)
11140-035 Invitrogen/GIBCO (CA, USA)
D5796 Sigma-Aldrich (St. Louis, USA)
41965-039 Invitrogen/GIBCO (CA, USA)
RPMI 1640 31870-074 Invitrogen/GIBCO (CA, USA)
Serum Free Media (SFM) SH30513 Hyclone (IL, USA)
McCoy’s 5A medium M4892 Sigma-Aldrich (St. Louis, USA)
0.25% Trypsin-EDTA (1X), Phenol Red 25200-056 Invitrogen/GIBCO (CA, USA)
Lipofectamine 2000 Reagent 11668-027 Invitrogen (CA, USA)
OPTIMEM 11058021 Invitrogen (CA, USA)
Geneticin G418 Sulphate 11811-031 Invitrogen/GIBCO (CA, USA)
AQUAGUARD-1 01-867-1B Biological Industries Israel
AQUAGUARD-2 01-916-1E Biological Industries Israel
DMSO Sigma-Aldrich (St. Louis, USA)
High Glucose Dulbecco’s Modified Eagle Medium 
(DMEM)
Company
L-Glutamine
Penicilline/Streptomicine
Fetal Bovine Serum
Non Essential Amino Acids (NEAA)
 
Table 3.5 List of cell culture solutions and reagents used during the project. 
 
 
3.1.4 Animal Experiments 
Animal experiments approved by Bilkent University Animal Ethical Review 
Panel were performed according to the regulations determined by the same 
committe, following the protocols stated in Bilkent University’s guidelines on the 
humane care and use of laboratory animals. All procedures complied with the 
guidelines of the Ministry of Agriculture (Official Gazette. No. 25464). BALB/c 
mice used were obtained from and maintained at Bilkent University Animal Housing 
Facility. 
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3.2 SOLUTIONS AND MEDIA 
 
3.2.1 Cell Culture Solutions 
Foetal Calf Serum (FCS) 
FCS that was stored in -20
o
C upon arrival was first thawed in water bath at 
37
o
C. When FCS was totally thawn, the water bath was adjusted to 56
o
C and the 
complement factors in FCS were inactivated by 45-60 minute incubation. The FCS is 
then filtered to remove the particulate material, aliquoted and stored at -20
o
C. 
 
Complete Media 
      Final Concentration  for 580 ml 
DMEM/RPMI/McCoy’s 5A    1 X   500 ml 
FCS       10%   58 ml 
NEAA       1%   5.8 ml 
P/S       1%   5.8 ml 
L-Glutamine      1%   5.8 ml 
 
SF-Media (Serum Free Media) 
      Final Concentration  for 515 ml 
DMEM/RPMI/McCoy’s 5A    1 X   500 ml 
NEAA       1%   5.2 ml 
P/S       1%   5.2 ml 
L-Glutamine      1%   5.2 ml 
 
P/S(-)-Media (Antibiotic Free Media) 
      Final Concentration  for 570 ml 
DMEM/RPMI/McCoy’s 5A    1 X   500 ml 
FCS       10%   57 ml 
NEAA       1%   5.7 ml 
L-Glutamine      1%   5.7 ml 
 
HAT-DMEM 
      Final Concentration  for 650 ml 
High Glucose DMEM    1 X   500 ml 
FCS       20%   130 ml 
NEAA       1%   6.5 ml 
P/S       1%   6.5 ml 
L-Glutamine      1%   6.5 ml 
50X HAT      1 X   13 ml 
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HT-DMEM 
      Final Concentration  for 650 ml 
High Glucose DMEM    1 X   500 ml 
FCS       20%   130 ml 
NEAA       1%   6.5 ml 
P/S       1%   6.5 ml 
L-Glutamine      1%   6.5 ml 
50X HT      1 X   13 ml 
 
Freezing Media 
      Final Concentration  for 10 ml 
Complete DMEM/RPMI/McCoy’s 5A  1 X   8 ml 
FCS       20%   1 ml 
DMSO      10%   1 ml 
 
Hybridoma Freezing Media 
      Final Concentration  for 10 ml 
FCS       90%   9 ml 
DMSO      10%   1 ml 
 
TNF-α Stock 
50 μg lyophilized TNF- (PeproTech, NJ, USA) with a specific activity of 2 x 
10
7
 Unit/mg was reconstituted in 500 μl filter-sterilized ddH2O to make a TNF-α 
stock of ~2000 Unit/µl. The stock was aliquoted and stored at -20oC. 
 
IgG1 Isotype Control Antibody Stock 
500 μg lyophilized IgG1 Isotype Control Antibody (R&D Systems, MN, USA) 
was reconstituted in 500 μl sterile PBS to make a IgG1 Isotype Control Antibody 
stock of 1 µg/µl. The stock was aliquoted and stored at -20oC. 
 
1000X BrdU Stock 
100 mg BrdU was reconstituted in 10 ml sterile PBS to make a BrdU stock of 
10 mg/ml. The stock was aliquoted and stored at -20
o
C. 
 
3.2.2 General Solutions 
1 M KCl 
   MWt    Final Concentration  for 100 ml 
KCl   74.55 g/mol   1 M   7.45 g  
dH2O           100 ml  
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1 M MgCl2 
   MWt    Final Concentration  for 100 ml 
MgCl26H2O  203.30 g/mol   1 M   20.3 g 
dH2O           100 ml  
 
10 N NaOH 
   MWt   Final Concentration  for 100 ml 
NaOH   40 g/mol  10 M   40 g   
dH2O          100 ml   
 
5 M NaCl  
   MWt   Final Concentration  for 250 ml 
NaCl   58.44 g/mol  1 M   73.05 g 
dH2O          250 ml   
 
10X PBS 
   MWt    Final Concentration  for 100 ml 
NaCl   58.44 g/mol  1.37 M   8 g  
KCl   74.55 g/mol  27 mM   0.2 g  
KH2PO4  136.09 g/mol  180 mM   0.24 g  
Na2HPO42H2O 177.96 g/mol  0.1 M    1.78 g 
dH2O           100 ml  
 pH of the 10X buffer was not adjusted (initially ~pH: 6.7).  
 When the buffer was diluted to 1X, the pH automatically became 7.4. 
 
PBS 
    for 1 L   
10X PBS Buffer  100 ml    
dH2O    900 ml 
 
PBS-T (0.5% Tween) 
    for 1 L   
PBS    1 L 
Tween-20   5 ml   
 
10X TBS (pH:8.0) 
   MWt    Final Concentration  for 100 ml 
Trisma-Base  121.14 g/mol  0.1 M    1.21 g 
NaCl   58.44 g/mol  1.5 M    8.76 g  
dH2O           80 ml  
pH was adjusted by concentrated HCl (37%) and 1 N HCl 
 Volume was adjusted with dH2O    100 ml 
 
TBS 
    for 1 L   
10X TBS   100 ml    
dH2O    900 ml 
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TBS-T (0.5% Tween) 
    for 1 L   
TBS    1 L 
Tween-20   5 ml   
 
1 M Tris-HCl 
   MWt   Final Concentration  for 100 ml 
Trisma-Base  121.14 g/mol  1 M   12.1 g  
dH2O          90 ml  
pH was adjusted by concentrated HCl (37%) and 1 N HCl 
 Volume was adjusted with dH2O   100 ml 
 
25 X Protease Inhibitor Cocktail (25 X PI) 
     Final Concentration  for 2 ml  
Protease Inhibitor Cocktail Tablet  25 X   1 tablet 
dH2O          2 ml   
 
1 N HCl 
    Final Concentration  for 10 ml  
dH2O         9.167 ml  
37%(w/w) HCl (12N)  1N   833 ml   
   Acid was added onto dH2O!  
 
0.5 M EDTA 
   MWt   Final Concentration  for 100 ml 
EDTA2H2O  372.24 g/mol  0.5 M   18.6 g  
dH2O          70 ml   
    
Note: EDTA is insoluble in water. dH2O was initially added only as much as 
70% of the solution volume (700 ml for a 1L solution). 10N NaOH was added with 
constant mixing until the pH was adjusted to 8.0. As the pH was close to pH:8.0, the 
insoluble EDTA dissolve, which decreased back the pH. 10N NaOH was continued 
to be added until all of the EDTA was dissolved and pH was 8.0. 
 Volume was adjusted with dH2O   100 ml 
 
2.5 M CaCl2 
   MWt   Final Concentration  for 50 ml 
CaCl22H2O  147 g/mol  2.5 M   18.375 g 
dH2O          50 ml   
 
TE 
     Final Concentration  for 100 ml 
1M Tris pH:8.0    10 mM  1 ml  
0.5 M EDTA (pH:8.0)   1 mM   200 µl   
dH2O          98.8 ml 
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0.5 M Pipes 
   MWt    Final Concentration  for 100 ml 
Pipes   302.36 g/mol               0.5 M   15.12 g 
dH2O           100 ml  
 
1 M MnCl2 
   MWt    Final Concentration  for 100 ml 
MnCl2   161,87 g/mol      1 M   16.2 g 
dH2O           100 ml  
 
1 M KOH 
   MWt   Final Concentration  for 100 ml 
KOH   56.11 g/mol  1 M   14 g   
dH2O          100 ml   
 
Na Azide (NaN3) 
   MWt   Final Concentration  for 10 ml 
Na Azide  g/mol   2% (w/v)  250 mg  
dH2O          10 ml   
 Note: NaN3 is extremely toxic and was weighed under laminar flow. 
 The working solution is 2/10.000 (used at 1/100 dilution). 
 
3.2.3 Cell Lysis Buffers 
RIPA Lysis Buffer 
    Final Concentration   for 1ml  
5M NaCl    150mM NaCl    30 ml   
1M Tris-Cl (pH: 7.4)  50 mM Tris-HCl (pH: 7.4)  50 ml   
0.5M EDTA   1 mM EDTA    2 ml   
Triton-X100   1% Triton-X100   10 ml   
10% Na-DOC   1% Na-DOC    100 ml   
10% SDS    0.1% SDS    10 ml   
25 X PI    1 X PI     40 ml   
dH2O         758 ml 
 
NP40 Lysis Buffer 
    Final Concentration   for 1ml  
5M NaCl    150mM NaCl    30 ml   
1M Tris-Cl (pH: 8)  50 mM Tris-HCl (pH: 8)  50 ml   
NP40    1% NP40    10 ml   
25 X PI    1 X PI     40 ml   
dH2O         870 ml 
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3.2.4 SDS-PAGE Solutions 
For SDS-PAGE, either commercial ready systems or conventional method was 
followed. When commercial systems were used, ready gels, buffers, running and 
transfer apparatus were purchased from Invitrogen (CA, USA). When the 
conventional method was used, conventional buffers listed below were utilised. 
 
3.2.4.1 Conventional SDS-PAGE Gel Buffers 
1 M Tris-HCl, pH: 6.8 
   MWt   Final Concentration  for 100 ml 
Trisma-Base  121.14 g/mol  1 M   12.1 g  
dH2O          90 ml  
(for Stacking Gel of the SDS-PAGE, pH was adjusted to 6.8) 
pH was adjusted by concentrated HCl (37%) and 1 N HCl 
 Volume was adjusted with dH2O   100 ml 
 
1.5 M Tris-HCl, pH: 8.8 
   MWt   Final Concentration  for 100 ml 
Trisma-Base  121.14 g/mol  1.5 M   18.1 g 
dH2O          90 ml  
(for Resolving Gel of the SDS-PAGE, pH was adjusted to 8.8) 
pH was adjusted by concentrated HCl (37%) and 1 N HCl 
 Volume was adjusted with dH2O   100 ml 
 
30% Acrylamide  (29% w/v Acrylamide, 1% w/v Bisacrylamide) 
     Final Concentration (w/v)  for 250 ml 
Acrylamide     29.2%    73 g 
N’-N’-Bis-methylene acrylamide  0.8%    2 g 
dH2O           200 ml  
 Volume was adjusted with dH2O    250 ml 
The solution was heated to 37
o
C to dissolve the chemicals. 
The solution was filtered and de-gased for ~20 min.  
The solution was cover with aliminum foil and stored at 4
o
C.  
 
10% SDS 
     Final Concentration (w/v)  for 250 ml 
SDS      10%    25 g 
dH2O          2 50 ml  
 
10% Ammonium Persulfate 
0.1 g APS was dissolved in 1 ml dH2O. (Prepared freshly prior to the experiment.) 
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Tris-Glycine SDS-PAGE Running Buffer (5X) 
   MWt         Final Concentrationof 5X for 250 ml 
Glycine  75.07 g/mol   1.25 M  23.75 g 
Trisma-Base  121.14 g/mol   125 mM  3.78 g 
SDS (from 10%)     0.5 %   12.5 ml 
dH2O           200 ml 
 Volume was adjusted with dH2O    250 ml 
Buffer was stored at 4
o
C.  
 
Tris-Glycine SDS-PAGE Transfer Buffer 5X 
   MWt         Final Concentrationof 5X for 250ml 
Glycine  75.07 g/mol   195 mM  3.6 g  
Trisma-Base  121.14 g/mol   240 mM  7.25 g  
SDS (from 10%)     0.185%  4.625 ml  
dH2O           225 ml  
 Volume was adjusted with dH2O    250 ml 
Buffer was stored at 4
o
C.  
When using, the buffer was diluted down to 1X with ddH2O 
and Methanol was added to a final concentration of 20%. 
 
5X SDS-PAGE Gel-Loading Buffer 
    Final Concentrationof 5X  for 10 ml  
1M Tris-HCl (pH. 6.8)  250 mM   2.5 ml 
Glycerol    50 % (v/v)   5 ml 
SDS     10% (w/v)   1 g 
1% BPB    0.1 % (w/v)   1 ml 
dH2O          1 ml 
-mercapto-ethanol (BME)  5% (w/v)   0.5 ml 
5X loading buffer was prepared without BME.  
BME was added just before using. 
 
3.2.5 Solutions for Staining the Proteins on SDS-Polyacrylamide Gels 
Coomassie Staining Solution 
        for 250 ml   
Coomassie Brilliant Blue G-250    25 mg    
95% Ethanol       12.5 ml   
Phosphoric Acid (85%)     25 ml    
dH2O         200 ml    
 Volume was adjusted with dH2O  250 ml 
The solution was filtered through Whatman No: 1.  
 
Coomassie Destaining Solution (Slow Destain) 
   Final Concentration   for 250 ml   
Methanol   20% (v/v)   50 ml    
Acetic Acid   7% (v/v)   17.5 ml  
dH2O         182.5 ml   
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3.2.6 Solutions for Staining Total Proteins on PVDF Membranes 
Ponceau-S Staining Solution 
Final Concentration  for 50 ml    
Acetic Acid (100%)  10% (v/v)  5 ml    
Ponceau-S   5 % (w/v)  2.5 g    
dH2O       45 ml 
 
Destaining after Ponceau-S staining was done simply washing with dH2O. 
 
3.2.7 Western Blotting Solutions 
Western Blocking Buffer (TBS-T 5% Milk) 
Final Concentration  for 10 ml   
TBS-T        10 ml   
Milk Powder (Marble)           5% (w/v)  0.5 g    
 
½ Blocking Buffer (TBS-T 2.5% Milk) 
Final Concentration  for 10 ml   
TBS-T        10 ml   
Milk Powder (Marble)         2.5% (w/v)  0.25 g 
 
3.2.8 ELISA Solutions 
0.1 M Sodium Bicarbonate (NaHCO3) 
              MWt  Final Conc.  for 100 ml 
Sodium Bicarbonate (Anhydrous) NaHCO3    84.01 g/mol      0.1 M      0.84 g 
dH2O                100 ml 
    
0.1 M Sodium Carbonate Na2CO3 
              MWt  Final Conc.  for 100 ml 
Sodium Carbonate (Anhydrous) Na2CO3   105.99 g/mol      0.1 M       0.53 g 
dH2O                100 ml 
 
Coating Buffer for ELISA (0.1M Sodium Bicarbonate Buffer, pH: 9.4) 
        for 100 ml 
0.1 M Sodium Bicarbonate (Anhydrous) NaHCO3  70 ml 
0.1 M Sodium Carbonate (Anhydrous) Na2CO3  30 ml 
 
ELISA Blocking Buffer (TBS-T 1% BSA) 
Final Concentration  for 10 ml   
TBS-T        10 ml   
BSA              1% (w/v)  0.1 g    
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PNPP (p-Nitrophenyl Phosphate Disodium) Substrate Solution 
One tablet of Sigma Fast
TM
 Tris-Buffer was dissolved in 20 ml dH2O. One 
tablet of Sigma Fast
TM
 PNPP was later dissolved in the prepared Tris buffer. PNPP 
solution was freshly prepared prior to the experiment. 
 
3.2.9 Immunofluorescence (IF) Solutions 
2% Paraformaldehyde (PFA) 
Final Concentration (w/v)  for 100 ml  
Paraformaldehyde          2 %   2 g    
PBS          100 ml 
The solution was mixed overnight on a heat block to dissolve the reagent. 
The solution was filtered, de-gased, aliquoted and stored at -20
o
C.  
 
Permeabilization Buffer 
Final Concentration (w/v)  for 100 ml  
Triton X-100           0.1 %   100 µl    
PBS         100 ml 
 
IF Blocking Buffer (PBS 10% FCS) 
Final Concentration (v/v)  for 10 ml  
Foetal Calf Serum (FCS)          10 %   1 ml 
PBS         9 ml 
 
3.2.10 Agarose Gel Electrophoresis Solutions 
50X TAE 
   MWt    Final Concentration  for 250 ml 
Trisma-Base  121.14 g/mol  2 M    60.5 g  
0.5 M EDTA pH:8.0    0.05 M   25 ml  
Glacial Acetic Acid        14.275 ml 
dH2O          211 ml  
 
6X Agarose Gel Loading Dye Solution 
     Final Concentration  for 25 ml 
1M Tris-HCl pH:7.6    10 mM  250 ml    
1% Bromophenol Blue   0.03% (w/v)  750 ml    
1% Xylene Cyanol FF   0.03% (w/v)  750 ml   
Glycerol     60%   15 ml    
0.5 M EDTA (pH:8.0)   60 mM  3 ml    
dH2O         5.25 ml  
BPB and Xylene Cyanol Stock solutions were prepared dissolving in dH2O 
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3.2.11 Bacterial Culture Media and Solutions 
LB (Luria-Bertani) Broth 
       for 250 ml 
Bacto-tryptone     2.5 g  
Yeast Extract      1.25 g 
NaCl       2.5 g   
dH2O       250 ml   
  pH was adjusted to 7.5 with 10 N NaOH.  
Volume was adjusted with dH2O  250 ml 
After preparation, LB Broth was autoclaved right away! 
 
2XTY Broth 
       for 250 ml 
Bacto-tryptone     4 g  
Yeast Extract      2.5 g 
NaCl       1.25 g   
dH2O       250 ml   
  pH was adjusted to 7.5 with 10 N NaOH.  
Volume was adjusted with dH2O  250 ml 
After preparation, 2XTY Broth was autoclaved right away! 
 
LB (Luria-Bertani) Agar 
       for 250 ml 
Bacto-tryptone     2.5 g   
Yeast Extract      1.25 g   
NaCl       2.5 g   
dH2O       225 ml  
Bactoagar      3.75 g   
  Before adding bactoagar, pH was adjusted to 7.5 with 10 N NaOH.  
After adjusting the pH, bactoagar was added, agar was melted into 
solution in the microwave 
Volume was adjusted with dH2O  250 ml 
After preparation, LB Agar was autoclaved right away! 
 
Ampicilline 1000X 
Ampicilline was dissolved in dH2O as 100 mg/ml stock solution. The solution 
was filter-sterilized and stored at -20
o
C in 500ml aliquots. 
 
Kanamycin 1000X 
Kanamycin was dissolved in dH2O as 25 mg/ml stock solution. The solution 
was filter-sterilized and stored at -20
o
C in 500ml aliquots. 
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Transformation Buffer (TB) 
     Final Concentration  for 100 ml 
0.5 M Pipes    10 mM Pipes   2 ml 
2.5 M CaCl2    15 mM   600 µl 
1 M KCl    250 mM   25 ml 
dH2O          63 ml 
1 M MnCl2    55 mM   5.5 ml 
Before adding MnCl2, pH was adjusted to 6.7 with 10 N KOH.  
Volume was adjusted with dH2O     100 ml 
The solution was filter sterilized and stored at 4
o
C. 
 
3.2.12 Sulforhodamine (SRB) Based Growth Assay Solutions 
100% Tricloroacetic Acid (TCA) 
    Final Concentration (w/v) for 100 ml  
Tricloroacetic Acid (TCA)   100%   100 g    
dH2O          100 ml 
The solution is aliquoted, covered with aluminium foil and stored at 4
o
C. 
Stock solution was diluted down to 10% with dH2O when to be used. 
Direct contact was avoided since TCA is extremely toxic. 
 
Sulforhodamine (SRB) Stain 
    Final Concentration (w/v) for 10 ml  
Sulforhodamine (SRB)   0.4%   0.04 g    
dH2O          10 ml 
The solution is freshly prepared before use and covered with aluminium foil. 
 
1% Acetic Acid 
    Final Concentration (v/v) for 100 ml  
Acetic Acid     1%   1 ml    
dH2O          99 ml 
 
10mM Tris Buffer (pH: 10.5) 
   MWt   Final Concentration  for 100 ml 
Trisma-Base  121.14 g/mol  10 mM  0.121 g  
dH2O          100 ml  
pH was 10.5 right away. 
The solution was kept at 4
o
C. 
 
3.2.13 Antibody Purification Buffers using Protein G Columns 
While purifying antibodies by FPLC method using Protein G columns, 20 mM 
phosphate buffer (pH: 7) is used as the binding buffer and 0.1 M Glycine-HCl (pH: 
3.7) is used as the elution buffer.  
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Phosphate Buffer will be prepared mixing Na-Phosphate Monobasic Buffer 
and Na-Phosphate Dibasic Buffer solutions in specific proportions (as indicated 
below) to obtain a solution with a given pH. 
 
200 mM Na-Phosphate Monobasic (NaH2PO4) Stock 
      MWt   Final Conc. for 250 ml 
Na-Phosphate Monobasic Monohydrate 138 g/mol 200 mM 6.90 g 
dH2O           250 ml  
 
200 mM Na-Phosphate Dibasic (Na2HPO4) Stock 
        MWt   Final Conc. for 250 ml 
Na-Phosphate Dibasic Dihydrate    177.96 g/mol 200 mM 8.90 g 
dH2O           250 ml  
 
Binding Buffer (20 mM Phosphate Buffer, pH: 7) 
        for 500 ml 
200 mM Na-Phosphate Monobasic (NaH2PO4)  19.5 ml 
200 mM Na-Phosphate Dibasic (Na2HPO4)   30.5 ml 
dH2O         450 ml  
 
Elution Buffer (0.1 M Glycine-HCl, pH: 2.7) 
MWt    Final Concentration  for 250 ml 
Glycine  75.07 g/mol             0.1 M   1.875 g 
dH2O           200 ml  
Continue adding HCl until the pH is 2.7 
Finally adjust the volume with dH2O   250 ml 
 
3.2.14 Flow Cytometry and Cell Cycle Analysis Buffers 
Flow Blocking Buffer 
    Final Concentration (w/v) for 100 ml  
BSA      1%   1 g 
NaN3      0.05%   0.05 g    
PBS         100 ml 
 
 
 
Propidium Iodide (PI) Staining Buffer 
Final Concentration (w/v)  for 5 ml 
1 mg/ml PI Stock    50 µg/ml   250 µl 
10 mg/ml RNaseA    0.1 mg/ml   50 µl 
Triton X-100     0.05%    25 µl    
PBS          4675 µl 
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3.2.15 SAβ-Gal Staining Solutions 
3.7 % Formaldehyde 
         Final Concentration (w/v) for 100 ml 
Concentrated Formaldehyde (37 %)   3.7 %   10 ml 
ddH2O          90 ml 
 
200 mM Citric Acid (Trisodium Salt) 
        MWt       Final Conc. for 100 ml 
Trisodium citrate•dihydrate  294.12 g/mol  0.2 M  5.88 g 
ddH2O          90 ml 
pH was adjusted to 6.0 by adding Citric Acid 
Finally adjust the volume with dH2O   100 ml 
  
1 M Phosphate Buffer (pH:6.0)  
        for 100 ml 
1 M Na-Phosphate Monobasic (NaH2PO4)   74.5 ml 
1 M Na-Phosphate Dibasic (Na2HPO4)   25.5 ml 
 
0.1 M K4Fe(CN)63H2O (Potassium Ferrocyanide) (Sigma P-9387) 
    MWt   Final Concentration  50 ml 
K4Fe(CN)63H2O  422.39 g/mol  0.1 M   2 g 
ddH2O          50 ml 
  The solution was light sensitive, and covered with aluminum foil. 
 
0.1 M K3Fe(CN)6 (Potassium ferricyanide) (Sigma P-8131) 
    MWt   Final Concentration  50 ml 
K3Fe(CN)6   329.25 g/mol  0.1 M   1.646 g 
ddH2O          50 ml 
  The solution was light sensitive, and covered with aluminum foil. 
 
100 mM X-gal (40 mg/ml) 
    MWt   Final Concentration  25 ml 
X-gal    408.64 g/mol  100 mM  1 g 
ddH2O          25 ml 
 The solution was covered with aluminum foil, aliquoted and kept at -20
o
C. 
 
Adriamycin (Doxorubicin HCl) Stock (1 mg/ml) 
    MWt   Final Concentration  100 ml 
Adriamycin   580 g/mol  1 mg/ml  0.1 g 
ddH2O          100 ml 
 The solution was covered with aluminum foil, aliquoted and kept at -20
o
C. 
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Camptothecin Stock (20 mM) 
    MWt   Final Concentration  20 ml 
Camptothecin      348.35 g/mol  20 mM  0.139 g 
DMSO        20 ml 
 The solution was covered with aluminum foil, aliquoted and kept at -20
o
C. 
 
SAβ-gal Staining Solution 
      Final Concentration  for 20 ml 
200 mM Trisodium Citric Acid pH:6.0   40 mM  4 ml 
1M Phosphate Buffer pH:6.0    200 mM  4 ml 
100 mM Potassium Ferricyanide   5 mM   1 ml 
100 mM Potassium Ferrocyanide   5 mM   1 ml 
5M NaCl      150 mM  600 μl 
1M MgCl2      2 mM   40 μl 
40 mg/ml X-gal     1 mg / ml  0.5 ml 
dH2O           8.86 ml 
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3.3 METHODS 
 
3.3.1 Cell Culture 
SK-BR-3 cells were grown in McCoy’s 5A medium. MDA-MB-361, T47D, 
MCF-7, BT-474 and Huh-7 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM). SP2/0 mouse myeloma cells were grown in DMEM, and generated 
hybridoma lines were grown in RPMI 1640, DMEM or Serum Free Media (SFM). 
Unless otherwise stated, all cell culture media was supplemented with 10% foetal 
calf serum (FCS), 1% penicillin/streptomycin (P/S), 1% non-essential amino acids 
and 1% L-glutamine. BT-474 cell growth medium was supplemented additionally 
with 10 µg/ml insulin. All cell lines were cultured as monolayers in humidified CO2 
incubators at 37
o
C. 
 
3.3.1.1 Thawing Cell Lines 
1. Cryotubes full of cell culture stocks were taken from liquid nitrogen tank and 
processed immediately. 
2. The cells were rapidly thawn at 37oC (either by hand or in water bath). 
3. The contents of each vial was aspirated by a 5 ml serological pipette and 
dispensed into a 15 ml falcon tube containing 10 ml fresh complete DMEM. 
4. The falcon tube was inverted immediately to dilute the DMSO in the freezing 
medim and centrifuged at 1000 rpm for 5 minutes. 
5. The supernatant was aspirated and the tube was flicked to resuspend the cell 
pellet. 
6. The cells were resuspended with 10 ml of “Thawing Media” and seeded on fresh 
100 mm tissue culture dishes (alternatively, resuspended with 13 ml media and 
plated on fresh 75 mm culture flasks) 
7. The plate (or the flask) was placed inside a CO2 incubator at 37
o
C and kept overnight. 
8. When the thawn cells attach the plate surface properly (~24 to 48 hours later depending 
on the cell type), the cell media is aspirated and replaced with fresh complete media. 
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3.3.1.2 Expansion of Adherent Cell Lines 
1. Cells attached to the 100 mm plate (or 75 mm flask) surface were grown until 
80% confluency inside a CO2 incubator at 37
o
C. 
2. When the cells reached 80% confluency (still at the logarithmic phase), the 
medium was aspirated and the cells were washed with 5 to 10 ml sterile PBS. 
3. PBS was aspirated thoroughly and 0.5 to 1 ml of trypsin was dispensed onto the 
plate surface and allowed to cover the total surface by tilting the plate. 
4. Plate is placed back inside the incubator and kept 3 to 5 minutes until the cells 
are detached (cell detachment was inspected with an inverted microscope.) 
5. When all the cells were detached from the plate and from each other, trypsin was 
inactivated by adding 10 ml fresh complete media. The suspension was thoroughly 
pipette back and forth to prevent cell clumps. 
6. The suspension was placed in a 15 ml falcon tube and centrifuged at 1000 rpm 
for 5 minutes. The supernatant was aspirated and cells were resuspended by flicking.  
7. The cells were resuspended in 10 ml fresh complete media and splitted 1/4 to 
1/10 depending on the cell type. The volume is brought up to 10 ml with fresh 
complete media and cells were seeded on a new tissue culture plate. Flasks with 
newly splitted cells were placed back in CO2 incubator at 37
o
C. 
8. Medium of the cells was renewed every 2 to 3 days until they were ready for next 
round of splitting (old medium was aspirated and fresh complete media was 
dispensed). 
 
3.3.1.3 Expansion of Suspension Cell Lines 
1. Suspension cultures were grown in upright flasks. Generally, the cells were 
grown in 15 to 25 ml complete media in 75 mm flasks. 
2. To check the health and confluency of suspension cells, the flasks were bent 
down. When the cells settled on the bottom of the flask, they were inspected with an 
inverted microscope. Healthy suspension cell cultures would appear round and shiny.  
3. When it was not able to distinguish individual cells in the crowd, the cells were 
splitted. Alternatively, the cells were splitted when their media started to turn yellow 
(when they were still at the logarithmic phase). 
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4. The flask was placed upright and the cells were resuspended in the solution by 
pipetting the cells up and down. When the suspension became homogeneous, the 
cells were aspirated leaving 1/5 to 1/10 of the cell suspension in the flask. 
5. The volume was completed upto 15 to 25 ml by adding fresh complete media and 
the flask was placed back in CO2 incubator at 37
o
C. 
 
3.3.1.4 Freezing Cell Lines 
1. When the cells reached highest confluency at their logarithmic phase, they were 
collected in 15 ml falcon tubes. In order to collect adherent cells, they were 
trypsinized as explained above.  Suspension cells were collected directly. 
2. The cells were centrifuged at 1000 rpm for 5 minutes, the supernatant was 
aspirated and the cells were resuspended by gentle flicking.  
3. The cells were resuspended in freezing media (the volume of the freezing media 
was strictly dependent on the cell type and confluency. While 5 ml was adequate for  
80% confluent Huh-7 cells grown on 75 mm flask, 3 ml was enough for SK-BR-3 
cells), aliquoted into previously labelled cryotubes and immediately placed at -20
o
C. 
4. After 1 to 2 hour incubation at -20oC, the cryotubes were placed at -80oC. 
5. After overnight incubation at -80oC, the cryotubes were transferred to liquid 
nitrogen tanks for longer storage. 
 
3.3.1.5 Transient Transfection of Huh-7 Cells 
Cell Seeding (Day 0) 
1. 3 x 105 cell/ml Huh-7 cell suspension was prepared in P/S(-) DMEM and 2 ml 
was seeded on each well in 6-well tissue culture plates. Plates were incubated 
overnight at 37oC in CO2 incubator for cell attachment. 
 
Transfection (Day 1) 
1. The next morning, the medium in all wells was aspirated and replaced with 2 ml 
OPTIMEM medium (Invitrogen/GIBCO, CA, USA). (It was essential to avoid serum 
and antibiotics); the plates were transferred back to the incubator. 
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2. In the mean time, DNA and Lipofectamine 2000 (Invitrogen/GIBCO, CA, USA) 
was prepared in OPTIMEM medium as follows: 
a) 5 µg DNA was diluted in 250 µl OPTIMEM medium in 1.5 ml tube. 
b) Tube b: 10 µl Lipofectamine 2000 was diluted in 250 µl OPTIMEM 
medium in 1.5 ml tube. 
3. Diluted Lipofectamine 2000 in 250 µl OPTIMEM medium was added onto the 
diluted DNA in 250 µl OPTIMEM medium, mixed by very gentle vortexing and 
incubated for 20 minuteas at RT to allow the formation of DNA-Lipofectamine 2000 
complex. 
4. Plates were taken from the incubator and 500 µl DNA-Lipofectamine 2000 
complex was added directly to each well drop by drop. The solution was mixed by 
gently shaking the plates, as if drawing “8” with the plates on the bench surface. 
5. The plates were placed back in the incubator and incubated at 37oC for 8 hours. 
6. 8 hours after the addition of transfection reagents, each well was aspirated, 
washed once with PBS and cells were fed with fresh complete DMEM. The plates 
were placed back in the incubator and incubated overnight at 37oC 
 
Day 2 
1. The next morning, media in all wells were aspirated, the wells were washed once 
with PBS and the cells were trypsinized.  
2. Trypsinized cells were seeded  as follows: 
a) Cells whose proteins would be collected and used for 
immunoprecipitation experiments were seeded on 100 mm culture dishes 
and grown at 37oC in CO2 incubator for 2 to 3 days until they reached ~80% 
confluency. Upon reaching ~80% confluency, the cells were scraped and 
lysed as explained in 3.3.6. 
b) Cells that would be used for immunofluorescence experiments were 
seeded on sterile coverslips placed in 6-well dishes. Each transfectant was 
seeded on 8 wells and grown at 37oC in CO2 incubator for 2 to 3 days until 
they reached ~80 % confluency.  
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3.3.2 Generation of anti-ERBB2 Monoclonal Antibodies 
Anti-ERBB2 monoclonal antibodies were prepared as described previously 
[290]. The detailed protocol is explained below. 
3.3.2.1 Immunization of BALB/c mice against human ERBB2 
1. 5-10x106 pathogen-free SK-BR-3 cells were washed three times with SF-DMEM 
and finally resuspended in 125 µl PBS. 
2. Complete Freund’s Adjuvant (CFA) solution was resuspended completely. 
3. 125 µl cell suspension was mixed with 125 µl homogenous CFA and the mixture 
was drawn up into a sterile 1 ml syringe. (Since the antigen was a cell-surface 
protein, extreme care was taken not to lyse the SK-BR-3 cells during the process.) 
4. CFA/cell emulsion was injected intraperitoneally to five BALB/c mice. 
5. BALB/c mice were re-immunized at three-week intervals by intraperitoneal 
injection of live SK-BR-3 cells mixed 1:1 with Incomplete Freund’s Adjuvant (IFA). 
6. In the following week after each booster injection, blood was collected from a 
tail bleed of all immunized animals and the sera were screened by ELISA for the 
presence of anti-ERBB2 antibodies. 
7.  After the fourth booster immunization, the last immunization was performed 
with recombinant human ERBB2 ECD/Fc fusion protein (R&D Systems, MN, USA). 
For the final immunization, 20 µg recombinant human ERBB2 ECD/Fc fusion 
protein resuspended in 125 µl PBS was mixed with 125 µl IFA and injected 
intraperitoneally to each BALB/c mice. 
8. On the third day of last immunization, mice were sacrificed by cervical 
dislocation (anaestatics were avoided) and their spleens were harvested and placed in 
50 ml sterile falcon tubes with SF-DMEM. 
3.3.2.2 Harvesting splenocytes and preparation of cells 
Preparation of SP2/0 Myeloma Cells 
1. At least one week prior to fusion, SP2/0 cells were started to be expanded. 
2. One day before the fusion, SP2/0 cells were splitted into fresh complete DMEM. 
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Preparation of Feeder Layer 
1. One day prior to fusion, a spleen from an un-immunized mice was harvested, 
brought to tissue culture facility and processed under aseptic conditions (in biological 
safety cabinet) hereafter. 
2.  The spleen was transfered to a 100 mm petri dish with 10 ml SF-DMEM and 
teased into single cell suspension by chopping with and squeezing between two 
sterile needles. 
3. Dissociated splenocytes were transferred to 50 ml falcon tubes filled with SF-
DMEM and centrifuged at 1500 rpm for 5 minutes. 
4. The supernatant was aspirated, the cell pellet was resuspended initially by gentle 
flicking and the tube was topped up with SF-DMEM to re-wash the splenocytes. 
5. Cell suspension was centrifuged at 1500 rpm for 5 minutes, the supernatant was 
aspirated and the cell pellet was resuspended in 100 ml HAT-DMEM. 
6. Cell suspension was gently aspirated by 10 ml pipette and 2 drops (~100 µl) cell 
suspension is dispensed to each well of a 96-well flat-bottom plate. 
7. Plates with the feeder layer cells were placed inside a CO2 incubator at 37
o
C. 
 
Preparation of Splenocytes from Immunized Mice 
1. On the day of fusion, spleens from immunized mice were harvested; the 
splenocytes were dissociated and washed as explained above. 
2. After the second wash with SF-DMEM, the cell suspension was centrifuged at 
1500 rpm for 5 minutes, the supernatant was aspirated, the cell pellet was 
resuspended in SF-DMEM and the cells were counted. 
 
3.3.2.3 Preparation of Hybridoma Clones and Subcloning 
Fusion of Splenocytes and SP2/0 Myeloma Cells 
1. SF-DMEM, HAT-DMEM and PEG were prewarmed in a 37oC water bath. 2 
beakers were prepared containing ~100-200 ml H2O at 37
o
C (to be used as a water 
bath in the laminar flow during the next steps. 
2. Cultured SP2/0 cells were washed twice with SF-DMEM, resuspended in SF-
DMEM and counted. 
3. SP2/0 cells and splenocytes were combined in 4:1 ratio.  
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4. The SP2/0 – splenocyte cell mixture was washed once with SF-DMEM. The cells 
were centrifuged at 1500 rpm for 5 minutes, the supernatant was aspirated well and 
the cell pellet was resuspended by gentle flicking. 
 Note: Proteins and HEPES were avoided since PEG would precipitate the 
proteins and HEPES could be toxic during cell fusion. 
5. Water bath beakers were placed inside the laminar flow. Falcon tubes having SF-
DMEM and PEG were placed in one the beakers. 
6. The falcon tube with the cells was gently flicked again to prevent cell pellet 
chunks and placed in the other water bath beaker. 
7. Drop-by-drop, 1 ml prewarmed PEG was added on to the mixed cell suspension 
(with a rate of ~1 ml/min). Cells were occasionally stirred by the pipette tip very 
gently. Finally, the cells were stirred for an additional minute. 
 Note: Since the cells were extremely gentle during fusion, they were never 
pipetted. 
8. Drop-by-drop, 1 ml prewarmed SF-DMEM was added on to the PEGylated cell 
suspension (with a rate of ~1 ml/min). Cells were occasionally stirred by the pipette 
tip very gently. The step was repeated with an additional ml of prewarmed HAT-
DMEM. 
9. Additional 10 ml prewarmed SF-DMEM was added on to the cell suspension 
over 2-3 minutes with occasional stirring. 
10. The cells were centrifuged at 1500 rpm for 5 minutes, the supernatant was 
aspirated and the cell pellet was resuspended initially by gentle flicking. 
11. 10 ml HAT-DMEM was forcefully discharged onto the cells to disrupt the cell 
pellets. Cell clumps were allowed to settle down and disrupted with pipette tip. 
12. The cells were resuspended in total ~100 ml prewarmed HAT-DMEM and 
aliquoted (~100 µl /well) onto 96-well plates with feeder layer.  
13. In order to feed the cells, in every 2 to 3 days, ~100 µl of media was aspirated 
above each well and 2 drops (~100 µl) of fresh HAT-DMEM was dispensed. 
14. Around 14th day, aminopterin should have killed all unfused SP2/0 cells, 
therefore feeding medium was changed to HT-DMEM. 
15. After three rounds of feeding with HT-DMEM, the aminopterin left in the wells 
would be diluted out, therefore feeding was carried out with complete DMEM. 
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16. The supernatant of the hybridomas were screened by ELISA when most of the 
wells with growing cells reach upto ~25% confluency (their media turned yellow 
within 2 days after re-feeding). 
17. 100 µl supernatant were collected from each well to be screened by ELISA and 
the wells were topped up with fresh complete DMEM. 
18. Hybridoma clones were screened by ELISA and positive clones were splitted to 
fresh plates and expanded. Half of the cells in each clone were frozen Hybridoma 
Freezing Media. The other half was subcloned. 
 
ELISA Screening of Hybridoma Clones 
ELISA assay which is comprehensively explained in 3.3.3 was utilized to 
screen hybridoma clones that produce antibodies against extracellular domain of 
human ERBB2 protein. Briefly, 96-well polysorb microtiter plates were coated 
overnight at 4
o
C with recombinant human ERBB2 ECD antigen (~50 ng/well). 100 
µl of each hybridoma supernatant was applied onto separate wells as the primary 
antibody and incubated for 1 to 2 hours at 37
o
C. Wells were further incubated with 
1/1000 diluted AP-conjugated anti-mouse IgG antibodies for one hour at 37
o
C to 
detect bound antibodies. 
 
Subcloning Hybridoma Cells for Establishing Monoclonal Cell Lines 
The ELISA positive hybridoma clones were subjected to subcloning by 
limiting dilution. In order to provide the necessary growth factors, the hybridoma 
cells were subcloned on a feeder layer. 
1. One day prior to subcloning, the feeder layer was prepared as explained above. 
(additionally, conditioned supernatant from SP2/0 cell cultures grown in complete 
DMEM could be filtered and used instead of feeder layer) 
2. Each selected hybridoma clone that has been expanded privously was collected 
and washed once with complete DMEM. The cell pellet was resuspended in fresh 
complete DMEM and cells were counted. 
3. The hybridoma cells were diluted in complete DMEM in order to give one cell 
per 100 µl and the cells were stirred thoroughly to make a homogenous suspension. 
4. 100 µl of cell suspension was seeded onto each well containing feeder layer. 
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5. Before feeding, the monoclonal wells were noted, to avoid picking polyclonal 
cell populations. When the media of the wells containing growing cells started to 
turn yellow, the monoclonality of the wells was inspected with an inverted 
microscope.  
6. Monoclonal wells were feeded every 2 to 3 days with freash complete DMEM. 
7.  When the wells were confluent enough, the sublones were ELISA screened. 
8. ELISA positive clones were further propagated and cell stocks were prepared. 
 
3.3.3 Indirect ELISA 
1. Antigen was diluted in “Coating Buffer” to make 250-500 ng/ml solution and 
100 ml solution was aliquoted into each well of Nunc Polysorb ELISA plate.  
2. Plate was covered with parafilm and incubated overnight at 4°C. 
3. The wells were emptied by finally tapping the plate onto paper towel. 
4. Each well was washed 3 times with 250 μl TBS. 
5. The wells were emptied by finally tapping the plate onto paper towel. 
6. 100 μl “ELISA Blocking Buffer” was added onto each well, plate was covered 
with parafilm and incubated 1 hour at 37°C. 
7. The wells were emptied and washed three times with 250 μl TBS-T. 
8. Primary antibody was either applied directly (i. e. hybridoma supernatant), or 
was diluted in TBS (i.e. concentrated pure antibody) and 100 μl antibody solution 
was added onto the each well. The plate was covered and incubated 1-4 hour at 37°C. 
9. The wells were emptied and washed four times with 250 μl TBS-T. 
10. AP-conjugated secondary antibody was diluted 1/1000 in TBS and 100 μl 
antibody solution was added onto the each well. The plate was covered and 
incubated 1 hour at 37°C. 
11. The wells were emptied and washed six times with 250 μl TBS-T. 
12. 100 μl “PNPP Substrate Solution” was added onto each well. The plate was 
covered and incubated ~30 min (or until color development is sufficiently) at RT. 
13. The signal intensity at 405 nm was measured using BioTek mQuant Elisa Reader.  
 
68 
 
3.3.4 Antibody Isotyping and Purification of anti-ERBB2 Antibodies 
Hybridoma cell cultures secrete monoclonal antibodies into the culture media. 
This culture media which contain 1 to 50 µg secreted antibody per ml can be 
collected and used for antibody purification. Alternatively, hybridoma cultures can 
be used for production of ascites in mice which contain antibodies at much higher 
concentrations (1 to 5 mg of secreted antibody per ml). Since 1 ml ascites can yield 
upto 5000 times more concentrated antibodies than ordinary hybridoma culture 
supernatants, ascites are commonly preferred when higher amounts of antibodies are 
needed to be produced. On the other hand, when grown in special serum free media, 
hybridoma supernatants are devoid of any contaminating immunoglobulins which 
may be present in ascites solutions. 
 
3.3.4.1 Collecting Antibodies from Hybridoma Supernatants 
1. Hybridoma cell cultures that were grown initially in Complete DMEM were 
adapted to Serum Free Media (SFM) through multiple dilution steps. 
a) Initially they were transferred to SFM containing 10% FCS (SFM10). 
b) When they grow in SFM10 enough to be splitted, they were transferred 
into SFM containing 5 % FCS (SFM5) 
c) Next they were splitted into SFM containing 2.5 % FCS (SFM2.5) 
d) This dilution was continued until the cells grew healthy in SFM 
containing 0.3% FCS. Antibody production efficiency of SFM adapted 
hybridoma cultures were monitored by ELISA assay. 
2. Hybridoma cells were grown for 5 to 7 days densely without renewing the media. 
3. When the culture media became highly acidic (yellow), the media was culture 
media was collected and centrifuged at 1500 rpm for 10 minutes. 
4. The supernatant was transferred into fresh 50 ml falcon tubes and pH was 
neutralized by adding 1 M Tris solution at pH:8. 
5. Neutralized supernatants were stored at -20oC. 
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3.3.4.2 Preparation and Collection of Ascites from Mice 
1. 6 to 11 weeks old five BALB/c mice were initially primed by intraperitoneal 
injection of 250 µl IFA. 
2. 7 days after IFA injection, 5 x 106 hybridoma cells resuspended in 250 µl PBS 
were injected to each mouse intraperitoneally. 
3. Abdominal distention of each mouse was monitored every other day. When 
ascetic fluid volume increased to a level that would discomfort and impair movement 
of mice (at days 7 to 15 depending on the mouse), they were anesthetized and the 
ascites was harvested using 20 gauge needle. 
4. Warm saline was injected intraperitoneally at a volume equal to the harvested 
ascites in order to prevent hypovolemic shock. The mice were transferred back to 
their cages and the tap date was recorded on the cage cards. 
5. Mice were monitored for few more weeks and tapped twice more, last one being 
performed after euthanasia (by servical dislocation). 
6. The collected ascites was incubated 30 to 60 minutes in a water bath at 37oC and 
centrifuged at 2500 rpm for 5 minutes at 4
o
C. 
7. Serum supernatant was transferred to 1.5 ml tubes and centrifuged at 13,000 rpm 
for 5 minutes at 4
o
C to remove fat. 
8. The supernatant was was transferred to fresh 1.5 ml tubes and stored at -20oC. 
 
3.3.4.3 Isotyping of Monocolonal Antibodies 
ProteinA and ProteinG beads have different affinities for different mouse 
immunoglobulin isotypes. In order to use the purification system with highest 
affinity, the isotype of each of the antibody clone was determined by an ELISA 
based method using a commercial Monoclonal Antibody Isotyping Kit (Thermo 
Thermo Fisher Scientific Inc., IL, USA) according to the protocol provided by the 
manufacturer. 
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3.3.4.4 Purification of Monoclonal Antibodies by FPLC using ProteinG 
Columns 
All of the samples and buffers including ddH2O and 20% ethanol were filtered 
and degassed before applying on to instrument in order to prevent system clogging 
and introduction of bubbles. 
 
1. In order to protect the ÄKTAexplorer™ FPLC instrument, initially a pressure 
alarm of 0.6MPa was set up. 
2. 5 ml Hi-Trap Protein G HP column was connected to the system and the system 
was washed first with 20% ethanol, then with ddH2O (10 column volume each). 
3. Instrument probes were transferred into solution bottles that would be used 
during purification. Probe A was placed in Binding Buffer (20 mM Phosphate, pH:7) 
and Probe B was placed in Elution Buffer (0.1 M Glycine-HCl, pH:2.7). Tubing 
system was washed with these buffers using “Pump Wash Basic” comment. 
4. The column was equilibriated with at least 10 column volumes of Binding 
Buffer. 
5. In the mean time, the filtered sample was loaded into the superloop while the 
valves were in “LOAD” position. 
6. The valves were transferred into “INJECT” position and the sample stored in the 
superloop was injected onto the column. Flow Through containing the sample 
unbound to the column was collected in 15 ml falcon tubes at the fraction collector. 
7. The column was washed with 5 column volumes of Binding Buffer to remove the 
unbound proteins. 
8. Bound antibodies were eluted with 5 to 10 column volumes of Elution Buffer and 
the eluates were collected in 5 ml falcon tubes. 
9. Antibodies eluted in Elution Buffer were immediately neutralized by addition of 
1 M Tris Buffer, pH:9 (1 ml Tris buffer was added per 5 ml eluate). 
10. All the elution tubes containing antibodies were pooled and concentrated using 
Amicon Ultra-15 Ultracel-10k concentrators as follows: 
a) Antibody eluates were loaded onto concentrators and centrifuged at 2500 
g (~3200 rpm) at 4
o
C until the volume above the concentrator filter was 
decreased down to ~1.5 ml. 
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b) Eluted buffer at the bottom of the concentrator tube was discarded and 
~10 ml sterile cold PBS was added onto the concentrated antibody 
solution; the tube content was mixed and centrifuged at 2500 g (~3200 
rpm) at 4
o
C until the volume above the concentrator filter was decreased 
down to ~1.5 ml. 
c) PBS collected at the bottom of the concentrator tube was discarded and 
buffer exchange was repeated once more with ~10 ml sterile cold PBS. 
d) The tube was centrifuged at 2500 g (~3200 rpm) at 4oC until the volume 
above the concentrator filter was decreased down to ~1 ml. 
11. The antibody concentration of the solution was measured on nanodrop at 280 nm. 
(5 volume Elution Buffer was mixed with 1 volume 1 M Tris pH:9 and used as 
blank) 
12. The concentrated antibody solution was transferred into fresh 0.5 ml tubes and 
stored at -20
o
C as 50 µl aliquotes. 
 
 
3.3.5 Cloning ERBB2-deletion Constructs 
3.3.5.1 Preparation of ERBB2-deletion Constructs 
Human ERBB2 constructs containing various combinations of the extracellular 
subdomains I – IV were created using the human ERBB2 full length construct 
OCABo5050G0219D-pDEST26 purchased from Source BioScience LifeSciences 
(Nottingham, UK) (will be mentioned as p219-D hereafter). p219-D is a pDEST26 
based vector where human ERBB2 cDNA was cloned 3-terminal to a 6-His tag 
between attB1 and attB2 TOPO-cloning sites. 
Initially, the total extracellular ERBB2 region was excised from p219-D and 
two additional cloning sites (NotI and XhoI sites) were introduced between the signal 
peptide and transmembrane (TM) domain (Figure 3.1). A nucleotide was added 
before the NotI site in order to prevent frameshift, and six additional nucleotides 
(corresponding to amino acids Val and Leu) were inserted between the NotI and 
XhoI sites in order to enable enough space for restriction enzyme binding during 
double digestion. This new plasmid was named pCC2001 and used as a backbone to 
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insert various extracellular ERBB2 subdomains amplified by PCR. Insertion of PCR-
amplified extracellular subdomain I into pCC2001 and generation of pCC2002 is 
demonstrated on Figure 3.2 as an example. Details on fragment preparation for other 
ERBB2 constructs can be seen on Table 3.6, Table 3.7 and Table 3.8 which provide 
information about the oligos used, fragments produced and plasmids constructed 
respectively. All plasmids were sequence verified using oligonucleotides listed on 
Table 3.9 as schematized on Figure 3.3. Both of the template plasmids (p219-D and 
pCC2001) were extensively sequenced. Since plamids pCC2002 to pCC2014 were 
produced by insertion of the PCR amplified extracellular subdomains into the 
sequence verified pCC2001, only the newly inserted extracellular ERBB2 regions 
and the transmembrane domain (TM) of pCC2002 to pCC2014 were sequenced 
(starting prior to first ATG, to the end of transmembrane domain, covering all the 
restriction sites used for each cloning). 
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Figure 3.1 Cloning of pCC2001. Through SacI-EcoRI digestion of p219-D, the 
backbone fragment FragCC2003 was prepared. 6xHis tag and the N-terminal 22 amino acids 
of the human ERBB2 cDNA forming the signal peptide (6H+SP) were amplified using PCR 
primers oligoCC2001 and oligoCC2002; producing the FragCC2001 with an inserted NotI 
restriction site at the 3’ end. Region between the 647th (beginning of TM) and 976th (EcoRI 
site inside TK) amino acids of the human ERBB2 cDNA was amplified using PCR primers 
oligoCC2003 and oligoCC2004; producing the FragCC2002 with an inserted NotI and XhoI 
restriction site at the 5’ end. The boxes named as I, II, III, IV represent four subdomains of 
ECD. 6H+SP: 6xHis tag and signal peptide domain, TM: transmembrane domain, TK: 
tyrosine kinase domain, 1255: last amino acid on human ERBB2 cDNA. 
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Figure 3.2 Cloning of pCC2002. Through NotI-XhoI digestion of pCC2001, the 
backbone fragment FragCC2004 was prepared. Extracellular subdomain I located between 
the 23
rd
 and 162
nd
 amino acids of the human ERBB2 cDNA was amplified using PCR 
primers oligoCC2005 and oligoCC2006; producing the FragCC2005 with inserted NotI and 
XhoI restriction site at the 5’ and 3’ ends respectively. The boxes named as I, II, III, IV 
represent four subdomains of ECD. 6H+SP: 6xHis tag and signal peptide domain, TM: 
transmembrane domain, TK: tyrosine kinase domain, 1255: last amino acid on human 
ERBB2 cDNA. 
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F/R Product
oligoCC2001 5'-AGCAGAGCTCGTTTAGTGAACC-3' 22 bp F FragCC2001 514(SacI)-535
oligoCC2002 5'-GCGGCCGCTGCTCGCGGCTCCGGGG-3' 25 bp R FragCC2001 (6xHis+SP)763-778+N+NotI
oligoCC2003 5'-TTGCGGCCGCGTATTACTCGAGAGAGCCAGCCCTC-3' 35 bp F FragCC2002 NotI +Val+Leu+ XhoI+2651-2663(TM)
oligoCC2004 5'-CGGGAGAATTCAGACACCAACTCC-3' 24 bp R FragCC2002 (TK)3622-(EcoRI)3645
F FragCC2005
F FragCC2009
F FragCC2012
F FragCC2016
F FragCC2019
oligoCC2006 5'-TTCTCGAGGAGCTGGGGGTTCCGCT-3' 25 bp R FragCC2005 (Subdomain I)1179-1195+XhoI+N+N
F FragCC2006
F FragCC2010
F FragCC2015
F FragCC2017
5'-CGCTCGAGAAAGATCTTCTTGCAGCC-3' R FragCC2006
R FragCC2009
F FragCC2007
F FragCC2011
R FragCC2007
R FragCC2010
R FragCC2013
R FragCC2016
oligoCC2011 5'-TTGCGGCCGCTGCTTCGTGCACACGG-3' 26 bp F FragCC2008 N+N+NotI+2135-2150(Subdomain IV)
R FragCC2008
R FragCC2011
R FragCC2014
R FragCC2017
R FragCC2018
oligoCC2013 5'-TTACTAGTGAGCTGGGGGTTCCGCT-3' 25 bp R FragCC2012 (Subdomain I)1179-1195+SpeI+N+N
F FragCC2013
F FragCC2018
oligoCC2015 5'-TTACTAGTTGCTTCGTGCACACGG-3' 24 bp F FragCC2014 N+N+SpeI+2135-2150(Subdomain IV)
R FragCC2015
R FragCC2019
N+N+NotI+1826-1843(Subdomain III)5'-TTGCGGCCGCGGGAGCCTGGCATTTCTG-3'
(Subdomain II)1808-1825+XhoI+N+N
N+N+NotI+ 1196-1212(Subdomain II)
N+N+NotI+779-796(Subdomain I)28 bp
27 bp
26 bp
28 bp
5'-TTCTCGAGGAGGTGGGTGTTATGGAGG-3'
5'-TTCTCGAGCTGCTCGGCGGGGCAG-3'
5'-TTACTAGTGGGAGCCTGGCATTTCTG-3'
5'-CGACTAGTAAAGATCTTCTTGCAGCC-3' (Subdomain II)1808-1825+SpeI+N+N
N+N+SpeI+1826-1843(Subdomain III)
(Subdomain IV)2635-2650+XhoI+N+N
(Subdomain III)2116-2134+XhoI+N+N
26 bp
26 bp
24 bp
27 bp
oligoCC2009
oligoCC2014
oligoCC2016
oligoCC2012
oligoCC2010
oligoCC2005 5'-AAGCGGCCGCACCCAAGTGTGCACCGGC-3'
5'-TTGCGGCCGCTGCTACCAGGACACGAT-3'oligoCC2007
oligoCC2008
Aim
Oligo Sequence Size Location on p219-D
 
Table 3.6 Oligonucleotide primers used during cloning of ERBB2 constructs. 
Sequence and size of each primer are shown on “Sequence” and “Size” columns. 
Highlighted sequences in color denote the introduced restriction sites (red: NotI, blue: XhoI, 
green: SpeI). The orientation (F/R) and amplification aims of each designed primer are 
shown on the “Aim” column.  Location of each primer on the template plasmid p219-D is 
shown on the “Location” column. Location of each primer on the human ERBB2 cDNA is 
highlighted and shown in brackets; the numbers indicate the complementary nucleotides on 
the template plasmid p219-D. NotI (red), XhoI (blue) and SpeI (green) sites introduced next 
to the complementary sequences are shown. SacI and EcoRI sites that were already present 
on the complementary plasmid sequence were shown in brackets and highlighted in pink. Six 
additional nucleotides (corresponding to amino acids Val and Leu) were inserted between 
the NotI and XhoI sites on oligo2003. F: forward, R: reverse, N: random nucleotide. 
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Method by template
FragCC2001 PCR oligoCC2001-CC2002 p219-D 259 bp SacI-6xHis-SP-NotI
FragCC2002 PCR oligoCC2003-CC2004 p219-D 1003 bp NotI-XhoI-TM-TK-EcoRI
FragCC2003 digestion SacI-EcoRI p219-D 6508 bp SacI-Backbone-CT-TK-TM-EcoRI
FragCC2004 digestion NotI-XhoI pCC2001 7757 bp NotI-SP-6xHis-SacI-Backbone-CT-TK-EcoRI-TM-XhoI
FragCC2005 PCR oligoCC2005-CC2006 p219-D 424 bp NotI-Subdomain I-XhoI
FragCC2006 PCR oligoCC2007-CC2008 p219-D 637 bp NotI-Subdomain II-XhoI
FragCC2007 PCR oligoCC2009-CC2010 p219-D 316 bp NotI-Subdomain III-XhoI
FragCC2008 PCR oligoCC2011-CC2012 p219-D 523 bp NotI-Subdomain IV-XhoI
FragCC2009 PCR oligoCC2005-CC2008 p219-D 1054 bp NotI-Subdomain I-II-XhoI
FragCC2010 PCR oligoCC2007-CC2010 p219-D 946 bp NotI-Subdomain II-III-XhoI
FragCC2011 PCR oligoCC2009-CC2012 p219-D 832 bp NotI-Subdomain III-IV-XhoI
FragCC2012 PCR oligoCC2005-CC2013 p219-D 426 bp NotI-Subdomain I-SpeI
FragCC2013 PCR oligoCC2014-CC2010 p219-D 315 bp SpeI-Subdomain III-XhoI
FragCC2014 PCR oligoCC2015-CC2012 p219-D 522 bp SpeI-Subdomain IV-XhoI
FragCC2015 PCR oligoCC2007-CC2016 p219-D 637 bp NotI-Subdomain II-SpeI
FragCC2016 PCR oligoCC2005-CC2010 p219-D 1363 bp NotI-Subdomain I-II-III-XhoI
FragCC2017 PCR oligoCC2005-CC2012 p219-D 1462 bp NotI-Subdomain II-III-IV-XhoI
FragCC2018 PCR oligoCC2014-CC2012 p219-D 831 bp SpeI-Subdomain III-IV-XhoI
FragCC2019 PCR oligoCC2005-CC2016 p219-D 1054 bp NotI-Subdomain I-II-SpeI
Synthesis
Fragment Size Elements
 
Table 3.7 Production of fragments used for contruction various ERBB2 
constructs. The method of synthesis for each fragment and the fragment lengths are shown 
on “Synthesis” and “Size columns respectively. From 5’ end to the 3’ end, the components 
of each fragment are given on “Elements” column. Highlighted sequences in color denote 
the restriction sites (red: NotI, blue: XhoI, green: SpeI, pink: SacI or EcoRI).  
 
 
 
Plasmid Ligation of Size Elements
p219-D 9621 bp 6xHis-SP-Subdomain I-II-III-IV-TM-TK-CT
pCC2001 FragCC2001 + FragCC2002 + FragCC2003 7770 bp 6xHis-SP-TM-TK-CT
pCC2002 FragCC2005 + FragCC2004 8181 bp 6xHis-SP-Subdomain I-TM-TK-CT
pCC2003 FragCC2006 + FragCC2004 8394 bp 6xHis-SP-Subdomain II-TM-TK-CT
pCC2004 FragCC2007 + FragCC2004 8073 bp 6xHis-SP-Subdomain III-TM-TK-CT
pCC2005 FragCC2008 + FragCC2004 8280 bp 6xHis-SP-Subdomain IV-TM-TK-CT
pCC2006 FragCC2009 + FragCC2004 8811 bp 6xHis-SP-Subdomain I-II-TM-TK-CT
pCC2007 FragCC2010 + FragCC2004 8703 bp 6xHis-SP-Subdomain II-III-TM-TK-CT
pCC2008 FragCC2011 + FragCC2004 8589 bp 6xHis-SP-Subdomain III-IV-TM-TK-CT
pCC2009 FragCC2012 + FragCC2013 + FragCC2004 8496 bp 6xHis-SP-Subdomain I-III-TM-TK-CT
pCC2010 FragCC2012 + FragCC2014 + FragCC2004 8703 bp 6xHis-SP-Subdomain I-IV-TM-TK-CT
pCC2011 FragCC2015 + FragCC2014 + FragCC2004 8916 bp 6xHis-SP-Subdomain II-IV-TM-TK-CT
pCC2012 FragCC2016 + FragCC2004 9120 bp 6xHis-SP-Subdomain I-II-III-TM-TK-CT
pCC2014 FragCC2012 + FragCC2014 + FragCC2004 9012 bp 6xHis-SP-Subdomain I-III-IV-TM-TK-CT  
Table 3.8 Fragment components of each ERBB2 construct. Except for p219-D, all 
listed plasmids are produced by the ligation of fragments listed on “Ligation of” column and 
size of each plasmid is listed on “Size” column. From 5’ end to the 3’ end, the protein coding 
regions on each plasmid are given on “Elements” column. 
 
77 
 
Oligo Sequence Size F/R Position on pCC2001
oligoCC2017 5'-TGAACCGTCAGATCGCCTGGAG-3' 22 bp F 530-551 (after SacI,before ATG)
oligoCC2018 5'-CTCATTCTGGATGACCAC-3' 18 bp R 1820-1837 (after EcoRI at TK)
oligoCC2019 5'-CTCCTCCTCGCCCTCTTG-3' 18 bp F 743-760 (inside SP, before NotI)
oligoCC2020 5'-GAATGCCAACCACCGCAGAG-3' 20 bp R 826-845 (after XhoI site, inside TM)
oligoCC2021 5'-CAGAGCTCGTTTAGTGAACC-3' 20 bp F 516-535 (after SacI,before ATG)
oligoCC2022 5'-GTGTACTTCCGGATCTTCTG-3' 20 bp R 899-918 (after XhoI site, inside TM)
oligoCC2023 5'-GGGCCAAACCTTACGATGGG-3' 20 bp F 1617-1636 (inside TK, before EcoRI at TK)
oligoCC2024 5'-CACATACTCCTCAGCATCCAC-3' 21 bp R 1913-1930 (after EcoRI site at TK, inside CT)
oligoCC2025 5'-GAGAGCTATGACGTCGCATGCAC-3' 23 bp R 2672-2694 (after stop codon)  
Table 3.9 Oligonucleotides used for sequence verification of the ERBB2 
constructs. Sequence and size of each primer used for sequence verification are shown on 
“Sequence” and “Size” columns. The orientation (F/R) and location of each primer on the 
template plasmid pCC2001 are shown on the “F/R” and “Location” columns respectively. 
 
 
Figure 3.3 Sequence verification of ERBB2 constructs. Template plasmid p219-D 
was sequence verified from the signal peptide (SP) to the end of Tyrosine Kinase (TK) 
domain including the EcoRI site used for cloning purposes. Template plasmid pCC2001 was 
sequence verified extensively starting upstream of the initial ATG codon prior to the 6H+SP  
site to downstream of the STOP codon after 1255
th
 amino acid of ERBB2 cDNA. 
Sequencing of pCC2014 is shown as an example of ERBB2 constructs containing various 
combinations of ERBB2 extracellular subdomains. To verify the sequences of their PCR-
amplified inserts, these constructs were sequenced using three primers shown on figure. 
Green arrows indicate the sequencing start sites and green dots indicate the verified 
sequences by each primer. The boxes named as I, II, III, IV represent four subdomains of 
ECD. 6H+SP: 6xHis tag and signal peptide domain, TM: transmembrane domain, TK: 
tyrosine kinase domain, 1255: last amino acid on human ERBB2 cDNA. 
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3.3.5.2 PCR-Amplification of human ERBB2 regions 
For PCR amplification upto 1kb, DyNAzyme™ II DNA Polymerase 
(Finnzymes, Espoo, Finland) was used. For amplification of fragments longer than 1 
kb, Phusion
®
 High-Fidelity DNA Polymerase (Finnzymes, Espoo, Finland) was 
used. Oligonucleotide primers that were used in PCR amplification reactions are 
listed on Table 3.6. Iontek (İstanbul, Turkey) synthesized primers were resuspended 
in autoclaved ddH2O to make 100 µM stock solutions and were stored at -20
o
C.  
 
PCR Amplification using DyNAzyme™ II DNA Polymerase 
     Final Concentration  For 75 µl reaction 
10X DyNAzyme™ Buffer Mg(-)  1X    7.5 µl 
10 ng/µl template DNA (p219-D)  2 ng/µl   15 µl 
2 mM dNTP     125 µM   4.5 µl 
5 µM Forward Primer   0.5 µM   7.5 µl 
5 µM Reverse Primer    0.5 µM   7.5 µl 
12.5 mM MgCl2    1 mM    6 µl 
DyNAzyme™ II DNA Polymerase  0.04 U/µl   1.5 µl 
dH2O           25.5 µl 
 
PCR Programme used with DyNAzyme
TM
 II DNA Polymerase 
Heated Lid    105
o
C 
Heated Lid before programme On 
Pause before programme  Off 
 
Initial Denaturation  02m00s 95.0
o
C 
Hot Start    Disabled 
 
Number Cycles   35 
 
Seq MAX 
o
C/s  00m30s 94.0
o
C 
Seq MAX 
o
C/s  00m10s 60.0
o
C 
Seq MAX 
o
C/s  01m30s 72.0
o
C 
 
Final Extension  04m00s 72.0
o
C 
 
Final Hold    10
o
C   
 
PCR Amplification using Phusion
®
 High-Fidelity DNA Polymerase 
     Final Concentration  For 75 µl reaction 
5X Phusion GC Buffer Mg(-)  1X    15 µl 
10 ng/µl template DNA (p219-D)  0.2 ng/µl   1.5 µl 
2 mM dNTP     200 µM   7.5 µl 
5 µM Forward Primer   0.5 µM   7.5 µl 
5 µM Reverse Primer    0.5 µM   7.5 µl 
Phusion
®
 High-Fidelity DNA Polymerase 0.02 U/µl   0.75 µl 
dH2O           35.25 µl 
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PCR Programme used with Phusion
®
 DNA Polymerase 
Heated Lid    105
o
C 
Heated Lid before programme On 
Pause before programme  Off 
 
Initial Denaturation  02m00s 98.0
o
C 
Hot Start    Disabled 
 
Number Cycles   35 
 
Seq MAX 
o
C/s  00m10s 98.0
o
C 
Seq MAX 
o
C/s  00m20s 60.0
o
C 
Seq MAX 
o
C/s  01m00s 72.0
o
C 
 
Final Extension  05m00s 72.0
o
C 
 
Final Hold    10
o
C   
 
PCR products were mixed with 1/5000 SybrGreen and run on 0.7% agarose 
gels. Since ethidium bromide is known to induce thymidine-dimers upon UV 
exposure, it was strictly avoided for visualization of fragments that will further be 
purified from agarose gel and be used for ligation. Under UV light, the correct sized 
bands were excised from the gel by sterile blades; the fragments were purified by 
QIAquick Gel Extraction Kit (QIAgen, CA, USA) according to the manufacturer’s 
instructions, eluted in total 70 µl elution buffer and stored at -20oC. (Typical 
fragment yield: 50 µl of 2-15 µg/ml) 
 
3.3.5.3 Restriction Digestion of PCR Products 
The PCR amplified and gel purified fragments were digested from their 5’ and 
3’ ends with the appropriate restriction enzymes to provide the sticky ends needed 
for fragment ligation. Restriction enzyme buffers were chosen to be compatible with 
both enzymes for the double digest reactions. 
 
     For 50 µl restriction reaction 
10X Restriction Enzyme Buffer   5 µl 
Restriction Enzyme 1     1 µl (5-10x103 Unit) 
Restriction Enzyme 2     1 µl (5-10x103 Unit)  
Gel-purified DNA Fragment    30 µl 
ddH2O       13 µl 
 
Incubated  
at 37
o
C for  
3 to 5 hours 
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Digested fragments were purified by QIAquick PCR Purification Kit (QIAgen, 
CA, USA) according to the manufacturer’s instructions, eluted in total 70 µl elution 
buffer and stored at -20
o
C.  
 
3.3.5.4 Ligation of Digested Fragments 
Ligation reactions were performed using T4 DNA Ligase (Fermentas, Vilnius, 
Lithuania), where backbone fragments were combined with insert fragments at 
various ratios from 1:1 to 1:8 respectively. A typical ligation reaction is examplified 
below. 
        For 20 µl ligation reaction 
10X T4 DNA Ligase Buffer    2 µl 
T4 DNA Ligase     1 µl 
Backbone Fragment     N  
Insert Fragment a     4N 
Insert Fragment b     4N  
 
N: molar amount of Backbone fragment added 
Volume was adjusted with sterile dH2O   20 µl 
 
After overnight incubation at 16
o
C, the ligase was inactivated by 10 minute 
incubation at 65
o
C; evaporated contents were collected at the bottom of the tube by a 
quick spin and the tube was stored at -20
o
C until transformation. 
 
3.3.5.5 Preparation of Competent DH5α E. coli Cells 
1. Since no antibiotic selection would be applied, all steps were carried out under 
strictly aseptic conditions. 
2. Using the DH5α glycerol stock stored at -80oC an LB-agar plate was streaked 
and incubated overnight at 37
o
C. 
3. A single DH5α colony was selected on the plate, inoculated in 3 ml 2XTY Broth 
and incubated overnight at 37
o
C. 
4. 0.5 ml from the liquid culture was taken, added into in a 500 ml flask containing 
fresh 100 ml 2XTY and incubated at 37
o
C until OD600 reaches 0.45-0.5 (~4 to 5 
hours). 
Incubated  
at 16
o
C 
overnight 
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5. The bacterial culture was transferred into two 50 ml falcon tubes and incubated 
10 minutes on ice. 
6. The tubes were centrifuged at 2500 g (~3000 rpm) for 10 minutes at 4oC and the 
supernatant was removed by gentle pouring (without disturbing the pellet). 
7. The pellet was initially resuspended by flicking and then 20 ml ice cold TB was 
added onto each tube, cells were resuspended completely by pipetting and collected 
in a single 50 ml tube. 
8. Cells in TB were incubated on ice for 10 minutes. 
9. The tubes were centrifuged at 2500 g (~3000 rpm) for 10 minutes at 4oC and the 
supernatant was removed by gentle pouring (without disturbing the pellet). 
10. The pellet was initially resuspended by flicking. 8 ml ice cold TB was added onto 
the cell suspension and cells were resuspended completely by pipetting. 
11. While mixing the cells gently (when a slow vortex was not present, the cells were 
mixed either by constant flicking or mixing with the pipette tip), 560 µl DMSO was 
slowly added onto the cell suspension (to make final 7% DMSO). 
12. The cell suspension was quickly aliquoted into sterile 1.5 ml tubes (500 µl per 
tube) and immediately frozen in liquid N2. 
13. The frozen competent cells were stored at -80oC until use.  
 
3.3.5.6 Transformation of Ligated Plasmids to DH5α 
1. 42oC water bath was prepared before the transformation. 
2. Competent DH5α cells were taken out from -80oC and thawed on ice. 
3. 100µl of competent DH5α was transferred into a fresh tube, 10 µl of the ligation 
reaction was added onto cell suspension and the solution was mixed by gentle 
flicking. 
4. DH5α-plasmid mixture was incubated for 10 to 30 minutes on ice. 
5. The tubes were transferred into 42oC water bath and the competent DH5α cells 
were heat shocked for 90 seconds for the plasmid to enter. 
6. After 90 seconds heat shock, the tubes were immediately transferred onto ice and 
incubated for 1 to 3 minutes. 
7. 1 ml fresh LB was added onto the heat shocked DH5α-plasmid mixture and cells 
were incubated 20 – 60 minutes at 37oC. 
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Note: Since ampicilline is bacteriostatic, cells will survive on ampicilline 
plates after recovery incubations in LB even as short as 30 minutes following 
heat shock. However, kanamycin is bacteriocidal and cells need to express 
resistance genes before being plated onto kanamycin plates, therefore these 
cells need to be incubated at least for 60 minutes in LB after heat shock. 
8. The cells were spun down for 30 seconds at 3500 rpm, the supernatant was 
removed by sterile 1 ml pipette leaving 50 µl LB on the cells and the cells were 
resuspended by flicking. 
9. The cells were resuspended gently by pipetting and transferred onto agar plates 
with antibiotics and spread homogeneously. 
10. The plates were inverted and incubated at 37oCfor 16 to 24 hours. 
 
3.3.5.7 Plasmid Isolation from transformed DH5α 
1. 6 to 12 colonies were selected on plates with DH5α cells transformed with 
ligated plasmids. 
2. Each colony was picked individually, transferred into 3 ml LB broth and was 
grown overnight at 37
o
C. 
3. The tubes were centrifuged at 4500 g for 15 minutes at 4oC and the supernatant 
was removed by gentle pouring (without disturbing the pellet). 
4. The pellets were lysed using the lysis buffer in QIAGEN Mini-Prep Kit and 
plasmid was isolated according the manufacturer’s instructions. (Typical plasmid 
yield: 50 µl of 100-500 µg/ml) 
 
3.3.5.8 Selection of Clones by Diagnostic Digest 
Using Clone Manager Suite 7 software, sequences of recently cloned plasmids 
and the backbone plasmid were compared and the restriction enzymes that would 
identify the correct insertion were selected. Newly constructed and backbone 
plasmids were digested with the same enzymes; each construct was checked by at 
least two different restriction enzyme digestions. 
1 unit restriction enzyme is defined as the enzyme sufficient to digest 1 µg 
DNA in a 50 µl reaction at 1 hour. Assuming that the concentration of each plasmid 
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would at most be 500 µg/ml, we have used excess amounts (1000 to 2000 Units) of 
enzymes for digesting 2 µl plasmid in a 3 to 5 hour reaction. 
 
          Master Mix for 10 plasmids (20 µl reaction each) 
10X Restriction Enzyme Buffer   20 µl 
Restriction Enzyme 1     2 µl (1000-2000 Unit/rxn) 
Restriction Enzyme 2     2 µl (1000-2000 Unit/rxn)  
ddH2O       156 µl 
 
1. 18 µl Master Mix was aliquoted into each tube containing 2 µl of different 
plasmid solutions. 
2. Plasmids were incubated with the restriction enzymes at 37oC for 3 to 5 hours. 
3. Digested plasmids were run on 0.7 to 1 % agarose gels and the band patterns 
were compared with the expected sizes. 
4. Plasmids having the correct band patterns were sent to sequencing. 
 
3.3.5.9 Sequence Verification of Constructed Plasmids 
Plasmid clones selected by diagnostic digest were sequenced by Iontek 
(İstanbul, Turkey) using the primers listed on Table 3.9. Sequence-verified plasmids 
were stored at -20
o
C. 
 
3.3.6 Cell Lysis and Protein Quantification 
When gentle lysis was needed, cells were lysed with a mild lysis buffer 
containing non-ionic detergent (1% NP40). When stronger lysis conditions were 
needed, RIPA lysis buffer containing ionic detergents (SDS and Na-DOC) was used. 
In order to ensure membrane disruption, cell lysates were further sonicated gently. 
Since SDS would interfere with the Bradford protein quantification assay, we have 
used BCA protein quantification assay kit from Thermo Fisher Scientific Inc. (IL, 
USA). 
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Cell Lysis 
1. Cells that were grown on 150 mm tissue culture plates until 80% confluency 
were washed twice with 10 ml PBS. The PBS was aspirated and the plates were 
placed on ice. 
2. While the cells were on ice, the cells were scraped with 5 to 10 ml cold PBS and 
collected in 15 ml falcon tubes. 
3. The cells were centrifuged at 1500 rpm for 5 minutes and the supernatant was 
aspirated completely and the cell pellet was kept at -80
o
C (which facilitates cell 
lysis). 
4. The cell pellet was taken from -80oC, thawn, 3 to 5 volume of appropriate lysis 
buffer was added onto each pellet. Cell suspension was transferred to 1.5 ml tubes 
and incubated on ice for 30 minutes by occasional flicking. 
5. If the cell suspension was not clear at the end of 30 minute incubation, the cell 
lysate was subjected to gentle sonication on an iced water bath in the cold room. The 
cells were sonicated 15 seconds at 40% amplitude. The tubes were kept on ice for at 
least 30 seconds and the sonication was repeated once more. 
6. The cell lysate was centrifuged at 13,000 rpm for 30 to 40 minutes. The soluble 
fraction was collected, and the total protein concentration was determined by BCA 
assay (Thermo Scientific Inc., IL, USA). 
7. The soluble lysate was aliquoted and stored at -80oC. 
 
3.3.7 Immunoprecipitation (IP) 
Even if the lysates were prepared by RIPA Lysis Buffer, the IP procedure was 
performed with the milder NP40 Lysis Buffer in order to preserve protein 
interactions. 
 
Immunoprecipitation of Huh-7 Lysates transfected with ERBB2 constructs 
1. 150 µg of Huh-7 total cell lysate was added onto 0.5 ml tubes and the volume 
was completed upto 600 µl with ice cold NP40 Lysis Buffer. 
2. 15 µg of purified antibodies were added to each tube containing Huh-7 lysates 
and the tubes were incubated for 2 hours on a rotator at the cold room (4
o
C). 
3. In the mean time, ProteinG-Agarose beads were equilibriated. 
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 N x 50 µl ProteinG-Agarose slurry was placed in a 1.5 ml tube and topped up 
with ice cold NP40 Lysis Buffer. (N: number of sample tubes) 
 Beads were centrifuged at 2000 rpm for 1 minute. 
 Supernatant was gently aspirated avoiding pellet disturbance. 
 Beads were washed two more times and finally resuspended in N x 50 µl 
NP40 Lysis Buffer. 
4. Tubes containing lysate-antibody mixture was spun down and 50 µl of 
equilibriated ProteinG-Agarose slurry was added onto each tube. 
5. ProteinG-lysate-antibody mixture was incubated for 4 hours on a rotator at the 
cold room (4
o
C). 
6. Following 4 hour incubation, tubes filled with ProteinG-lysate-antibody mixture 
were centrifuged at 2000 rpm for 1 minute. 
7. Supernatant was gently collected using 200 µl pipette tips avoiding pellet 
disturbance and saved in fresh tubes (in case, unbound fraction was needed for 
analysis). 
8. Beads were washed three times with 600 µl NP40 Lysis Buffer, centrifuged at 
2000 rpm for 1 minute and the supernatant was aspirated. 
9. Finally, 50 µl 5X SDS Loading dye (with 5% β-mercaptoethanol) was added 
onto the beads and the beads were boiled for 10 min, and placed on ice (or stored at -
20
o
C). 
 
3.3.8 SDS-PAGE 
SDS-PAGE was either performed with conventional methods, or by NuPAGE
®
 
Bis-Tris ready gels and solutions from Invitrogen (CA, USA) were used. 
 
3.3.8.1 Conventional SDS-PAGE 
Preparation of Tris-Glycine SDS-PAGE Gels 
When conventional SDS-PAGE system was used, the proteins in the sample 
were first stacked on a 5% stacking gel, and then separated on 8% resolving gel 
under denaturing conditions.  
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1. The Biorad Mini-PROTEAN® 3 Cell glass plates (BioRad, CA, USA) were 
assembled according to the manufacturer’s instructions.  
2. In two separate 50 ml tubes, resolving and stacking gel mixture were prepared as 
explained on Figure 3.4 and Figure 3.5 without TEMED and APS. 
3. Acquired volume of APS and TEMED were added to resolving gel mixture, 
stirred and poured between inner and outer glass plates leaving sufficient space for 
stacking gel. A small volume was left in the tube to monitor polymerization status. 
4. The acrylamide solution was overlaid with isopropanol.  
5. When the resolving gel was polymerized completely, isopropanol was poured off 
and the top of the gel was washed several times with dH2O to remove unpolymerized 
acrylamide. Remaining water was drained using a whatman paper (without touching 
the gel) 
6. Acquired volume of APS and TEMED were added to stacking gel mixture, 
stirred and poured on polymerized resolving gel. The comb was immediately inserted 
into the stacking gel, removing all air bubbles. A small volume was left in the tube to 
monitor polymerization status. 
7. When polymerization was complete, the gels were assembled on the running 
apparatus and inserted into the running tank. 
8. The space between two gels was completely filled with 1X Tris-Glycine SDS-
PAGE running buffer, the combs were removed carefully and the wells were washed 
with a syringe filled with running buffer. 
9. Remaining running buffer was poured into the tank so that the bottoms of the 
gels were dipped into the buffer. 
 
 
87 
 
 
Figure 3.4 Resolving gel for SDS-PAGE 
 
 
Figure 3.5 Stacking gel for SDS-PAGE 
 
Resolving Proteins on Tris-Glycine SDS-PAGE Gels 
1. The protein samples in 1X SDS-PAGE loading buffer (containing 5% -
mercaptoethanol) were boiled in water bath for 10 minutes. 
2. Boiled samples were immediately placed on ice, spun down gently and loaded on 
the wells of the gel. 
3. The gel apparatus was attached to power supply and run at 80 V until the proteins 
exit stacking gel. Once the proteins enter resolving gel, the voltage was increased 
upto 120 V. 
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4.  As the dye-front (bromophenol blue) has left the bottom of the resolving gel, the 
gel run was stopped and the plates were removed from the electrophoresis apparatus.  
5. Resolved proteins on the SDS polyacrylamide gel were either transferred to a 
PVDF membrane or stained with Coomassie Brillant Blue R250. 
 
Transfer of Resolved Proteins on SDS-Polyacrylamide Gels to PVDF 
1. The running apparatus was disassembled, the gels were transferred into 1X Tris-
Glycine Transfer Buffer and incubated for at least 10 minutes. 
2. In the mean time, the PVDF membrane of size equal to the gel was labelled from 
the top and incubated in methanol for 1 minute, washed with ddH2O and placed into 
1X Tris-Glycine Transfer Buffer. 
3. Two pieces of Whatmann paper at equal size and four transfer pads supplied by 
the transfer apparatus were also placed in 1X Tris-Glycine Transfer Buffer. 
4. Two fiber pads, one Whatmann paper, the gel, PVDF, another Whatman paper, 
two more fiber pads were placed on top of each other in this order. The stack was 
placed into the Biorad Mini Trans-Blot Cell transfer apparatus (BioRad, CA, USA) 
full of 1X Tris-Glycine Transfer Buffer (gel facing the cathode, PVDF facing the 
anode) 
5. Proteins were transferred for 90 minutes at 80 V in the cold room. 
6. The transfer apparatus was disassembled; PVDF was soaked into Western 
Blocking Buffer and proceeded as explained in 3.3.9. 
 
3.3.8.2 SDS-PAGE using Commercial NuPAGE™ Bis-Tris System 
Resolving Proteins on Commercial NuPAGE™ Bis-Tris Gels 
1. The ready 4-12% NuPAGE™ gels were removed from their plastic bags and 
assembled on the running apparatus according to the manufacturer’s instructions.  
2. The space between two gels was completely filled with 1X MOPS SDS Running 
Buffer, the combs were removed carefully and the wells were washed with a syringe 
filled with running buffer. 
3. Remaining running buffer was poured into the tank so that the bottoms of the 
gels were dipped into the buffer. The tank is placed inside an ice bath to prevent 
melting of the gel during high voltage runs. 
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4. The protein samples prepared in 1X NuPAGE LDS Sample Buffer (containing 
5% -mercaptoethanol) were incubated at 70oC for 10 minutes. 
5. Heated samples were immediately placed on ice, spun down gently and loaded on 
the wells of the gel. 
6. The gel apparatus was attached to power supply and run at 200 V for 90 minutes. 
7.  As the dye-front (bromophenol blue) has left the bottom of the gel, the gel run 
was stopped and the plates were removed from the electrophoresis apparatus.  
8. Resolved proteins on the SDS polyacrylamide gel were either transferred to a 
PVDF membrane or stained with Coomassie Brillant Blue R250. 
 
Transfer of Resolved Proteins on NuPAGE™ Bis-Tris Gels to PVDF 
The transfer of proteins from NuPAGE™ Bis-Tris gels to PVDF membranes 
was similar to that of conventional Tris-Glycine system, except the NuPAGE™ 
transfer apparatus and transfer buffers were used. 
 
3.3.8.3 Coommassie Staining of Total Proteins Resolved by 
Polyacrylamide Gel Electrophoresis 
1. The running apparatus was disassembled; the gels were soaked in Coomassie 
Staining Solution and incubated for 45 to 60 minutes at RT on a slow shaker. 
2. The staining solution was drained; gel was soaked in Coomassie Destaining 
Solution and incubated at RT on a slow shaker until the destaining solution was blue. 
3. The staining solution was renewed few times until the gel background was totally 
destained but protein bands were adequately visible. 
Note: If the gel was to be destained overnight, it was soaked in slow destain 
solution, the contained was covered with parafilm and placed at 4
o
C to prevent over 
destaining and gel drying. 
 
3.3.9 Western Blotting 
1. PVDF membrane was removed from the transfer apparatus, soaked into Western 
Blocking Buffer and incubated gently for 1 hour at RT on a slow shaker. 
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2. In the mean time, primary antibodies were diluted in “1/2 Western Blocking 
Buffer” at concentrations denoted in Table 3.10. 
3. The blocking buffer was drained; the PVDF was soaked in the primary antibody 
solution and incubated overnight at 4
o
C.  
4. Next morning, the primary antibody solution was drained and the PVDF was 
washed three times with TBS-T for a total of 30 minutes on a fast shaker. 
5. In the mean time, HRP conjugated secondary antibodies were diluted in “1/2 
Western Blocking Buffer” at concentrations denoted in Table 3.10. 
6.  TBS-T was drained; the PVDF was soaked in the secondary antibody solution 
and incubated gently for 1 hour at RT on a slow shaker. 
7. The secondary antibody solution was drained and the PVDF was washed three 
times with TBS-T for a total of 30 minutes on a fast shaker. 
8. TBS-T was drained well; the PVDF was placed on a glass plate; 1 ml 
SuperSignal West Femto Maximum Sensitivity Substrate was added on the PVDF 
membrane and incubated for 5 minutes. 
9. PVDF membrane was drained, covered with stretch film and chemiluminescent 
signal was captured by Kodak films which were further developed in Hyperprocessor 
(GE Healthcare, WI, USA) 
 
 
Reagent Name Catalogue Number Dilution Incubation
anti-ErbB2 (CB11) antibody ab8054 Abcam (MA, USA) 1/500 overnight 4oC 
anti-phospho ErbB2 antibody sc-1011694 Santa Cruz (California, USA) 1/300  2 hour RT
anti-Akt antibody 9272 Cell Signaling (MA, USA) 1/200  2 hour RT
anti-phospho Akt antibody 9271 Cell Signaling (MA, USA) 1/200  2 hour RT
anti-Erk1/2 antibody 9107 Cell Signaling (MA, USA) 1/200  2 hour RT
anti-phospho Erk1/2 antibody 9106 Cell Signaling (MA, USA) 1/200  2 hour RT
anti-CyclinD1 antibody sc-246 Santa Cruz (California, USA) 1/200  2 hour RT
BH1 6 ug/ml overnight 4oC 
BH2 6 ug/ml overnight 4oC 
BH5 6 ug/ml overnight 4oC 
BH6 6 ug/ml overnight 4oC 
BH7 6 ug/ml overnight 4oC 
anti-mouse IgG (Fc specific)–Peroxidase antibody A0168 Sigma-Aldrich (St. Louis, USA) 1/2000 to 1/5000 1 hour RT
Trastuzumab (Herceptin) Roche Ltd (Basel, Switzerland) 8 ug/ml 3 hour RT
anti-human IgG (Fc specific)?Peroxidase antibody A0170 Sigma-Aldrich (St. Louis, USA) 1/2000 to 1/5000 1 hour RT
anti-Calnexin antibody C4731 Sigma-Aldrich (St. Louis, USA) 1/10,000 1 hour RT
anti-rabbit IgG (whole molecule)–Peroxidase antibody A6154 Sigma-Aldrich (St. Louis, USA) 1/5000 1 hour RT
Company
 
Table 3.10 Antibodies and assay conditions used for immunoblotting.  
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3.3.10 Immunofluorescence (IF) 
1. The cells were seeded at ~30-50% confluency on sterile coverslips placed in 6-
well tissue culture dishes. 
2. When the cell confluency reached 70-80% (after 36 to 48 hours), the cells were 
washed twice with sterile PBS and the PBS was aspirated. 
3. 2 ml 2% paraformaldehyde (PFA) was added onto the wells from the sides 
(avoiding direct drips onto the cells in order to prevent cell detachment prior to 
fixation.); the dishes were incubated for 15 minutes at RT at dark. 
4. After 15 minute fixation, PFA was aspirated and cells were incubated in 2 ml of 
Permeabilization Buffer for 3 to 5 minutes. 
5. The cells were washed three times with PBS (If necessary, the cells may be 
stored at 4
o
C for one week in PBS after this step) 
6. PBS was aspirated and the cells were incubated for 30 to 60 minutes at RT in 2 
ml IF Blocking Buffer. 
7. In the mean time, purified antibodies to be used as primary antibodies were 
diluted in PBS-T at concentrations denoted in Table 3.11 (hybridoma supernatants 
were used without dilution). 
8. IF Blocking Buffer was aspirated; the cells were washed once with PBS-T for 5 
minute and PBS-T was aspirated. 
9. Primary antibodies were added at a volume enough to cover the coverslip surface 
and incubated for 1 to 3 hour at RT. 
10. Primary antibody solution was aspirated; the cells were washed three times with 
PBS-T (5 minute each) and PBS-T was aspirated. 
11. In the mean time, Alexa Fluor labelled secondary antibodies were diluted in PBS-
T at concentrations denoted in Table 3.11. 
12. Secondary antibodies were added at a volume enough to cover the coverslip 
surface and incubated for 1 hour at RT at dark. 
13. Secondary antibody solution was aspirated; the cells were washed three times 
with PBS-T (5 minute each) and PBS-T was aspirated. 
14. Finally, coverslips were washed once with dH2O to remove salts that would 
crystallize after mounting and disturb the vision during the microscopic detection. 
15. The coverslips were mounted onto the pre-labeled microscopy slides using 
ProLong Gold Antifade Reagent with DAPI (Invitrogen, CA, USA). 
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16. The fluorescent signal was detected using Axio Imager.A1 microscope (Jena, 
Germany). 
 
 
Reagent Name Catalogue Number Dilution Incubation
mouse monoclonal anti-BrdU (Bu20a) antibody M0744 Dako (Glostrup, Denmark) 1/500 1/500
anti-ErbB2 (CB11) antibody ab8054 Abcam (MA, USA) 1/50 1-3 hour RT
BH1 10 ug/ml 1-3 hour RT
BH2 10 ug/ml 1-3 hour RT
BH5 10 ug/ml 1-3 hour RT
BH6 10 ug/ml 1-3 hour RT
BH7 10 ug/ml 1-3 hour RT
IgG1 isotype control antibody MAB002 R&D Systems (MN, USA) 10 ug/ml 1-3 hour RT
anti-mouse IgG (H+L) Alexa Fluor® 488 A11029 Invitrogen (CA, USA) 1/500 1 hour RT
anti-mouse IgG (H+L) Alexa Fluor® 568 A11031 Invitrogen (CA, USA) 1/500 1 hour RT
Trastuzumab (Herceptin) Roche Ltd (Basel, Switzerland) 5 ug/ml 1-3 hour RT
anti-human IgG Alexa Fluor® 488 A11013 Invitrogen (CA, USA) 1/500 1 hour RT
Company
 
Table 3.11 Antibodies and assay conditions used for immunofluorescence. 
 
3.3.11 Sulforhodamine (SRB) Based Growth Assay 
Cell Treatment 
1. Cells at their logarithmic phase were trypsinized and diluted to give ~1-4 x 104 
cell/ml in Complete Media. 
2. 100 µl of cell suspension was seeded on each well of 96-well tissue culture plate 
and incubated for 2 hours in a CO2 incubator at 37
o
C. 
3. In the mean time, purified antibodies were diluted in complete media (20 µg/ml). 
4. 50 µl of diluted antibodies were added on each well (for 5 µg/ml final antibody 
concentration in 200 µl culture) and the plates were incubated for 4 hours in a CO2 
incubator at 37
o
C. 
5. In the mean time, 4X TNF-α solutions ranging from 250 Unit/ml to 16,000 
Unit/ml were prepared by diluting TNF-α stock (~2000 Unit/µl) in complete media. 
6. After 4 hour incubation, 50 µl 4X TNF-α was added onto each well to make a 
final TNF-α concentration of 62.5-4000 Unit/ml in 200 µl culture. For the negative 
control wells, 50 µl of complete media was added instead of 50 µl 4X TNF-α. 
7. The plates were placed back in the CO2 incubator and incubated for 6 days at 
37
o
C.  
8. SRB analysis was performed as described by Vichai and Kirtikara [291]. 
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Cell Fixation 
1. Stock TCA was diluted down to 10% with cold dH2O and kept on ice. 
2. 96 well plates were gently washed twice with 200 µl PBS. Being careful not to 
detach the yet unfixed cells, plates were gently tapped on tissue paper to remove the 
excess liquid. 
3. 100 µl 10% TCA solution was added onto each well; the plates were covered 
with aluminum foil and incubated at 4
o
C for 1 hour. (It was important not to exceed 1 
hour in order to prevent false staining during SRB incubation) 
4. After fixation, the plates were emptied, tapped on tissue paper to remove residual 
liquid and washed 4 times with ~200 µl dH2O. 
5. The plates were emptied, tapped on tissue paper to remove residual liquid and 
dried at RT at dark. (If necessary, dried plates may be stored at dark at RT and 
processed later.) 
 
SRB-Staining 
1. When plates with fixed cells were completely dried, 50 µl of freshly prepared 
SRB stain was added onto each well and incubated for 10 minutes at RT at dark. 
2. After 10 minute staining, the plates were emptied, tapped on tissue paper to 
remove residual stain and washed 6 times with 1% Acetic Acid. 
3. The plates were emptied, tapped on tissue paper to remove residual liquid and 
dried at RT at dark. (If necessary, dried plates may be stored at dark at RT and 
processed later.) 
 
SRB Read-Out 
1. When plates with stained cells were completely dried, exactly 200 µl cold 10 mM 
Tris Buffer was added onto each well and SRB stain was fully dissolved by thorough 
pipetting (Since this is a quantification assay, care was taken to pipette precisely the 
same volume to each well and to avoid evaporation). 
2. The absorbances at 515 nm were read by µQuant Microplate Reader. 
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3.3.12 Flow Cytometry 
1. Cells at their logarithmic phase were trypsinized and resuspended in Complete 
Media (3-10 x 10
5
 cells per sample). Trypsinized cells were inspected with an 
inverted microscope to ensure complete cell detachment before inactivating trypsin. 
2. The cells were transferred into a 15 ml falcon tube, centrifuged at 800 rpm for 3 
to minutes and the supernatant was aspirated. 
3. The cells were washed twice with at least 10 ml PBS each, the supernatant was 
aspirated and the cells were resuspended applying mechanical force to the bottom of 
the tube in only one direction (or simply by flicking).  
Note: Care was taken to achieve a cell suspension with highest healthy single 
cell concentration, preventing both cell necrosis and cell clumps before fixation. 
4. 5 ml 2% PFA was added onto the resuspended cell pellet drop by drop (with 
constant flicking) and the cells were fixed for 15 minutes at dark. 
5. After fixationi the cells were centrifuged at 1500 rpm for 5 to minutes and the 
supernatant was aspirated. 
6. The cells were washed 4 times with 5 ml Flow Blocking Buffer, centrifuged at 
1500 rpm for 5 to minutes and the supernatant was aspirated. 
7. The cells were resuspended by flicking and blocked in 5 ml Flow Blocking 
Buffer for 30 to 60 minutes. 
8. The cells were centrifuged at 1500 rpm for 5 to minutes, the supernatant was 
aspirated; the pellet was resuspended by flicking and blocking step was repeated 
once more. 
9. In the mean time, the antibodies were diluted in 50 µl Flow Blocking Buffer. 
10. Steps 7 – 8 were repeated and the cells were blocked once more. 
11. The cell pellet was flicked, resuspended in N x 50 µl Flow Blocking Buffer and 
cell suspension was aliquoted into N x 1.5 ml tubes (N: the number of samples).  
12. Antibody solution prepared at step 9 was added onto each cell suspension and 
cells were incubated for 60 minute at RT (cells were flicked occasionally to 
resuspend cells and enable homogenous staining). 
13. 1 ml Flow Blocking Buffer was added onto each tube, tubes were centrifuged at 
2000 rpm for 5 minutes. 
14. The supernatant was aspirated and the cells were washed twice with Flow 
Blocking Buffer. 
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15. The tubes were centrifuged at 2000 rpm for 5 minutes, the supernatant was 
aspirated and the cells were resuspended by flicking. 
16. 100 µl of 1/500 diluted Alexa conjugated secondary antibodies were added to 
each tube and cells were incubated for 60 minute at RT (cells were flicked 
occasionally to resuspend cells and enable homogenous staining). 
17. Cells were washed as explained in Steps 13 – 14 and the cells were resuspended 
by flicking. 
18. 500 µl PBS was added onto each tube and cells were transferred into FACS tubes 
of size 12x75 mm. 
19. Staining densities were read using FACSCalibur Flow Cytometer and analyzed 
by CellQuest Software (Becton Dickinson, NJ, USA) 
 
3.3.13 Long-term bromodeoxyuridine (BrdU) incorporation assay 
Long-term bromodeoxyuridine (BrdU) incorporation assay is used to assess the 
change in proliferative capacity of cells in the total population. When treated with 
BrdU for 24 hours, cells undergoing permanent cell cycle arrest cannot incorporate 
BrdU into nuclear DNA [292]. 
 
Cell Treatment (Day 0) 
1. Sterile coverslips were placed inside each well of 12-well dishes and 400 µl 
Complete McCoy’s 5A was added onto each well. 
2. SK-BR-3 cells at their logarithmic phase were trypsinized and diluted to give 2.5 
x 10
4
 cell/ml in Complete McCoy’s 5A. 
3. 400 µl of cell suspension was seeded on each well and incubated for 2 hours in a 
CO2 incubator at 37
o
C. 
4. In the mean time, purified antibodies were diluted in Complete McCoy’s 5A (50 
µg/ml). 
5. 100 µl of diluted antibodies were added on each well (for 5 µg/ml final antibody 
concentration in 1 ml culture) and the plates were incubated for 4 hours in a CO2 
incubator at 37
o
C. 
6. In the mean time, TNF-α stock was diluted in Complete McCoy’s 5A (4000 
Unit/ml). 
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7. After 4 hour incubation, 100 µl 10,000 Unit/ml TNF-α was added onto each well 
to make a final TNF-α concentration of 1000 Unit/ml in 1 ml culture. For the 
negative control wells, 100 µl Complete McCoy’s 5A was added instead of TNF-α 
solution. 
Note: Time point at TNF-α addition was taken as t:0  
8. The plates were placed back in the CO2 incubator and incubated for 6 days at 
37
o
C. 
 
BrdU Application (t:24 hr, t:48 hr, t:72 hr, t:96 hr, t:120 hr, t:144 hr) 
Starting from 24
th
 hour after TNF-α addition, different wells were chased with 
BrdU at every time point in 24
th
 hour intervals. Each BrdU chase lasted 24 hours. 
1. 1000X BrdU Stock was diluted down to 50X in Complete McCoy’s 5A 
2. 20 µl 50X BrdU was added to each well to be examined and plate was gently 
shaken to enable homogenous solution (Final BrdU concentration was 10 µg/ml). 
3. The plates were placed back in the CO2 incubator and incubated for 24 hours at 
37
o
C. 
 
Anti-BrdU Staining 
Anti-BrdU staining was performed similiar to immunofluorescence protocol 
explained in 3.3.10 except for minor variations explained below in details. 
 
1. Cells on coverslips were washed twice with 1 to 2 ml PBS. 
2. PBS was aspirated and the cells were fixed with 1 ml ice cold 70% Ethanol for 5 
minutes on ice (Ethanol was dispensed from the side of the well, avoiding direct 
dripping onto the cells). Ethanol was aspirated and slides were air dried. 
3. In order to denature dsDNA, the cells were treated with 1 ml 2N HCl for 20 
minutes at RT and washed twice with PBS. 
4. Cells were incubated in 1 ml IF Blocking Buffer for 30 to 60 minutes at RT. 
5. The cells were washed twice with PBS-T and PBS-T was aspirated well to 
prevent antibody leak from the coverslip surface at the next step. 
6. Anti-BrdU antibody was diluted 1/500 in PBS-T and 50-70 µl of the antibody 
solution was added onto each coverslip. Cells were incubated with the antibody for 1 
to 3 hours at RT (Coverslips were inspected occasionally to prevet leak). 
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7. The cells were washed twice with PBS-T and PBS-T was aspirated well. 
8. Alexa488 conjugated anti-mouse secoundary antibody was diluted 1/500 in PBS-
T; 50-70 µl of the antibody solution was added onto each coverslip and incubated for 
1 hour at RT at dark. 
9. The cells were washed twice with PBS-T and PBS-T was aspirated well. 
10. Finally, the coverslips were washed once with dH2O. 
11. The coverslips were mounted onto the pre-labeled microscopy slides using 
ProLong Gold Antifade Reagent with DAPI (Invitrogen, CA, USA). 
12. The fluorescent signal was detected using Axio Imager.A1 microscope. 
13. 3 to 5 frames per coverslip was captured and the percent BrdU incorporation was 
calculated after manual counting of BrdU
+
 and BrdU
-
 nuclei. 
% BrdU Incorporation: %P of 1
st
 frame + %P of 2
nd
 frame + ... + %P of N
th
 frame 
       N 
 (%P: percent positivity value for each frame, N: total number of frames) 
 
3.3.14 Cell Cycle Analysis by Flow Cytometry 
Cell Seeding 
1. SK-BR-3 cells at their logarithmic phase were trypsinized and diluted in 
Complete McCoy’s 5A media as follows: 
~12.5 x 10
3
 cell/ml for samples to be collected on 6
th
 day. 
~50 x 10
3
 cell/ml for samples to be collected on 1
st
, 2
nd
 and 3
rd
 day. 
2. 2 ml cell suspension was seeded on each well of 6-well tissue culture plate and 
incubated for 36 hours in a CO2 incubator at 37
o
C to allow enough time for proper 
cell attachment. 
 
Cell Treatment t:0 
1.  2 ml fresh Complete McCoy’s 5A media containing test samples was prepared 
for each sample (2 ml/sample/time point) 
a) 2 ml complete Complete McCoy’s 5A media was added into each tube for 
each time point. 
b) 40 µg of purified antibody per 2 ml Complete McCoy’s 5A was added 
into each tube. 
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c) 2000 Unit TNF-α per 2 ml Complete McCoy’s 5A was added into each 
appropriate tube. 
 
2. 36 hours after cell plating, the old media was aspirated, cells were washed with 2 
ml PBS and PBS was aspirated 
a) (-) control samples that were to be collected at t:0 were trypsinized and 
collected, fixed and stored as explained below. 
b) Fresh media containing the appropriate reagents were added onto other 
wells and cells were incubated at 37
o
C in the CO2 incubator until cell 
fixation. 
 
Cell Fixation t:24, t:48, t:72, t:144 
1. Since apoptotic cells detach from the plate surface and remain in the supernatant, 
the culture media in each well was collected into a separate falcon tube (labelled 
prior to the collection). 
2. Each well washed washed with 2 ml PBS and PBS was transferred into the 
appropriate falcon tubes containing the detached cells. 
3. Adherent cells in each well were trypsinized (3 drops of trypsin per well) for 3 to 
5 minutes at 37
o
C. Trypsin was inactivated by 1 ml Complete McCoy’s 5A media 
and single cell suspension was transferred into the appropriate falcon tubes 
containing the cells collected in previous steps. 
4. Cell suspensions were centrifuged at 1500 rpm for 5 minutes; the supernatant 
was aspirated and the cells were resuspended by flicking. 
5. 1 ml PBS was added onto each tube and cells were resuspended properly by 
gentle pippetting. 
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6. Cell suspensions were vortexed vigorously, and 2.5 ml of 100% ice-cold absolute 
EtOH was added dropwise to prevent cell clumps during fixation (final 70% EtOH). 
7. Cell suspensions were incubated in fixative on ice for 30 min with occasional 
vortexing. 
8. Fixed cell suspensions were stored at 4oC. 
 
Cell Staining 
1. Fixed cells were centrifuged at 1500 rpm for 5 minutes at 4oC. 
2. The supernatant was aspirated and the cells were resuspended by flicking. 
3. 500 µl PI Staining Solution was added onto each pellet and the suspension was 
pipetted gently couple of times to break cell clumps. 
Note: Since PI was light-sensitive, tubes were kept at dark after this step. 
4. Cells were incubated 40 minutes in PI Staining Solution at 37oC with occasional 
vortexing. 
5. After 40 minutes staining, 3 ml PBS was added onto each tube and the cells were 
centrifuged at 1500 rpm for 5 minutes at 4
o
C. 
6. The supernatant was aspirated and the cells were resuspended by flicking. 
7. 200 to 500 µl PBS was added onto the cell suspension (according to the pellet 
size) and the cells were analysed by Flow Cytometer. 
 
Cell Analysis 
1. The instrument and software were prepared as follows: 
Instrument  
 Sheat Fluid was filled upto 80% 
 Waste container was emptied 
 Valve was turned on to provide vacuum 
 First the Flow Cytometer, then the computer was turned on 
 Flow Cytometer was kept at “Standby” mode at “Lo” 
Software 
 Cell Quest Pro was opened 
 Acquire menu  Connect to cytometer 
(“Acquisition Control” window should always be open) 
 Cytometer menu  Status  
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(When the instrument is at “Standby” mode, it will read “Not Ready”) 
(“Sheat Fluid” and “Waste Tank” should read “OK”) 
 Acquire menu  Parameter Description 
(“SetUp” should be “√” during setup, therefore the data will not be saved.) 
(When the samples are read, “SetUp” should be unchecked to save the data) 
(Directory and the file name for each data were changed from this menu 
before sample read) 
 Acquire menu  Acquisition and Storage  
(The number of cells to be read were entered) 
 Cytometer menu  Detectors/Amps 
Voltage (increases/decreases fluorescence intensity) 
E-1 (decreases signal of large events) (E-1 was used for PI analysis) 
 
FL1 (for Annexin) 
FL2 (for PI) (FL2 was used for PI analysis) 
FL3 (for PI) 
 
FL2-A (Area) for total fluorescence 
FL2-W (Width) 
FL2-H (Max Fluorescence Emission) 
 Cytometer menu  Instrument Settings 
(Browsing the hard disk, previously saved setting file was selected) 
 Set  Done 
(Every time the settings were changed, “event count” was controlled from 
Acquire menu  Acquisition and Storage) 
2. Before the cells were read, a template was opened to visualize the graphics on the 
screen (as seen on Figure 3.6) 
3. Before the cells were read, following windows should remain open on the screen: 
 Cytometer menu  Status  
 Cytometer menu  Detectors/Amps 
 Acquire menu  Counters 
 Acquire menu  Acquisition Control 
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Running the Samples 
1. Instrument setting was changed from “Standby” to “Run” and, “Status” on the 
screen was read “Ready” 
2. While running the samples, SetUp is initially ticked, gate was selected as shown 
on Figure 3.6 B, in order to avoid multicellular clumps. 
3. FL2-A levels were fine-tuned from “Detectors/Amps”. 
 First and second peaks seen on Figure 3.6 C should sit on 200 and 400. 
“Voltage” and “Amp Gain” on “Detectors/Amps” menu was fine-tuned for 
every sample before sample read. 
 “Voltage” setting shifts the total graph to right or left on the x-axis 
 “Amp Gain” setting changes the width between two peaks 
4. When the setting were fine tuned  Pause  Abort 
5. To read to samples, SetUp is unticked  Acquire 
6. Once enough events were obtained, the instrument automatically stoped 
counting, saved the data and increased the number of the data file name by one. 
7. After each data, SetUp was ticked not to save the runs in between. 
8. Cells remaining in the tubing were washed with dH2O and events were monitored 
on the screen (no events should be detected unless the system is clogged or the dH2O 
tube was contaminated). 
9. For each new sample, Steps 3 to 6 were repeated.  
 
Data Analysis 
1. An analysis file was prepared for each data as seen on Figure 3.6.   
2. Initially the analysis template file was opened, the data folder was browsed and 
the same data file was selected for each graph.  
3. On the histogram graph (Figure 3.6 C), gates M1, M2, M3 and M4 were set for 
apoptotic, G0/G1, G2/S and M-phase cells respectively. 
4. The analysis file was saved. 
5. The file is renamed with the next data number and data files of new data were 
selected for each graph in order to keep M1, M2, M3 and M4 gates constant. (M1, 
M2, M3 and M4 were adjusted slightly only when the voltage level during the 
102 
 
sample read was not set properly leading to deviation of G0/G1 and M-phase peaks 
from 200 and 400 respectively). The analysis file was saved. 
6. Step 5 was repeated for each data file. 
 
 
Figure 3.6 Typical read out of a PI stained cell suspension A) X-axis (FSC-H) 
shows the size of each cell, Y-axis (SSC-H) shows the complexity (granular, etc) of each 
cell. B) X-axis (FL2-W) shows the width of each cell, (FL2-A) indicates the area of total 
fluorescence observed on each cell. C) The histogram showing the number of cells (x-axis) 
with each fluorescence level (y-axis). D) Histogram statistics for each reading show number 
of apoptotic (M1), G0/G1 (M2), G2/S (M3) and M phase (M4) cells. 
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3.3.15 Senescence Associated β-Gal (SAβ-gal) Assay 
Senescence associated beta galactosidase activity is used as a biomarker to 
distinguish senescent cells from quiescent cells. While both cell types are unable to 
incorporate BrdU due to the cessation of DNA synthesis; only senescent cells were 
shown to display SAβ-gal activity [293, 294]. 
 
Cell Treatment (Day 0) 
1. Sterile coverslips were placed inside each well of 12-well dishes. 
2. SK-BR-3 cells at their logarithmic phase were trypsinized and diluted to give 
1.25 x 10
4
 cell/ml in Complete McCoy’s 5A. 
3. 800 µl of cell suspension was seeded on each well and incubated for 2 hours in a 
CO2 incubator at 37
o
C. 
4. In the mean time, purified antibodies were diluted in Complete McCoy’s 5A (50 
µg/ml). 
5. 100 µl of diluted antibodies were added on each well (for 5 µg/ml final antibody 
concentration in 1 ml culture) and the plates were incubated for 4 hours in a CO2 
incubator at 37
o
C. 
6. In the mean time, TNF-α stock was diluted in Complete McCoy’s 5A (4000 
Unit/ml). 
7. After 4 hour incubation, 100 µl 10,000 Unit/ml TNF-α was added onto each well 
to make a final TNF-α concentration of 1000 Unit/ml in 1 ml culture. For the 
negative control wells, 100 µl Complete McCoy’s 5A was added instead of TNF-α 
solution. 
Note: Time point at TNF-α addition was taken as t:0  
8. The plates were placed back in the CO2 incubator and incubated for 6 days at 
37
o
C. 
 
Saβ-gal Staining (t:6 day) 
1. Cells on coverslips were washed twice with 1 to 2 ml PBS. 
2. PBS was aspirated and the cells were fixed with 1 ml 3.7% Formaldehyde for 15 
minutes at RT (The plates were kept at dark). 
3. Formaldehyde was aspirated and the cells were washed three times with 2 ml 
PBS. 
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4. PBS was aspirated SAβ-gal Staining Solution was added onto each enough to 
cover cells completely. 
NOTE: The SAβ-gal solution should be FRESHLY prepared and FILTERED 
before each use. 
5. Petri dishes containing coverslips were incubated in a 37oC incubator at 
DARK!!!. 
NOTE: The petri dishes should be placed in a 37
o
C incubator without CO2 
circulation. !!!  
 The presence of CO2 will alter the pH of the staining solution, and 
nonspecific staining will result.  
 Petri dishes should be incubated with lids closed to prevent evaporation.  
 In addition, care should be taken to ensure that the plates are not tilted and the 
staining solution covers the whole area of the dish. 
6. Development of a blue color in senescent cells was checked using a light 
microscope.  
7. As soon as such coloration is detected, aspirate the staining solution and wash 
cells 3x with dH2O. 
NOTE: Time required for blue coloration to develop depends on cell type.  
 Wait 2 to 4 hr after adding the staining solution before monitoring. Color 
development usually is complete after 16 hr.  
 Some nonspecific staining, which is caused by loss of the buffering capacity 
of the staining solution, may be observed after a long staining incubation. 
 Compare experimental sample with a negative control to detect color 
development.  
 A proliferating cell population and/or a quiescent cell population may serve 
as good controls. 
8. After more than 8 hr of incubation, some salt crystals may be observed. These 
crystals can be removed by repeated washing with water. 
9. 1-2 ml nuclear-fast red was added onto each coverslip, and incubated for 4-6 min. 
10. Cells on the coverslips were washed twice with dH2O (incubation in not needed; 
just rinsed and aspirated). 
11. The coverslips were mounted onto the glass slides using 80% glycerol or a 
commercial mounting media. 
12. The coverslips on the slide were sealed with colorless nail polish. 
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3.3.16 Analyses of Multiple Drug Interactions 
Drug interactions between BH-antibodies and TNF-α were analysed by two 
independent methods; Bliss model of independence [295] and Loewe model of 
additivity [296][297].  
The Bliss independence model [295] is also called the effect multiplication or 
the fractional product and the interaction score is calculated by multiplying maximal 
effects of drug 1 and drug 2.  
Bliss Interaction Score=   , where 
 
f1,2: effect (relative cell survival) obtained by combination of drug 1 and drug 2 
f1: maximum effect (minimal relative cell survival) obtained with drug 1  
f2: maximum effect (minimal relative cell survival) obtained with drug 2  
 
Drug 1 and 2 are accepted to be at “no interaction” (or acting “independently”), 
when the Bliss score is 1. For scores less than 1, drugs are accepted to behave 
“synergistic”, and for scores higher than 1, drugs are accepted to behave 
“antagonistic”.  
 
Interaction score for Loewe additivity model is calculated as follows [296, 
297]: 
Loewe Interaction Score=   , where 
 
d1: dose of drug 1 in the mixture producing an effect (relative cell survival) “y” 
d2: dose of drug 2 in the mixture producing an effect (relative cell survival) “y” 
Dy,1: dose of drug 1 producing an effect (relative cell survival) “y” when used alone 
Dy,2: dose of drug 2 producing an effect (relative cell survival) “y” when used alone 
 
For Loewe score equal to 1, drug 1 and 2 are accepted to act “additive”. For 
scores less than 1, drugs are accepted to behave “synergistic”, and for scores higher 
than 1, drugs are accepted to behave “antagonistic”.  
While cell survival data of treatments performed with different doses of drug 1, 
drug 2 and their combination are needed at for Loewe analysis, treatments performed 
only with the maximal effective dose are sufficient for analysing the data according 
   f1,2 
 f1 x f2 
  d1            d2 
 Dy,1      Dy,2 
+ 
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to Bliss method. Therefore cell treatments performed at single antibody (5 µg/ml) 
and TNF-α (1000 Unit/ml) concentrations were analysed only by Bliss method of 
independence. Corrcoef function of MatLab was used for the correlation analysis.  
 
3.3.17 Statistical Analyses 
Experimental data were presented as mean of samples tested at least in 
triplicates, with T Bars showing the standart deviation values. Statistical analysis of 
experiments that have been performed at least in triplicate was done using Student’s t 
test. 
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4 RESULTS 
 
4.1 Generation of Novel Monoclonal Antibodies Directed to 
Extracellular Domain of Human ERBB2 
Using a combined immunization protocol explained in Section 3.3.2, we 
generated hybridoma clones producing novel monoclonal antibodies against 
extracellular domain (ECD) of human ERBB2. Briefly, five BALB/c mice were 
initially immunized with live SK-BR-3 human breast cancer cells that overexpress 
ERBB2 on their cell surface. After four intraperitoneal live SK-BR-3 injections, the 
final injection was performed with 20 µg recombinant human ERBB2 ECD/Fc 
fusion protein (R&D Systems, MN, USA) (Figure 4.1). 
 
 
Figure 4.1 Structure of recombinant human ERBB2 ECD/Fc fusion protein 
used for immunization and ELISA assays. As explained by the manufacturer (R&D 
Systems, MN, USA), the recombinant protein has been constructed by fusing extracellular 
region (Met 1 – Thr 652) of human ERBB2 protein to the N-terminus of human IgG Fc 
region (Pro 100 – Lys 330) with a C-terminal 6-histidine tag. The final protein product was a 
disulfide-linked homodimeric protein devoid of ERBB2 signal peptide (Met 1 – Ser 22) 
which was removed by a proteolytic cleavage. The mature protein starting from Thr 23 was 
documented to migrate at ~131 kDa under denaturing conditions.  
 
Hybridoma culture supernatants were screened for the presence of anti-ERBB2 
antibodies using microtiter plates coated with recombinant human ERBB2 ECD/Fc 
fusion protein (will be called as “recombinant ERBB2-ECD” hereafter). Hybridoma 
clones that were found to produce reactive antibodies in this initial ELISA screen 
were expanded for further analysis and characterization. 
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4.2 Characterization of Novel anti-ERBB2 Monoclonal Antibodies 
Expanded hybridoma clones were subcloned to assure monoclonality and re-
screened by ELISA to select the clones producing anti-ERBB2 antibodies with 
highest reactivity. 
 
4.2.1 Novel Antibodies React Selectively With Human ERBB2 ECD 
Since EGFR and ERBB2 are known to possess sequence homology (Figure 
4.2), and BALB/c mice were initially immunized with SK-BR-3 cell line known to 
overexpress both EGFR and ERBB2; we screened the hybridoma supernatants for 
EGFR-ECD cross-reactivity in addition to their reactivity to ERBB2-ECD. Five 
hybridoma clones (BH-antibodies; namely BH1, BH2, BH5, BH6 and BH7) 
displaying high reactivity for ERBB2, without any EGFR cross-reactivity on ELISA 
assay were selected for further analyses (Figure 4.3). 
 
4.2.2 Comparison of Binding Strengths of Novel Antibodies for 
Human ERBB2 
The immunoglobulin isotype of the five selected antibodies was detected by 
Monoclonal Antibody Isotyping Kit (Thermo Scientific Inc., IL, USA) and all were 
found to be IgG1 with -light chains. 
In order to study their biochemical properties, BH-antibodies (BH1, BH2, 
BH5, BH6, BH7) were initially purified using Protein G affinity chromatography 
(Section 3.3.4) from culture supernatants of hybridoma clones grown in serum free 
media (SFM). For assays where antibodies were needed in higher quantities, BH-
antibodies were also purified from mice ascites (Section 3.3.4.2). 
Recombinant and cellular ERBB2 binding efficiencies of purified antibodies 
(Figure 4.4) were tested by ELISA, flow-cytometry and immunofluorescence assays. 
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Figure 4.2 Pairwise 
alignment of EGFR 
and ERBB2 amino 
acid sequences. 
Amino acid sequences 
of human EGFR 
isoform a 
(gi|29725609|ref|NP_0
05219.2|) and human 
ERBB2 isoform a 
(gi|54792096|ref|NP_0
04439.2|) were aligned 
using Clustal W2. “*” 
indicates conserved 
residues. “:” indicates 
residues having 
strongly similar 
properties ( > 0.5 in the 
Gonnet PAM 250 
matrix.).  “.” indicates 
residues having weakly 
similar properties ( ≤ 
0.5 in the Gonnet PAM 
250 matrix.). Small and 
hydrophobic amino 
acids (AVFPMILW) 
are shown in red. 
Acidic amino acids 
(DE) are shown in 
blue.  Basic amino 
acids (RK) are shown 
in magenta. Amino 
acids with hydroxyl, 
sulfhydryl or amine 
groups (STYHCNGQ) 
are shown in green. 
Other amino and imino 
acids are shown in 
grey. 
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Figure 4.3 ERBB2 and EGFR reactivities of novel anti-ERBB2 monoclonal 
antibodies. 50 ng/well recombinant ERBB2-ECD or EGFR-ECD coated Nunc-polysorb 
microtiter plates were incubated with hybridoma culture supernatants containing secreted 
antibodies. Strength of antigen-antibody interaction was colorimetrically detected (OD 405 
nm) by the alkaline phosphatase activity following the incubation with alkaline phosphatase-
conjugated anti-mouse IgG antibodies. (Samples were tested in duplicates and the average 
antibody binding strengths are shown on Y-axis.) 
 
 
Figure 4.4 BH-antibodies purified by Protein-G affinity chromatography. 8 µg 
purified BH-antibodies were run on SDS-PAGE. The gel was stained with coomassie 
brilliant blue G-250 to analyse the purity of the antibody preparations. Increasing amounts of 
bovine serum albumin (BSA) loaded on neighboring wells was used for quantification. 
 
 
4.2.3 Comparison of Affinities for Recombinant ERBB2-ECD by 
ELISA 
Affinities of BH-antibodies for recombinant ERBB2-ECD were compared by 
ELISA assay. BH1, BH6 and BH7 antibodies presented the strongest binding activity 
for recombinant human ERBB2-ECD. BH5 antibody displayed the lowest binding 
capacity, whereas BH2 had intermediate activity (Figure 4.5). These observations 
strongly suggested that we produced three anti-ERBB2 antibodies with high affinity, 
one with low and one with intermediate affinities. 
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Figure 4.5 Analysis of BH-antibody affinities for recombinant ERBB2 by 
ELISA. 50 ng/well ERBB2 ECD-coated Nunc-polysorb plates were incubated with 
increasing concentrations of purified anti-ERBB2 antibodies. Strength of antibody binding 
was colorimetrically detected (OD 405 nm) by the alkaline phosphatase activity following 
the incubation with alkaline phosphatase-conjugated anti-mouse IgG antibodies. T Bars: SD.  
 
 
4.2.4 Comparison of Affinities for Cellular ERBB2-ECD by Flow 
Cytometry 
The affinity of BH-antibodies for cellular ERBB2 was tested by flow 
cytometry on breast cancer cell lines expressing low (T47D) and high (BT-474) 
levels of ERBB2 [171, 298, 299] (Figure 4.6, Figure 4.7).  
When tested on T47D cells, BH1 and BH6 displayed highest shifts in staining 
intensity as compared to isotype control antibody. No BH5 binding was detectable at 
any tested condition; as illustrated by overlapping BH5 and IgG1 istotype control 
peaks at every concentration. BH2 displayed a weak binding that was more 
significant at higher antibody concentrations (10 µg/ml) (Figure 4.6, Figure 4.7).  
When tested on BT-474 cells, all BH-antibodies displayed strong intensity 
shifts at every antibody concentration, BH1 producing the best shift (Figure 4.6, 
Figure 4.7). In addition, two separate peaks with different fluorescence intensities 
were observed when BT-474 cells were incubated with BH2 and BH5 antibodies at 
concentrations below and above 20 µg/ml (Figure 4.6). This suggests that BH2 and 
especially BH5 might react with two distinct sub-populations of BT-474. 
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Figure 4.6 Analysis of BH-antibody affinities for cellular ERBB2 by Flow 
Cytometry (A). ~3x105 T47D (left column) or ~5x105 BT-474 (right column) cells were 
incubated with increasing amount of BH-antibodies (0.5 – 40 µg antibody/sample) in 100 µl. 
Anti-ERBB2 incubation of paraformaldehyde fixed single cell suspensions was followed by 
Alexa-488-conjugated secondary antibodies and fluorescence intensities were measured by 
flow cytometry. Each graph shows fluorescence intensities of cells stained with the same 
antibody at different concentrations. Maximum fluorescence emissions at 488 nm are shown 
on x-axis (FL1-H) and cell counts are shown on y-axis. IgG1-isotype control antibody (IgG) 
at equal concentrations were used as negative controls. (-) indicates the control samples 
which were incubated only with Alexa-488-conjugated secondary antibodies without any 
prior primary antibody incubation. 
 
 
 
Figure 4.7 Analysis of BH-antibody affinities for cellular ERBB2 by Flow 
Cytometry (B). ~3x105 T47D (left column) or ~5x105 BT-474 (right column) cells were 
incubated with increasing amount of BH-antibodies (0.5 – 2 µg antibody/sample) in 100 µl. 
Anti-ERBB2 incubation of paraformaldehyde fixed single cell suspensions was followed by 
Alexa-488-conjugated secondary antibodies and fluorescence intensities were measured 
using flow cytometry. Each graph shows fluorescence intensities of cells stained with 
different primary antibodies used at same concentration. Maximum fluorescence emissions 
at 488 nm are shown on x-axis (FL1-H) and cell counts are shown on y-axis. IgG1-isotype 
control antibody (IgG) at equal concentrations were used as negative controls. (-) indicates 
the control samples which were incubated only with Alexa-488-conjugated secondary 
antibodies without any prior primary antibody incubation. 
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4.2.5 Comparison of Affinities for Cellular ERBB2-ECD by Indirect 
Immunofluorescence 
Binding strengths of BH-antibodies to endogeneous ERBB2 protein were 
compared by indirect immunofluorescence assay using human breast cancer cell 
lines expressing diferent levels of ERBB2 (Figure 4.8). 
Fluorescence in situ hybridization (FISH) using probes against ERBB2 gene 
and chromosome 17 centromere showed that MCF-7 had three chromosome 17 and 
two ERBB2 signals. MDA-MB-361 provided 4-8 chromosome 17, and 8-12 ERBB2 
signals. Both SK-BR-3 and BT-474 displayed 5-6 chromosome 17 signals and highly 
amplified ERBB2 signals (Figure 4.8 A). Most of T47D cells displayed three 
chromosome 17 and three ERBB2 copies (data not shown). These findings were in 
perfect agreement with a previous study reporting 47, 43, 11 and 2.5 copies of the 
ERBB2 gene in BT-474, SK-BR-3, MDA-MB-361 and MCF-7, respectively [299].  
BH-antibodies displayed highly correlated immunoreactivities with respect to 
ERBB2 gene copy numbers; all five antibodies displayed strong fluorescence 
intensities on cellular membranes of breast cancer cell lines expressing high (BT-
474, SK-BR-3) and moderate (MDA-MB-361) levels of ERBB2. On the contrary, 
ERBB2 signals on MCF-7 cells were negative or barely detectable. Highest signal 
intensities were obtained by BH1 and BH6 antibodies, followed by BH2, BH7 and 
BH5 (Figure 4.8 B-G).  
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Figure 4.8 Analysis of cellular ERBB2 by indirect immunofluorescence using 
BH-antibodies. A) For FISH analysis, human breast cancer cells with different ERBB2 
levels were harvested at confluence, fixed and subjected to dual-color FISH using Texas 
Red-labeled ERBB2 (red) and FITC-labeled chromosome 17 α-satellite CEP17 (green) DNA 
probes. B-G) For immunofluorescence assays, cells were seeded on coverslips on 6-well 
plates and incubated 36 hours in cell culture medium at 37
o
C. Paraformaldehyde fixed and 
permeabilised cells were incubated with 20 µg/ml BH-antibodies for two hours. Photographs 
are representative of merged images of BH-antibody binding detected using Alexa-488-
conjugated anti-mouse IgG and nuclei counterstained with DAPI. (-) indicates the control 
samples where the cells were incubated only with Alexa-488-conjugated secondary 
antibodies without any prior primary antibody incubation. 
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4.3 Human ERBB2 Epitope(s) Recognized by BH-antibodies 
 
4.3.1 The Role of Structural Integrity of ERBB2 in Antibody Binding 
In order to confirm the specificity of BH-antibodies for ERBB2, we performed 
western blot assays using different breast cancer cell line lysates prepared at mild 
(NP40) or stringent (RIPA) conditions. NCL-CB11 (CB11 in short) antibody against 
intracellular ERBB2 epitope was used as a positive control. While western blot 
analysis of breast cancer cell line lysates with CB11 antibody provided positive 
signals (Figure 4.9) representing their ERBB2 amplification status [299], neither 
BH-antibodies, nor Trastuzumab detected ERBB2 in this experimental setting (data 
not shown).  
 
 
 
Figure 4.9 Western blot analysis of endogenous ERBB2 expression on different 
breast cancer cell lines. 30 µg total cell lysates of RIPA lysed MCF-7, MDA-MB-361, 
SK-BR-3 and BT-474 breast cancer cell lines were subjected to western blot assay using 
CB11 antibody raised against an intracellular ERBB2 epitope. ERBB2 protein band is seen 
at 185 kDa. Calnexin signal was used  to verify equal loading (data not shown) 
 
 
Next, endogeneous ERBB2 was immunoprecipitated by Trastuzumab to 
concentrate the protein before analysis (Figure 4.10 A). While ERBB2 present in the 
soluble fraction remained totally in the flow through fraction in the absence of 
Trastuzumab (Figure 4.10 A, Lane 2, 4), it was totally captured by Protein G-
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conjugated beads in the presence of Trastuzumab (Figure 4.10 A, Lane 1), depleting 
ERBB2 from the flow through (Figure 4.10 A, Lane 3). Yet, no reactivity of BH-
antibodies was detected in western blot assays with this ERBB2 enriched conditions 
either (Figure 4.10 B). 
 
 
 
Figure 4.10 Analysis of antibody binding to endogenously expressed ERBB2 
denatured under reducing conditions. Endogenously expressed ERBB2 present in 15 
mg T47D RIPA lysate was immunoprecipitated by 240 µg Trastuzumab. A) T47D cell lysate 
(Lane 5) was incubated with Protein G-conjugated beads in the presence (Lane 1) or 
absence (Lane 2) of Trastuzumab. ERBB2 protein captured by the beads (Lane 1 and 2) and 
left unbound in the flow-through fraction (Lane 3 and 4) are shown. Proteins resolved on 
SDS-PAGE was subjected to western blot assay using CB11 antibody. B) Endogenous 
ERBB2 enriched by Trastuzumab immunoprecipitation was subjected to western blot assay 
using BH-antibodies. CB11 antibody was used as a positive control to locate the 185 kDa 
ERBB2 band. 
 
 
Based on these findings, we hypothesized that the epitope(s) recognized by 
BH-antibodies were unstable under denaturing conditions of SDS-PAGE, although 
they remained stable after paraformaldehyde fixation used in indirect 
immunofluorescence (Figure 4.8) and flow cytometry experiments (Figure 4.6, 
Figure 4.7).  
Therefore, we tested antibody immunoreactivies for native ERBB2 protein by 
immunoprecipitating endogenous ERBB2 in the cell lysates by BH-antibodies. RIPA 
lysates of T47D cells were subjected to immunoprecipitation with different 
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antibodies, and antigen binding was tested by western blot assay using CB11 
antibody. Although incapable of binding to ERBB2 proteins denatured during SDS-
PAGE, all antibodies tested were able to immunoprecipate ERBB2 in RIPA lysates 
(Figure 4.11). BH1 (with the highest affinity), BH2, BH6 and BH7 antibodies 
efficiently precipitated the native ERBB2 and almost depleted the protein in the 
lysate. Whereas, as expected from flow cytometry analyses, BH5 poorly precipitated 
the ERBB2 protein present in T47D lysates, leaving the protein mostly in the “flow-
through (unbound) fraction”. These findings provided evidence that newly generated 
antibodies recognized conformation-dependent epitope(s) on endogenously 
expressed ERBB2 protein. 
 
 
 
 
Figure 4.11 Immunoprecipitation of endogenous ERBB2 by BH-antibodies. 
Endogenously expressed ERBB2 present in 2 mg T47D RIPA lysate was 
immunoprecipitated by 20 µg BH-antibodies or Trastuzumab (Tzm). Antigen-antibody 
complexes that were captured onto Protein G-conjugated beads were eluted by boiling in 
SDS-PAGE loading dye (left panel). ERBB2 proteins that were uncaptured by the antibody-
bead complex remained in the flow through (right panel). Proteins resolved under 
denaturing conditions were subjected to western blot assay using CB11 antibody. 
Trastuzumab was used as a positive control for ERBB2 immunoprecipitation. (-) is the 
negative control where T47D lysate was incubated with Protein-G beads in the absence of 
any antibody. ERBB2 protein band is detected at 185 kDa. 
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4.3.2 BH-antibodies Do Not Compete for The ERBB2 Epitope 
Recognized by Trastuzumab 
To compare epitopes targeted by BH-antibodies and Trastuzumab, we have 
performed ELISA-based and immunofluorescence-based competition experiments. 
Two different approaches were pursued using ELISA technique to test 
competition between BH-antibodies and Trastuzumab for ERBB2-ECD [300]. For 
both approaches, the wells of an ELISA-plate were initially coated with recombinant 
ERBB2-ECD protein. In the first, we aimed to find out whether prior incubation with 
Trastuzumab would block epitopes on ERBB2-ECD that are to be recognized by 
BH-antibodies, and therefore decrease the signal received upon binding of BH-
antibodies. As seen on Figure 4.12, prior incubation with excess Trastuzumab did 
not decrease the BH-antibody binding to the recombinant ERBB2-ECD protein. In 
the second approach, we wanted to see whether prior incubation with BH-antibodies 
would block the Trastuzumab-binding epitopes and decrease binding of 
Trastuzumab. As seen on Figure 4.13, prior incubation with excess amount (250ng) 
of BH-antibodies did not decrease the Trastuzumab signal. These reciprocal 
experiments suggested that BH-antibodies do not share the same epitope with 
Trastuzumab. 
Competition between BH-antibodies and Trastuzumab for endogeneous 
ERBB2 protein was investigated by immunofluorescence using two approaches 
[257] where SK-BR-3 cells were incubated with combination of Trastuzumab and 
BH-antibodies. In the first, cells were incubated with increasing levels of 
Trastuzumab in addition to one of the BH-antibodies and the change in BH-antibody 
signal was analysed (Figure 4.14 left panel). As a second approach, SK-BR-3 cells 
were incubated with a combination of equal amounts of Trastuzumab and BH-
antibodies and the change in Trastuzumab signal was analysed (Figure 4.14 right 
panel). None of the samples revealed a significant competition between Trastuzumab 
and BH-antibodies, confirming the absence of epitope sharing. 
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Figure 4.12 Trastuzumab does not compete with BH-antibodies for ERBB2-
ECD binding on ELISA assays. Wells coated with 25 ng recombinant ERBB2-ECD 
protein were treated either with excess (250 ng) Trastuzumab (Tzm) or IgG1 isotype control 
antibody. Then 25 ng of BH-antibodies were added. Following the incubation with alkaline 
phosphatase-conjugated anti-mouse IgG antibodies, the colorimetric signal was measured at 
405 nm. (-) represents negative control wells directly treated with alkaline phosphatase 
conjugated anti-mouse IgG antibodies, following competitor antibody incubation. Error bars 
represent standard deviation of samples tested in duplicates.  
 
  
 
 
Figure 4.13 BH-antibodies do not compete with Trastuzumab for ERBB2-ECD 
binding on ELISA assays. Wells coated with 25 ng recombinant ERBB2-ECD protein 
were initially treated with HRP conjugated anti-human IgG in order to block the human Fc 
regions on the coated antigen. Wells were then treated either with excess (250 ng) BH-
antibodies or excess IgG1 isotype control antibody. Then 25 ng of Trastuzumab was added. 
Following the incubation with alkaline phosphatase-conjugated anti-human IgG antibodies, 
the colorimetric signal was measured at 405 nm. (-) represents negative control wells directly 
treated with alkaline phosphatase conjugated anti-human IgG antibodies, following 
competitor antibody incubation. Error bars represent standard deviation of samples tested in 
duplicates. 
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Figure 4.14 BH-antibodies and Trastuzumab do not share the same epitope on 
cellular ERBB2 protein. SK-BR-3 cells grown on coverslips were fixed by 2% 
parafolmaldehyde, permeabilized and incubated with a combination of Trastuzumab (Tzm) 
and one of the BH-antibodies. Left panel: 20µg/ml BH-antibodies were competed with 
5µg/ml, 20µg/ml or 100µg/ml Trastuzumab, and the binding was detected by Alexa568-
conjugated anti-mouse IgG antibodies. Right panel: 20µg/ml Trastuzumab was competed 
with 20 µg/ml BH-antibodies, and the binding was detected by Alexa488-conjugated anti-
human IgG antibodies. Photographs are representative of merged images of anti-ERBB2 
binding detected using Alexa-conjugated secondary antibodies and nuclei counterstained 
with DAPI. 
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4.3.3 Identification of Epitopes Recognized by BH-antibodies 
In order to delineate the epitope(s) recognized by BH-antibodies, we 
constructed a series of plasmids to express truncated forms of ERBB2 at its ECD. 
Putative domains on human ERBB2 protein and their corresponding locations on the 
coding mRNA are shown on Figure 4.15 [58, 99, 266, 301, 302]. Each construct, 
whose cloning was explained in details at Section 3.3.5, contains different 
combinations of ECD-subdomains surrounded by the signal peptide (SP) and 
transmembrane (TM) domains of the full length human ERBB2 (Figure 4.16).  
Briefly, ERBB2-extracellular domain (ECD I-II-III-IV) was extracted from the 
plasmid vector expressing full-length human ERBB2 protein (OCABo5050G0219D; 
shortly called p219-D here), leaving the coding sequence for the N-terminal 22 
amino acid signal peptide intact. pCC2001 was produced by inserting Not I and Xho 
I sites between the signal peptide sequence and the sequence encoding the C-terminal 
domain starting from the transmembrane region. DNA sequences allowing the 
inclusion of domains I, II, III and IV of ECD under different combinations were 
amplified by PCR and inserted into pCC2001 plasmid using the Not I, Spe I and Xho 
I sites (Figure 4.16). In addition to the vectors containing single ECD domains or 
multiple domains consecutively, we have designed various constructs that fuse 
distant subdomains, in order to mimic physiological folding (i.e subdomain I-IV). 
The integrity of cloned sequences has been verified by DNA sequencing. Attempts 
for cloning pCC2013 and pCC2015 constructs failed to produce plasmids with 
correct nucleotide sequences; therefore they were excluded from the ERBB2 
construct panel and were not used in further analyses. 
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Figure 4.16 ERBB2 deletion 
constructs expressing 
different ECD-subdomains. 
Extracelullar subdomains (ECD I-
II-II-IV) were deleted from p219-
D plasmid coding full length 
human ERBB2 protein to 
construct pCC2001 backbone 
plasmid. PCR-amplified 
individual ERBB2 ECD 
subdomains (shown in blue boxes 
numbered from I to IV) were 
introduced between NotI and 
XhoI sites on pCC2001 at 
different combinations to produce 
other truncated ERBB2 constructs 
(pCC2002-pCC2015) shown in 
red. Numbers in black correspond 
to the amino acid positions on full 
length human ERBB2 protein. 
Letters in purple represent the 
restriction enzyme sites added 
between the inserted subdomains; 
N: Not I, S: Spe I, X: Xho I. SP:  
Signal Peptide, TM:  
Transmembrane domain, TK:  
Tyrosine Kinase domain. 
(pCC2013 and pCC2015 were 
excluded from the construct panel 
since their cloning did not 
produce plasmid clones with 
correct  nucleotide sequences.) 
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Huh-7 cells that express low levels of endogenous ERBB2 protein [303] were 
transiently transfected with plasmids to express different forms of ERBB2, and 
immunoreactivity of each antibody was tested by immunofluorescence (Figure 
4.17), and combined immunoprecipitation-western blot (Figure 4.19) assays. Huh7 
cells transfected with backbone pDEST26 vector and pCC2001 vector expressing a 
truncated ERBB2 construct lacking all ECD domains were used as negative controls. 
Huh7 transfection efficiency was lower than 100%. This enabled visualization 
of two distinct populations on the same slide; unransfected wild-type cells expressing 
endogenous levels of ERBB2, and transfected cells overexpressing ectopic ERBB2. 
Since ectopic ERBB2 signal was easily discriminated from endogenous ERBB2 
signal, high affinity recognition of endogenous ERBB2 protein was not 
misinterpreted as low affinity recognition of truncated ERBB2 proteins.  
CB11 antibody that is directed against an intracellular epitope shared by all 
constructs was used as a positive control to confirm the expression of full length and 
truncated forms of ERBB2 transgene. While cells transfected with empty vector 
(pDETS26) were unstained, all ERBB2 transfectants (pCC2001-pCC2014 and p219-
D) were successfully detected with CB11, indicating that all constructs were 
efficiently transfected, transcribed and translated (Figure 4.17). Another control was 
Trastuzumab that is directed against an epitope located at domain IV of the 
extracellular region of ERBB2 [17]. All truncated forms of ERBB2 protein 
containing domain IV (pCC2005, pCC2008, pCC2010, pCC2011 and pCC2014) 
provided strongly positive signals with Trastuzumab (Figure 4.17), indicating that 
not only the intracellular domains but also the extracellular domains of the deletion 
constructs were expressed successfully. Western blot analysis of the transfectants 
also confirmed the expression of the deletion constructs at their expected sizes 
(Figure 4.18). 
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Figure 4.17 Epitope mapping of anti-ERBB2 antibodies using indirect 
immunofluorescence. Huh7 cells were transfected either with full-length ERBB2 
construct (p219-D), empty vector (pDEST26), or truncated ERBB2 constructs (pCC2001-
pCC2014) were cultivated for 48 hours, and subjected to indirect immunofluorescence as 
described in Figure 4.8. Briefly, transfectants were reacted with 10 µg/ml BH1, BH2, BH5, 
BH6, BH7, Trastuzumab (Tzm) or 1/50 diluted CB11. Photographs are merged images of 
anti-ERBB2 binding detected using Alexa488-conjugated secondary antibodies and nuclei 
counterstained with DAPI. (-): no primary antibody. 
 
 
 
Figure 4.18 Verification of protein products of ERBB2 constructs. RIPA lysates 
of Huh7 cells that were transfected with ERBB2 constructs were resolved on SDS-
PAGE and were subjected to western blot assay using CB11 antibody. Red arrow indicates 
the endogeneous ERBB2 band. 
 
 
 
BH1 and BH6 which have ERBB2 affinities higher than that of BH2, BH5 and 
BH7 as suggested by the previous indirect ELISA (Figure 4.5), flow cytometry and 
(Figure 4.6) indirect immunofluorescence (Figure 4.8) analyses, recognized the low 
level endogenous ERBB2 in Huh7 cells transfected with the empty vector 
(pDEST26), producing a faint background staining. All five BH-antibodies 
effectively recognized the cells expressing the full-length ERBB2 constructs (p219-
D); producing strong staining that was easily distinguished from the endogenous 
ERBB2 signal. However, none of the BH-antibodies significantly reacted with 
truncated ERBB2 proteins containing individual ECD subdomains, alone or in 
combination (Figure 4.17). The immunofluorescence results indicated that BH-
antibodies recognize conformational epitopes which are disturbed in the absence of 
any of the ERBB2 ECD-subdomains. 
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In order to see whether low-affinity recognition of the deletion constructs by 
BH1, BH2, BH5 and BH6 would enable them to pull down the products of pCC2006, 
pCC2007 or pCC2012, transfectant lysates were immunopreciptated by BH-
antibodies, Trastuzumab and CB11; and probed with CB11 (Figure 4.19). pCC2008-
transfectant lysate (containing ECD-IV recognized by Trastuzumab) was also 
included in the test panel as an internal control. Total cell lysates were run next to 
immunoprecipitates, to show the exact location of the expected bands (indicated by 
arrows on Figure 4.19).  
Intracellular ERBB2 domains were intact on all truncated ERBB2 proteins and 
CB11 successfully immunoprecipitated ERBB2 proteins in all tested lysates. 
Trastuzumab was documented to recognize a conformational epitope formed by the 
amino acids present totally on ECD-IV therefore presence of ECD-IV was sufficient 
to create that epitope [17]. Trastuzumab successfully immunoprecipitated the 
truncated ERBB2 protein present in pCC2008-lysates (containing ECD-IV), 
indicating the efficiency of the assay procedure. In addition, it also pulled down the 
endogeneous ERBB2 present in Huh7 cells. 
While all of the BH-antibodies successfully immunoprecipitated the ectopic 
full-length ERBB2 protein present in p219-D lysates, they failed to pull-down 
truncated ERBB2 proteins (Figure 4.19). These results, supporting the previous 
indirect immunofluorescence analyses with truncated ERBB2 transfectants (Figure 
4.17), indicate that BH-antibodies are directed to an epitope, or closely related 
epitopes present only on structurally intact ECD of ERBB2, and the reactivity of 
antibodies was lost when any one of the four subdomains of the ERBB2 ECD was 
deleted. Therefore, all five antibodies require the structural integrity of ECD for 
recognition of ERBB2 receptor. 
BH1 and BH6 stood out among the other BH-antibodies in that they stained the 
endogenous full-length ERBB2 in Huh7 cells in indirect imuunofluorescence assays. 
High-exposure of the IP-immunoblots also demonstrated that, both BH1 and BH6 
were able to pull-down low-level expressed endogenous ERBB2 in Huh7 cells, 
illustrating the strength of their affinity for ERBB2. 
 
 
129 
 
 
Figure 4.19 Epitope mapping of anti-ERBB2 antibodies using combined 
immunoprecipitation-western blot assay. Huh7 cells that were transfected with full 
length (p219-D) and truncated ERBB2 constructs were RIPA lysed and immunoprecipitated 
with BH-antibodies, Trastuzumab, CB11 or IgG1 isotype control antibody. Precipitated 
proteins were subjected to western blot assay using CB11 antibody. “(-)” is the negative 
control sample, where the lysates were incubated with protein G beads without any antibody. 
The input lysate is shown on the last lane of each blot. Red arrows indicate the endogeneous 
ERBB2 band. 
 
 
4.4 Biological Activity of anti-ERBB2 Antibodies 
 
4.4.1 Effect of BH-antibodies on Breast Cancer Cell Growth 
Novel monoclonal antibodies recognising conformational ERBB2 epitopes 
hold promise as breast cancer therapeutics. Therefore the biological activities of BH-
antibodies were investigated on ERBB2-overexpressing human breast cancer cell 
line SK-BR-3.  
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Affinity purified anti-ERBB2 antibodies were added into SK-BR-3 culture 
media and relative cell growth was tested following 6 days of cell culture as 
explained above (Section 3.3.11). When SK-BR-3 cells were treated with anti-
ERBB2 antibodies alone, all BH-antibodies significantly decreased the cell density 
upon 6-day treatment. BH6 and BH1 antibodies displayed stronger inhibitory effects 
on SK-BR-3 target cells, by lowering relative cell growth to 62% and 71% 
respectively, as compared to isotype control antibody (Figure 4.20). 
 
 
Figure 4.20 Effects of BH-antibodies on SK-BR-3 cell growth. SK-BR-3 cells were 
plated onto 96-well plates and incubated at 37°C with 5% CO2. After 2 hours of incubation, 
BH-antibodies, Trastuzumab (Tzm) or IgG1 isotype control antibody (IgG) were added (5 
μg/ml), and the cells were incubated for 6 days. After 6 days of treatment, the percentages of 
surviving cells to controls, defined as 100% survival, were determined by Sulforhodamine B 
assay. Each antibody was tested in triplicates in more than ten independent experiments and 
the average values are represented as SK-BR-3 relative cell growth (%). T Bars, SD. *, 
decrease in relative cell growth wrt IgG isotype control treatment (p0.05). 
 
 
We performed a dose-effect curve assay with anti-ERBB2 antibodies, to find 
the lowest concentration that significantly decreases SK-BR-3 cells growth (Figure 
4.21). Under these conditions, as little as 1.25 μg/ml BH6 and 5 µg/ml BH1 was 
sufficient to cause significant growth inhibition (p=0.039 and p=0.005 respectively).  
A panel of other breast cancer cell lines with different levels of ERBB2 
expression was also tested for their sensitivity to BH-antibodies (Figure 4.22). While 
all BH-antibodies displayed significant growth inhibition on MDA-MB-361 cells, 
only BH1 performed a significant growth inhibition on BT-474 cells in comparison 
to isotype control antibody. As expected, none of the anti-ERBB2 antibodies tested 
induced a significant change in the relative cell growth of MCF-7 and T47D cell 
lines with low level ERBB2 expression. 
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Figure 4.21 Dose effect of BH-antibodies on SK-BR-3 cell growth. SK-BR-3 cells 
were treated with increasing amounts of (0.01-20 μg/ml) BH-antibodies or IgG1 isotype 
control antibody (IgG) as explained in Figure 4.20. Each condition was tested in triplicates 
and the average values are represented as relative cell growth (%). T Bars, SD. 
 
 
 
Figure 4.22 Effects of BH-antibodies on breast cancer cell panel with different 
levels of ERBB2 expression. Breast cancer cell lines expressing high levels of ERBB2; 
MDA-MB-361 and BT-474, and low levels of ERBB2; MCF-7 and T47D were treated with 
BH-antibodies as explained in Figure 4.20. Each treatment was tested in triplicates and the 
average values are represented as relative cell growth (%). T Bars, SD. *, decrease in relative 
cell growth wrt IgG isotype control treatment (p0.05). 
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It has been previously reported that tumor cells develop TNF-α-resistance due 
to increased signalling through growth factor receptors [279], and amplified 
expression of ERBB2 in breast cancer cells induces resistance to TNF-α cytotoxicity 
[83, 280]. In order to determine whether anti-ERBB2 antibodies were able to 
sensitize SK-BR-3 cells to TNF-α, cells were treated with anti-ERBB2 antibodies for 
6 days in the presence of TNF-α as explained before [84].  
In the experimental setting where 1000 Unit/ml TNF-α was applied together 
with 5 µg/ml anti-ERBB2 antibodies, all BH-antibodies caused a substantial decrease 
in SK-BR-3 growth rate, reversing TNF-α resistance (Figure 4.23). When SK-BR-3 
cells were treated with TNF-α only, a partial growth inhibition (43 %) was observed. 
When BH2, BH5, BH6 and BH7 were used in combination with TNF-α, they 
triggered 70-80 % growth inhibition; a response rate similar to Trastuzumab. With 87 
% growth inhibition, BH1 was far stronger than BH2, BH5, BH6, BH7 and 
Trastuzumab in the presence of TNF-α. 
 
 
 
Figure 4.23 Effects of BH-antibodies together with TNF-α on SK-BR-3 cell 
growth. SK-BR-3 cells were plated onto 96-well plates and incubated at 37°C with 5% 
CO2. After 2 hours of incubation, antibodies (5 μg/ml) were added, and cells were incubated 
for 4 hours prior to 1000 Unit/ml TNF-α addition. After 6 days of incubation, the 
percentages of surviving cells to controls, defined as 100% survival, were determined by 
Sulforhodamine B assay. Each antibody was tested in triplicates in more than ten 
independent experiments and the average values are represented as SK-BR-3 relative cell 
growth (%). T Bars, SD. *, decrease in relative cell growth wrt IgG isotype control treatment 
in the presence of TNF-α (p0.05). **, decrease in relative cell growth wrt Trastuzumab 
(Tzm) treatment in the presence of TNF-α (p0.05). 
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We tested increasing concentrations of BH-antibodies in the presence of 1000 
Unit/ml TNF-α to find the lowest antibody concentrations causing significant TNF-α 
sensitization of SK-BR-3 cells (Figure 4.24). Under these conditions, as little as 0.25 
μg/ml BH-antibodies were sufficient to significantly enhance TNF-α-mediated 
growth inhibition (p<0.005). Only one antibody, namely BH7, displayed a slightly 
weaker enhancer activity, reaching significance at 1.25 μg/ml concentration (p 
<0.02). Enhancer effects of BH-antibodies were nearly saturated at 2.5 μg/ml 
concentration (p <0.0007), reaching to 80 % growth inhibition. These effects were 
specific to BH-antibodies, since IgG1 isotype control antibody did not modify TNF-α 
response. 
 
 
 
Figure 4.24 Dose effect of BH-antibodies on SK-BR-3 cell growth in the 
presence of 1000 Unit/ml TNF-α. SK-BR-3 cells were treated with increasing amounts 
of (0.01-20 μg/ml) BH-antibodies or IgG1 isotype control antibody (IgG) in the presence of 
1000 Unit/ml TNF-α as explained in Figure 4.23. Each condition was tested in triplicates 
and the average values are represented as relative cell growth (%). T Bars, SD. 
 
 
Next, increasing concentrations of TNF-α were tested in the presence of 5 
µg/ml anti-ERBB2 antibodies to find the minimal TNF-α concentration that 
potentiates the growth inhibition of BH-antibodies (Figure 4.25). The lowest dose of 
TNF-α used in these experiments (62.5 U/ml) produced 27±5% growth inhibition. 
Increasing doses of TNF-α resulted in a limited increase of growth inhibition 
reaching to only 46±2% with the highest dose of TNF-α used in the experiments 
(4000 U/ml). When we repeated TNF-α treatments in the presence of 5 μg/ml IgG1 
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isotype control antibody, cellular response to TNF-α was not affected. In contrast, all 
five BH-antibodies (5 μg/ml) dramatically enhanced TNF-α-induced growth 
inhibition. Combination of 5 μg/ml BH1, BH2, BH5 or BH7 antibodies with 62.5 
U/ml TNF-α allowed more than 70% growth inhibition (p0.005). While BH6 had 
the highest growth inhibiton effect on SK-BR-3 cells when used alone, enhancement 
of its growth inhibition by TNF-α was slightly lower than for other BH-antibodies; 
leading to 60% growth inhibition in the presence of 62.5 U/ml TNF-α (p0.005). At 
the highest TNF-α dose used (4000U/ml); the presence of BH-antibodies increased 
the growth inhibition up to 85% (p0.005). 
 
 
 
Figure 4.25 Dose effect of TNF-α on SK-BR-3 cell growth in the presence of 5 
µg/ml BH-antibodies. SK-BR-3 cells were treated with BH-antibodies or IgG1 isotype 
control antibody (IgG) (5 µg/ml) in the presence of increasing TNF-α concentrations (0-4000 
Unit/ml) as explained in Figure 4.23. Each condition was tested in triplicates and the 
average values are represented as relative cell growth (%). T Bars, SD. 
 
 
A panel of other breast cancer cell lines with different levels of ERBB2 
expression were also tested for their sensitivity to 5 µg/ml BH-antibodies in the 
presence of 1000 Unit/ml TNF-α (Figure 4.26).  
BT-474 cells which express high levels of ERBB2 displayed partial TNF-α 
resistance similar to SK-BR-3 cells. TNF-α had 60% growth inhibitory effect on BT-
474 cells when used alone, and Trastuzumab sensitized the cells to TNF-α. On the 
contrary, while BH-antibodies increased TNF-α sensitivity on SK-BR-3 cells 
(Figure 4.23), they displayed an antagonistic effect on BT-474 cells; reaching to 
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total suppression of TNF-α-induced growth inhibition when used in combination 
with BH-antibodies (Figure 4.26).  
TNF-α was almost totally toxic for MDA-MB-361 cells; causing 96% decrease 
in the relative cell density when used alone. This drastic TNF-α induced growth 
inhibition/toxicity was slightly decreased by addition of BH1, BH2, BH5 and BH7 to 
the regimen (95-92% growth inhibition). Trastuzumab further increased the TNF-α 
induced growth inhibition to 98% (Figure 4.26). 
Previously, T47D cells were shown to be irresponsive to BH-antibodies 
(Figure 4.22); 1000 Unit/ml TNF-α alone or in the presence of BH-antibodies did 
not cause any significant growth inhibition either (Figure 4.26). BH1 and BH7 
caused modest but significant increase in T47D relative cell growth under these 
conditions. 
TNF-α at this concentration displayed stronger toxicity on MCF-7 cells than it 
displayed on MDA-MB-361 cells. While no anti-ERBB2 antibody related effect was 
expected on this low ERBB2-expressor, it was not possible to observe any potential 
additive/synergic interaction of BH-antibodies with TNF-α, due to the complete 
TNF-α toxicity. On the contrary to MDA-MB-361 cells, anti-ERBB2 antibodies had 
no suppressive effect on TNF-α toxicity; therefore it may be inferred that BH-
antibodies don’t function antagonistic to TNF-α on MCF-7 background under tested 
conditions (Figure 4.26). 
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Figure 4.26 Effects of BH-antibodies together with TNF-α on breast cancer cell 
panel with different levels of ERBB2 expression. Breast cancer cell lines expressing 
high (MDA-MB-361 and BT-474), and low (MCF-7 and T47D) levels of ERBB2 were 
treated with BH-antibodies as explained in Figure 4.23. Each treatment was tested in 
triplicates and the average values are represented as relative cell growth (%). T Bars, SD. *, 
decrease in relative cell growth wrt IgG isotype control treatment in the presence of TNF-α 
(p0.05). **, increase in relative cell growth wrt IgG isotype control treatment in the 
presence of TNF-α (p0.05). 
 
 
4.4.2 Effect of BH-antibodies in Combinatorial Treatments 
In order to examine drug interactions between BH-antibodies, we used BH-
antibodies in paired combinations and tested their effect on SK-BR-3-growth 
(Figure 4.27). In the absence of TNF-α, combinations of BH1+BH7 and BH2+BH6 
were found to be significantly stronger than each of the individual antibodies alone 
(p0.05). When pairwise BH-antibody combinations were examined in the presence 
of 1000 Unit/ml TNF-α, BH7 combinations with BH2, BH5 and BH6 decreased SK-
BR-3 cell growth more than any of the participant antibodies alone (p0.05). In the 
presence of TNF-α, BH1 was found to be the most potent antibody and none of the 
BH-antibody combinations could reach the growth suppression attained by BH1 
alone (Figure 4.27). In order to investigate whether the observed decrease in cell 
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growth was a simple additive effect due to the increased total antibody concentration, 
we conducted another experiment. Here, SK-BR-3 growth responses to paired 
combinations of 2.5 µg/ml BH-antibodies were compared with individual treatments 
with each BH-antibody at 5 µg/ml concentration. Growth inhibitions obtained with 
BH2+BH7 and BH6+BH7 combinations in the presence of 1000 Unit/ml TNF-α 
were significantly higher than individual BH-antibodies used at 5 µg/ml 
concentration (data not shown). 
 
 
 
 
Figure 4.27 Effect of paired BH-antibody combinations on SK-BR-3 cell growth. 
SK-BR-3 cells were treated with BH-antibodies either alone or in paired combinations. Each 
individual antibody was used 5µg/ml per treatment and assays were performed as explained 
in Figure 4.23. IgG1 isotype control antibody treatment was used as negative control. Each 
condition was tested in triplicates and the average values are represented as relative cell 
growth (%). T Bars, SD. *, significant increase in the growth inhibitory effect of both agents 
(p0.05). 
 
 
In order to examine the drug interactions between BH-antibodies and 
Trastuzumab, each of the BH-antibodies was paired with Trastuzumab and their 
effect on SK-BR-3 cell growth was determined (Figure 4.28). For this, the growth of 
SK-BR-3 cells treated with combinations of equal amounts (2.5 µg/ml) of BH 
antibodies and Trastuzumab were compared with individual antibody treatments. In 
the absence of TNF-α, Trastuzumab combinations with BH2, BH5 and BH6 were 
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significantly stronger in SK-BR-3 growth inhibition than individual antibody 
treatments at equal doses. When the effect of the combined treatments (2.5 µg/ml 
each) were compared with individual antibody treatments performed at 
concentrations equal to the total antibody concentration in the combinations (5 
µg/ml), BH6+Trastuzumab was still significantly more potent than either of the 
individual antibodies. When used together with TNF-α, Trastuzumab combinations 
with BH2 and BH6 were significantly stronger in SK-BR-3 growth inhibition than 
individual antibody treatments both applied at equal doses (2.5 µg/ml) and twice 
doses (5 µg/ml). In the presence of TNF-α, BH1 alone was found to be the most 
potent antibody and neither Trastuzumab or BH-antibodies alone, nor other BH-
antibodies combined to Trastuzumab could reach the growth suppression attained by 
BH1 alone. 
 
 
 
 
Figure 4.28 Effects of drug interactions between BH-antibodies and 
Trastuzumab on SK-BR-3 cell growth. SK-BR-3 cells were treated with BH-antibodies 
and Trastuzumab (Tzm) either alone or in combination and assays were performed as 
explained in (Figure 4.23). Combined treatments where BH-antibodies and Trastuzumab 
were both used at 2.5 µg/ml were compared with treatments performed with 2.5 µg/ml or 5 
µg/ml individual antibodies. IgG1 isotype control antibody treatment (5 µg/ml) was used as 
negative control. Each condition was tested in triplicates and the average values are 
represented as relative cell growth (%).T Bars, SD. *, significant increase in the growth 
inhibitory effect of both agents (p0.05). 
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Previous results suggested that combining BH-antibodies with TNF-α has 
opposite effects on different cellular backgrounds. In order to investigate drug 
interactions between BH-antibodies and TNF-α in more details, we have analysed the 
growth responses of different breast cancer cell lines both according to Bliss model 
of independence and Loewe model of additivity.  
Previously, SK-BR-3, BT-474, MDA-MB-361, T47D and MCF-7 cells were 
treated with maximal effective doses of anti-ERBB2 antibodies (5 µg/ml), TNF-α 
(1000 Unit/ml) and their combination (Figure 4.29).  
On SK-BR-3 background, TNF-α combinations of all anti-ERBB2 antibodies 
had significantly stronger growth inhibitory effects than antibody-only and TNF-α 
only treatments  (denoted by “*” on Figure 4.29) The suggested synergy between 
TNF-α and BH-antibodies were confirmed by their Bliss scores significantly lower 
than 1 (0.35-077). However, while Trastuzumab+TNF-α combination had a 
significantly stronger growth inhibitory effect on SK-BR-3 cells than individual 
agents, it appeared “independent” on Bliss analysis, with a score of 0.95. 
On BT-474 background, BH1, Trastuzumab and TNF-α had significant growth 
inhibitory effects when used alone. However addition of all BH-antibodies 
significantly eliminated growth inhibitory effect of TNF-α (denoted by “**” on 
Figure 4.29), suggesting suppression. For BH2, BH5 and BH6, the growth inhibition 
caused by the antibodies alone were also suppressed when they were used in 
combination with TNF-α. The suggested antagonism between TNF-α and BH-
antibodies was confirmed by their Bliss scores significantly higher than 1 (1.40-
3.08). While Trastuzumab+TNF-α had significantly stonger growth inhibitory effect 
than TNF-α and Trastuzumab alone (denoted by “*” on Figure 4.29), its Bliss score 
(1.21) was higher than 1, indicating an antagonistic interaction. 
On MDA-MB-361 background, all BH-antibodies had significant growth 
inhibitory effects when used alone. In addition, under these conditions, TNF-α was 
almost completely toxic when used alone. When BH1, BH2, BH5 and BH7 were 
combined with TNF-α, they caused a modest but significant decrease on TNF-α 
toxicity (denoted by “**” on Figure 4.29). Bliss analysis generating scores higher 
than 1 (1.88-5.87) indicated antagonistic interactions between TNF-α and all BH-
antibodies. While Trastuzumab appeared ineffective on MDA-MB-361 cells when 
used alone, it significantly increased the growth inhibitory effect of TNF-α (denoted 
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by “*” on Figure 4.29), generating a Bliss score significantly lower than 1 (0.60) 
indicative of synergy. Though Bliss analysis suggest synergistic or antagonistic 
interactions between TNF-α and anti-ERBB2 antibodies, a definitive conclusion was 
not possible due to the high TNF-α toxicity in MDA-MB-361 cells. 
 
 
 
Figure 4.29 Effects of BH-antibodies on SK-BR-3 cell growth. Breast cancer cell 
lines expressing high (SK-BR-3, BT-474 and MDA-MB-361); and low (MCF-7 and T47D) 
levels of ERBB2 were treated with 5 µg/ml anti-ERBB2 antibodies, 1000 Unit/ml TNF-α or 
their combination and assayed as explained in Figure 4.23. Each treatment was tested in 
triplicates and the average values are represented as relative cell growth (%). T Bars, SD. *, 
significant increase in the growth inhibitory effect of both agents, when they are used in 
combination (p 0.05). **, significant decrease in the growth inhibitory effect of the most 
potent agent (p 0.05). Bliss scores of each drug combination are shown below each 
treatments. Hypothetical growth inhibition values that would have been observed if tested 
drugs behaved independently are shown as “no interaction” bars. 
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Neither anti-ERBB2 antibodies, nor TNF-α had any growth inhibitory effect on 
T47D cells. Bliss scores close to 1 confirm their independence under these conditions 
(Figure 4.29).  
Low ERBB2-expressing cell line MCF-7 was totally irresponsive to all of the 
anti-ERBB2 antibodies tested. On the contrary, TNF-α had a totally toxic effect on 
these cells when applied at a concentration of 1000 Unit/ml, therefore it was not 
possible to analyse drug interactions with anti-ERBB2 antibodies under tested 
conditions. 
In order to investigate drug interactions in a detailed manner, we have 
concentrated on one of the most potent BH-antibodies; BH1. BH1 (0, 0.16, 0.312, 
0.625, 1.25, 2.5 and 5 μg/ml) and TNF-α (0, 8, 16, 32, 62.5, 125, 250 and 500 U/ml) 
were combined at various doses and their effect on the growth of five selected breast 
cancer cell lines were analysed (Figure 4.30, Figure 4.31). In addition to testing 
growth of each cell line in 42 concentration combinations of BH1 and TNF-α, cell 
responses to each drug alone at increasing doses were also determined in this setting, 
which were necessary for the analysis of drug interactions according to Loewe model 
of additivity. Interactions between BH1 and TNF-α were analysed by both Bliss and 
Loewe methods and the interaction scores according to each method are given on 
Figure 4.30.  
It was previously shown that SK-BR-3 cells were sensitive to BH1 and TNF-α 
when used alone or in combination (Figure 4.20, Figure 4.23). Increasing doses of 
BH1 and TNF-α were found to decelerate the relative SK-BR-3 growth when used 
alone (Figure 4.30, Figure 4.31). Addition of BH1 at increasing doses potentiated 
the growth inhibiton observed by TNF-α at every dose tested (Figure 4.31). 
Increasing doses of TNF-α also had a similar effect at every BH1 dose tested, 
suggesting synergy between BH1 and TNF-α (Figure 4.31). Analyses of the data by 
both Bliss and Loewe methods indicated synergy between BH1 and TNF-α on SK-
BR-3 cells with interaction scores lower than 1 (Figure 4.30). 
It was previously shown that BT-474 cells were sensitive to solo BH1 and 
TNF-α treatments to a certain extent (Figure 4.22, Figure 4.26). While their TNF-α 
sevsitivity was found to be increased at increasing doses, sensitivity to BH1 
treatment alone at increasing doses was masked by high standard deviation observed 
(Figure 4.30, Figure 4.31). Although this prevented calculation of Loewe scores, 
142 
 
strong suppression of TNF-α-mediated growth inhibition observed even at very low 
BH1 doses (0.16 µg/ml) indicated significant antagonism strongly correlating with 
the previous results (Figure 4.26) and was confirmed by Bliss score higher than 1 
(Figure 4.30). 
Increasing doses of BH1 and TNF-α decreased the relative MDA-MB-361 
growth when used alone (Figure 4.30, Figure 4.31). While Bliss scores implied 
modest antagonism on MDA-MB-361 cells, Loewe analysis indicated a synergic 
interaction (Figure 4.30). Analyses of the relative growth levels in more details 
(Figure 4.31 right panel) suggested that derivation of single interaction scores may 
be an oversimplification as a TNF-α threshold was observed; above and below which 
the agents showed opposite interaction patterns. Above TNF-α IC50 concentration 
(125 Unit/ml), BH1 was found to decrease TNF-α toxicity, suggesting an 
antagonistic interaction. However below IC50 concentration (125 Unit/ml), BH1 
increased TNF-α toxicity, suggesting a synergic interaction. 
Although standard deviation values were high for T47D cells, it was clear that 
these cells were irresponsive to both agents when they were used alone or in 
combination (Figure 4.30, Figure 4.31); therefore Loewe score was not determined 
for this cell line either. On the other hand, Bliss score higher than 1 indicated 
antagonistic interaction between BH1 and TNF-α (Figure 4.30). 
While increasing doses of TNF-α decreased the relative MCF-7 growth when 
used alone (Figure 4.30, Figure 4.31), MCF-7 was irresponsive to BH1 treatment 
(Figure 4.30 left panel), therefore Loewe score was not determined for this cell line. 
On the other hand, with a Bliss score of 1.07, BH1 and TNF-α were found to act 
totally independent of each other on MCF-7 background.  
BH1 and TNF-α have synergic growth inhibitory effects on SK-BR-3 and 
MDA-MB-361 cells, they act antagonistic on BT474 cells and independently on 
MCF-7 cells. T47D cells were irresponsive to both agents. Therefore it can be 
inferred that there is a cell-dependent interaction between BH1 and TNF-α. 
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Figure 4.30 Interaction between BH1 and TNF-α on different breast cancer cell 
lines. SK-BR-3, BT-474, BDA-361, T47D and MCF-7 cells were treated with various 
combinations of BH1 (0, 0.16, 0.312, 0.625, 1.25, 2.5 and 5 μg/ml) and TNF-α (0, 8, 16, 32, 
62.5, 125, 250 and 500 U/ml) for 6 days and assayed as previously explained on Figure 
4.23. Average values representative of relative growth levels at each condition tested in 
triplicates are shown on the bubble graph. Bliss and Loewe interaction scores between BH1 
and TNF-α are shown next to the name of each cell line. ND, not determined. 
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Figure 4.31 Linear analyses of interaction between BH1 and TNF-α on different 
breast cancer cell lines. SK-BR-3, BT-474, BDA-361, T47D and MCF-7 cells were 
treated with various combinations of BH1 (0, 0.16, 0.312, 0.625, 1.25, 2.5 and 5 μg/ml) and 
TNF-α (0, 8, 16, 32, 62.5, 125, 250 and 500 U/ml) for 6 days and assayed as previously 
explained on Figure 4.23. Each treatment was tested in triplicates and the average values are 
represented as relative cell growth (%). T Bars, SD. (for visual clarity, T Bars are placed on 
one of the graphs for each cell line on which the data is displayed less overlapping).  
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4.4.3 Mechanism of Growth Inhibition Induced by BH-antibodies on 
SK-BR-3 Cells 
BH-antibodies significantly enhanced TNF-α mediated growth inhibition of 
SK-BR-3 cells even at very low doses (0.25 µg/ml, p<0.005), reaching to 80 % 
growth inhibition at higher doses (2.5 µg/ml, p <0.0007) (Figure 4.24). In addition, 
as little as 1.25 μg/ml BH6 and 5 µg/ml BH1 was sufficient to cause significant 
growth inhibition (p=0.039 and p=0.005 respectively) when used alone in SK-BR-3 
cells (Figure 4.21). In order to understand the mechanism of these effects, we have 
analysed BrdU-incorporation, SAβ-gal positivity and cell-cycle distribution of the 
treated cells.  
Long-term bromodeoxyuridine (BrdU) incorporation assay allows the detection 
of cells with permanent withdraw from cell cycle [292, 304]. When asynchronously 
growing cells are subjected to 24 hour BrdU incorporation assay, proliferating cells 
undergoing S-phase are labeled positively. Non-proliferating cells remain BrdU 
negative. Therefore, we tested 24 hour BrdU incorporation of SK-BR-3 cells treated 
with anti-ERBB2 antibodies or isotype control antibody for 1-6 days.  
When used alone, BH-antibodies displayed a modest but significant decrease in 
DNA-synthesis starting from day 2 (p<0.03, Figure 4.32). Following 72 hour 
treatment with a BrdU chase during the last 24 hours (day 2), cells treated with IgG1 
(5 μg/ml) control antibody displayed 95±3% BrdU incorporation, indicating that 
most of the cells were under proliferative state. Treatment with different anti-ERBB2 
antibodies (5 μg/ml) resulted in a modest, but statistically significant (p<0.03) 
inhibition of BrdU incorporation (Figure 4.32 Day2). The highest inhibition effect 
was observed with BH1 antibody, reaching to 45 % decrease in BrdU incorporation 
on day 6, similar to Trastuzumab (Figure 4.32 Day6).  
Treatment of cells with TNF-α (1000 U/ml) in association with IgG1 control 
antibody (5 μg/ml) caused progressive reduction in BrdU incorporation; increasing 
from 32 % inhibition on day 1 to 65 % inhibition on day 6. On the other hand, 
combination of anti-ERBB2 antibodies with TNF-α significantly accelerated this 
effect, leading to strong inhibition as early as day 1. The decrease in BrdU 
incorporation was 75 % on day 1 when TNF-α was combined with BH1 (p<0.0005), 
even stronger than Trastuzumab which caused 68 % inhibition (p<0.005) (Figure 
4.32 Day1).  
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Since BrdU incorporation was progressively and significantly decreased in the 
cells treated with TNF-α alone, the significance of addition of anti-ERBB2 
antibodies started to fade in time. In addition, a modest increase in BrdU 
incorporation was observed on later days with TNF-α combinations containing anti-
ERBB2 antibodies, due to the selection and expansion of resistant clones in time 
(Figure 4.32 Days 4-6). 
 Taken together, these findings indicated that both anti-ERBB2 antibodies and 
TNF-α provoked permanent loss of DNA synthesis in a substantial fraction of SK-
BR-3 cells. In addition, BH1 was persistently effective in inducing proliferation 
arrest both in the presence and absence of TNF-α, suggesting a potential for a 
putative anti-proliferative agent for the treatment of ERBB2-overexpressing cancers 
(Figure 4.32). 
In order to understand the role of senescence in the observed proliferation 
inhibition, we have examined SAβ-gal positivity of SK-BR-3 cells treated with 5 
µg/ml BH1, 1000 U/ml TNF-α or with their combination for 6 days (Figure 4.33).  
No substantial senescence induction was observed on SK-BR-3 cells after 1 or 
3 days of BH-antibody treatment (data not shown). When cells were analysed after 6 
days, only a limited extent of spontaneous senescence was detected on untreated SK-
BR-3 cells, which was modestly increased by 1000 U/ml TNF-α. However, 6 day 
treatment with 5 µg/ml BH1 led to significant amount of SAβ-gal positivity on SK-
BR-3 cells both in the presence and absence of 1000 U/ml TNF-α (Figure 4.33). 
While BH1 treatment significantly increased the fraction of SAβ-gal positive cells, 
its combination with TNF-α had a stronger effect on SK-BR-3 cells; drastically 
decreasing the colony sizes in addition to increasing the SAβ-gal positivity. As seen 
on SRB (Figure 4.23, Figure 4.24) and BrdU incorporation assays (Figure 4.32), 
both the total cell amount and the proliferation index considerably decreased on 6
th
 
day of BH1+TNF-α treatment. SAβ-gal assay additionally revealed that, most of the 
surviving cells entered senescence (Figure 4.33). Trastuzumab-mediated SAβ-gal 
positivity was similar to BH1 both in the absence and presence of TNF-α (Figure 
4.33). 
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Figure 4.32 Effects of BH-antibodies on SK-BR-3 DNA synthesis in the presence 
or absence of TNF-α. SK-BR-3 cells plated on coverslips in 12-well dishes were treated 
with 5 µg/ml BH-antibodies, Trastuzumab or IgG1 isotype control antibody with or without 
1000 U/ml TNF-α. Cells were pulsed with BrdU on day 1-6 following the addition of TNF-
α. Following 24 hour BrdU pulse, the cells were fixed and stained by anti-BrdU antibody. 
Signal detection was made by Alexa488-conjugated anti-mouse IgG antibody. Nuclei were 
counterstained with DAPI and examined using using Zeiss Axio Imager.A1 microscope. 
Representative photographs (3 frames per coverslip) were acquired. BrdU-incorporation 
index = (BrdU-positive cells/Total cells)x100. *, p<0.07 with respect to IgG or IgG+TNF-α. 
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Figure 4.33 Analysis of senescence induction upon BH1 treatment in the 
presence or absence of TNF-α. SK-BR-3 cells plated on coverslips in 12-well dishes 
were treated with 5 µg/ml BH1, Trastuzumab or IgG1 isotype control antibody with or 
without 1000 U/ml TNF-α. After 6 day treatment, cells were formaldehyde fixed and SAβ-
gal stained for 12 hours. Nuclei was counterstained with nuclear fast red and and cells were 
observed under light microscopy. SAβ-gal positive cells contain dark blue spots suggesting a 
senescent phenotype. 100 µM CPT (camptothecin) and 50 ng/ml Adriamycin were used as 
positive controls of senescence induction. 
 
 
In order to investigate the changes occurring in cell cycle distribution upon 
treatment with anti-ERBB2 antibodies in the absence or presence of TNF-α, we have 
analysed propidium iodide (PI)-stained 10,000 SK-BR-3 cells by flow cytometry 
(Figure 4.34).  
A time-dependent effect was observed on the distribution of cells between G1 
(Figure 4.34 C) and G2/M-phases (Figure 4.34 E) of cell cycle when SK-BR-3 cells 
were treated with 20 µg/ml anti-ERBB2 antibodies alone. While the fraction of 
G2/M-phase cells was increased on day 1 being accompanied with a decrease in the 
fraction of G1-cells, more pronounced effect of the antibody treatment on day 3 
onwards was the significant increase of cells present at G1-phase; suggesting an 
initial G2/M-arrest followed by G1-arrest (Figure 4.34 C and E). In addition, all 
anti-ERBB2 antibodies caused a significant decrease in the fraction of S-phase cells 
as early as day 1 (Figure 4.34 E). On the other hand, when used in the absence of 
TNF-α, anti-ERBB2 antibodies only had a modest effect on the fraction of SubG1-
cells (Figure 4.34 A).  
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Figure 4.34 Effects of BH-antibodies on SK-BR-3 cell cycle. SK-BR-3 cells plated 
on coverslips in 12-well dishes were treated with 20 µg/ml BH-antibodies, Trastuzumab 
(Tzm) or IgG1 isotype control antibody ± 1000 U/ml TNF-α were fixed on day1, day2, day3 
or day6. For each condition, propidium iodide stained 10,000 cells were analysed with flow 
cytometry. Day1 and day2 samples were seeded on the same day at 10
5
 cells/well. Day3 and 
day6 samples were seeded on the same day at 10
5
 cells/well and 2.5x10
4
 cells/well, 
respectively. 
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When SK-BR-3 cells were treated with 1000 U/ml TNF-α, the fraction of cells 
at G1-phase significantly increased as early as day 1 (Figure 4.34 D), accompanied 
with a decrease in S-phase (Figure 4.34 F) and G2/M-phase cells (Figure 4.34 H), 
suggesting G1-arrest. The change in cell cycle distribution induced at day 1 
continued throughout the 6 days analysed and was modestly enhanced by the 
addition of 20 µg/ml anti-ERBB2 antibodies (Figure 4.34 D, F, H). While the 
addition of anti-ERBB2 antibodies had a modest influence on the fractional change 
of G1-phase, S-phase and G2/M-phase cells caused by 1000 U/ml TNF-α treatment, 
they significantly increased the fraction of SubG1-cells in the presence of TNF-α on 
day 3 onwards, suggesting a role for apoptosis induction (Figure 4.34 B). 
Since BH1-treatment have decreased both the relative cell growth (Figure 
4.20, Figure 4.21) and the BrdU incorporation (Figure 4.32) of SK-BR-3 cells 
stronger than the other BH-antibodies, it was selected for further analysis. As the 
change in cell cycle distribution and BrdU-incorporation of SK-BR-3 cells treated 
with BH1 ±TNF-α were analysed together (Figure 4.35), the decrease in BrdU 
incorporation caused by BH1 antibody treatment was associated with a decrease in 
DNA-synthesis both in the presence and absence of TNF-α (Figure 4.35 C and E).  
When BH1 was used alone, BrdU incorporation decreased progressively in 6 
days (Figure 4.35 E). While the decrease in BrdU incorporation was coupled with 
G2/M-arrest on the first day of treatment (Figure 4.35 D), G1-arrest was dominant 
on day 2 onwards (Figure 4.35 B).  
Inhibition of BrdU incorporation caused by 1000 U/ml TNF-α was slightly 
stronger than 5 µg/ml BH1 treatment alone; both effects increased progressively in 
time in a parallel manner (Figure 4.35 E).  
Addition of BH1 modestly enhanced the effects of TNF-α on SK-BR-3 cell 
cycle distribution. The drastic and immediate decrease observed in BrdU 
incorporation (that was already saturated on day 1) when BH1 treatment was 
combined with TNF-α did not have a similarly strong complement in a single phase 
of the cell cycle. Rather, it appeared that the strong inhibition of BrdU incorporation 
was the result of the combined changes in all cell cycle phases. On the other hand, 
BH1 + TNF-α almost doubled the SubG1 fraction of cells on day 3 onwards (Figure 
4.35 A). 
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Figure 4.35 Change in cell cycle 
distribution and BrdU 
incorporation of SK-BR-3 cells 
upon BH1 treatment with or 
without TNF-α. A-D, SK-BR-3 
treated with 20 µg/ml BH1 or IgG1 
isotype control antibody ± 1000 U/ml 
TNF-α were fixed on day1, day2, 
day3 or day6. Cell cycle distribution 
of 10,000 propidium iodide stained 
cells were analysed with flow 
cytometry. Day1 and day2 samples 
were seeded on the same day at 10
5
 
cells/well. Day3 and day6 samples 
were seeded on the same day at 10
5
 
cells/well and 2.5x10
4
 cells/well, 
respectively. E, SK-BR-3 cells 
treated with 5 µg/ml BH1 or IgG1 
isotype control antibody with or 
without 1000 U/ml TNF-α were 
pulsed with BrdU on day 1-6 
following the addition of TNF-α. 
Following 24 hour BrdU pulse, the 
cells were fixed and stained by anti-
BrdU antibody. Signal detection was 
made by Alexa488-conjugated anti-
mouse IgG antibody. Nuclei were 
counterstained with DAPI and 
examined using using Zeiss Axio 
Imager.A1 microscope. 
Representative photographs (3 frames 
per coverslip) were acquired. BrdU-
incorporation index = (BrdU-positive 
cells/Total cells)x100. *, p<0.07 with 
respect to IgG or IgG+TNF-α. 
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ERBB2-mediated cell proliferation is documented to be stimulated through two 
major signal transduction cascades; PI3K-Akt mediated and Ras-Erk mediated 
pathways. While Raf/MEK/Erk activation induces Cyclin D1 promoter, increasing 
Cyclin D1 protein expression, leading to passage through restriction point [305]; 
PI3K mediated Akt activation is mainly responsible for phosphorylation and 
degradation of p27, in turn releasing CDK2 which will induce cell cycle progression 
upon interacting with Cyclin E [306]. Anti-ERBB2 antibodies Trastuzumab and 
Pertuzumab were shown to inhibit both Akt and Erk1/2 phosphorylation, leading to 
growth inhibition of cells that overexpress ERBB2 [102, 113, 206, 253]. 
In order to investigate the effects of BH1-treatment on effector pathways 
downstream ERBB2, we have treated SK-BR-3 cells with 10 µg/ml BH1 for 
different periods of time during 24 hours and analysed the changes in the 
phosphorylation status of ERBB2, Erk1/2 and Akt, in addition to the expression 
levels of Cyclin D1 (Figure 4.36). No significant change was observed in the 
expression levels of the proteins examined in untreated samples during 24 hours 
(Figure 4.36 A). While active Akt levels decrease starting from the 8th hour of BH1-
treatment, there was a sudden increase in the level of phospho Erk1/phospho Erk2, 
starting as early as 1 hour, showing a partial decrease between 4 and 24 hours of 
treatment (Figure 4.36 B). In parallel with these changes, we also observed 
progressive accumulation of Cyclin D1 levels detected as early as 4 hours of 
treatment (Figure 4.36 B). BH1-treatment did not induce a significant change in 
ERBB2 phosphorylation (Figure 4.36 B). Co-treatment of SK-BR-3 cells with 10 
mg/ml BH1 and 1000 U/ml TNF- displayed essentially the same type of alterations, 
suggesting that TNF-α did not modify the effects of BH1 antibody on phospho-Akt, 
phospho-Erk1/2 and Cyclin D1 in SK-BR-3 cell line (Figure 4.36 D). Indeed, 
treatment of cells with 1000 U/ml TNF-α alone did not affect any of the parameters 
studied, except inducing a delayed inhibition of Akt phosphorylation at 24 hours 
(Figure 4.36 C). 
Cyclin D1 levels in the cell were shown to be regulated in a cell cycle 
dependent manner. Necessary for the G1-checkpoint, Cyclin D1 remains elevated 
during G1-phase. Later, its expression is lost at the beginning of DNA-synthesis in S-
phase, and induced back at G2-phase [307]. In a review discussing the bi-phasic 
transition of G0/G1 checkpoint, Jones and Kazlauskas suggested that activated 
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MEK/Erk which is responsible for Cyclin D elevation is necessary to push the cells 
from G0 to early-G1, but is insufficient to proceed through late-G1. On the other 
hand, PI3K that is dispensible for the early-G1 transition, is necessary to drive the 
cells through late-G1 [308]. In parallalel with this review, roles of Raf/MEK/Erk and 
PI3K/Akt pathways in inducing Cyclin D1 promoter [305, 309, 310] and stabilization 
of Cyclin D1 protein through Akt-mediated inhibition of GSK-3β [311] respectively 
are extensively documented in literature [312].  
On the other hand, some groups demonstrated that, Erk phosphorylation is 
dispensible for the regulation of Cyclin D1 protein level [313], while PI3K is both 
necessary and sufficient for the induction of Cyclin D1 protein expression [314]. In 
addition, Wnt1-dependent GSK-3β inhibition is suggested as a substitute for 
PI3K/Akt pathway for Cyclin D1 stabilization [315]. Alternatively, Akt was 
suggested to induce Cyclin D1 stabilization through a totally GSK-3β-independent 
mechanism [316]. 
While required for G1/S transition, Cyclin D1 levels should decline in S-phase 
to allow DNA synthesis as elevated Cyclin D1 expression was shown to block DNA 
synthesis upon binding and inactivating PCNA [317]. Cyclin D1 accumulation in 
nucleus during S-phase was shown to disturb DNA replication, inducing double 
strand breaks leading to activation of DNA-PK, activation of Akt, in turn triggering a 
positive feedback loop of Cyclin D1 overexpression through suppression of GSK3β-
mediated Cyclin D1 degradation [318]. In addition, high amounts of Cyclin D1 was 
detected in senescence cells [319, 320].  
Cyclin D1 induction after mitogenic induction is a widely accepted 
phenomenon driving cells through G1/S transition and is accompanied with active 
Erk and Akt. On the other hand, the observed increase in Cyclin D1 levels can not be 
attributed to the renewal of cell culture media at time:0, since the cells were not 
serum-starved and synchronized prior to treatment; in addition there was no 
detectable Cyclin D1 induction in SK-BR-3 cells that received fresh media without 
BH1 antibodies (Figure 4.36 A). Therefore the Cyclin D1 increase observed upon 
BH1-treatment (Figure 4.36 B and D) is an accumulation rather than mitogenic 
induction upon media renewal. In addition, while Cyclin D1 increase was expected 
to follow Akt activation upon mitogenic induction, the observed Cyclin D1 
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accumulation observed following BH1-treatment was accompanied with a decrease 
in the level of phosphorylated Akt, negating the role of media renewal.  
In accordance with the literature cited above; decreased cellular growth 
(Figure 4.20, Figure 4.21), decreased BrdU-incorporation (Figure 4.32, Figure 
4.35), increased SAβ-gal staining (Figure 4.33), and Cyclin D1 accumulation 
(Figure 4.36 B and D) in addition to the changes in cell cycle distribution of BH1-
treated SK-BR-3 cells (Figure 4.34, Figure 4.35), suggests a role for BH1-treatment 
in induction of G0/G1-arrest.  
 
 
 
Figure 4.36 Effects of BH1±TNF-α treatment on molecular responses 
contributing to SK-BR-3 cell survival. SK-BR-3 cells were either untreated (A) or 
treated up to 24 hours with BH1 antibody (10 µg/ml) (B), TNF- (1000 U/ml) (C) or the 
combination of both agents (D). Cell lysates were prepared from cells harvested at indicated 
times (hr, hours) and expression of phospho-ERBB2 (pERBB2), phospho-Akt (pAkt), total 
Akt (Akt), phospho-Erk1/phospho-Erk2 (pErk1/2), total Erk1/Erk2 (Erk 1/2) and Cyclin D1 
were analysed by western blotting. Calnexin was used as a loading control. Untreated cells 
were incubated in a parallel experiment in the absence of any treatment. (Utr1, lysates of 
untreated cells collected after 1 hour.) 
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5 DISCUSSION AND CONCLUSION 
 
5.1 Novel anti-ERBB2 Antibodies Recognize Conformational 
Epitope(s) Restricted to Intact ERBB2-ECD 
Aiming to develop alternative therapeutics targeting ERBB2 receptor, we have 
generated five monoclonal antibodies against extracellular region of human ERBB2. 
The ex-vivo characteristics of these novel antibodies were investigated; significant 
ERBB2-affinity and anti-proliferative effect was demonstrated.  
All BH-antibodies efficiently reacted with human ERBB2 protein. While BH1 
and BH6 were the antibodies with highest affinity both for recombinant (Figure 4.5) 
and endogeneous ERBB2 (Figure 4.6, Figure 4.8), BH2 and BH5 were remarkable 
in that, when used at different antibody concentrations they produced two distinct 
BT-474 peaks with different fluorescence intensities (Figure 4.6). With no identified 
ligand, ERBB2 is a receptor known to homo-dimerize upon overexpression, 
suggesting the presence of different conformations in ERBB2-overexpressing cells 
[14]. It is possible that BH-antibodies have different affinities for distinct ERBB2 
conformations (i.e monomeric or dimeric), and they may interact with the less 
favoured conformations only when they are supplied in high concentrations. On the 
other hand, since cancer cells are unstable in nature, it is acknowledged that, despite 
being clonogenic, they may still contain distinct sub-populations. Therefore, another 
possibility is that, BH2 and BH5 may selectively interact with distinct BT-474 sup-
populations depending on the assay conditions. These sup-populations may diverge 
from each other in their level of ERBB2 expression, favoring homodimerization; 
alternatively they may express ERBB2 proteins with altered structure due to acquired 
genetic modifications. It should be noted that the recombinant ERBB2 protein used 
for the final booster immunization was a disulfide-linked ERBB2 homodimer which 
raises the possibility that BH-antibodies might be produced against conformational 
epitopes formed upon homodimerization. Supporting this possibility, the low affinity 
BH5 antibody interacted with ERBB2 proteins present on ERBB2-overexpressing 
BT-474 cells which were expected to contain high amounts of ERBB2 homodimers, 
but was inefficient in detecting ERBB2 proteins present on T47D cells (Figure 4.7). 
156 
 
Another indication for the recognition of conformational epitopes came from 
IP-western blot analyses. While BH-antibodies successfully pulled-down native 
ERBB2 (Figure 4.11), they failed to detect ERBB2 resolved under denaturing 
conditions of SDS-PAGE (Figure 4.10). The same feature which was also shared by 
Trastuzumab suggested that they all recognized conformational epitopes. 
Competition experiments indicated that BH-antibodies did not share the same 
epitope with Trastuzumab (Figure 4.12, Figure 4.13, Figure 4.14). In order to find 
which subdomains of ERBB2-ECD were responsible for the construction of each 
epitope, we aimed to mimic physiological folding and have cloned various ERBB2-
constructs where the extracellular subdomains were combined in different 
combinations (Figure 4.16).  
There was no significant interaction between BH-antibodies and the products 
of these artificial ERBB2 constructs. None of the BH-antibodies recognized 
individual ECD subdomains when they were cloned alone. Even when they were 
cloned in pairs, the fluorescent signal detected by BH-antibodies was very faint 
suggesting that the proper conformation of their epitope(s) may contain amino acids 
from all four subdomains; absence of any subdomain interfering strongly with the 
antibody recognition (Figure 4.17). On the other hand, even if all the amino acids 
constructing the epitope(s) are located on a single subdomain, presence of all the 
other subdomains may still be necessary to build the precise conformation. 
Trastuzumab recognizes a conformational epitope as well. However, all amino acids 
participating in its epitope formation were localized on subdomain IV [17] and its 
presence was sufficient for Trastuzumab recognition as indicated by the positive 
signals obtained with all truncated ERBB2 products containing subdomain IV 
(Figure 4.17). On the contrary, as also suggested by immunofluorescence results, all 
BH-antibodies recognize conformational epitopes whose construction necessitate the 
presence of all four ERBB2 ECD-subdomains. 
None of the BH-antibodies could immunoprecipitate ectopicly expressed 
ERBB2 products other than the full length protein (Figure 4.19); confirming the 
immunofluorescence results (Figure 4.17) and supporting the necessity of all four 
subdomains for successful antibody interaction. 
Huh-7 cells had low level endogeneous ERBB2 expression. While 
Trastuzumab was able to pull-down endogeneous ERBB2 in Huh-7 cells, only BH1 
157 
 
and BH6 managed weak immunoprecipitation (Figure 4.19). Though weakly, BH1 
and BH6 also detected endogeneous ERBB2 present in Huh-7 cells in 
immunofluorescence assays, unlike other BH-antibodies (Figure 4.17). The 
insensitivity of BH2, BH7 and especially of BH5 for ERBB2 in cells with low 
ERBB2 expression (Figure 4.7, Figure 4.17) supports the importance of 
overexpression-induced ERBB2 conformations for these antibodies. 
Covalent modifications, protein-protein interactions and external factors such 
as ligand concentration, pH and ionic strength induce conformational changes on 
proteins, influencing their functionality in vivo. While certain conformations are 
needed for the normal cellular activities, other conformations may be responsible for 
activation of destructive pathways. For this reason, rather than targeting hot spots 
present in every conformation, recent drug development strategies have narrowed 
their focus on targeting specific protein conformations and therefore conformational 
epitopes [321]. For some molecules, antibodies were generated that would 
specifically target oligomeric forms without interacting with the monomers [322]. 
Bioactive antibodies that are most effective against ERBB2-overexpressing 
tumors recognize conformational epitopes located at ECD subdomains involved in 
either receptor activation [17] or receptor dimerization [99]. Thus, the bioactivity of 
anti-ERBB2 antibodies may be strongly dependent on both the critical regions they 
occupy on the receptor and the conformations favoured for antibody recognition. 
Clarification of whether BH-antibodies recognize conformations present on 
structurally different ERBB2 proteins or conformations specifically induced upon 
overexpression needs further investigation. In either case, one of the most important 
aims of developing cancer therapeutics is to minimize damage caused for healthy 
cells; and antibodies capable of selective targeting will prove useful in clinic where 
there is increasing need to limit side-effects. 
 
5.2 Novel anti-ERBB2 Antibodies Perform Growth Inhibitory 
Effects on ERBB2-overexpressing Breast Cancer Cells and 
Influenced by TNF-α in a Cell Type Dependent Manner 
Novel monoclonal antibodies recognising conformational ERBB2 epitopes 
hold promise as breast cancer therapeutics. Therefore ex vivo effects of novel anti-
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ERBB2 antibodies were tested in five different breast cancer cell lines displaying 
different degrees of ERBB2 amplification and ERBB2 expression (Figure 4.8).  
Individually tested novel anti-ERBB2 antibodies (5 µg/ml) significantly 
decreased the relative growth of SK-BR-3 cells upon 6-day treatment and the 
strongest growth inhibition was obtained by BH6 and BH1 antibodies which lowered 
the relative cell growth to 62% and 71% respectively (Figure 4.20). When used 
alone, BH-antibodies were less effective as growth inhibitors, in comparison to 
Trastuzumab. This was not surprising. Indeed, even Trastuzumab has a modest 
growth inhibitory effect (56%), and Pertuzumab, the best therapeutic alterative to 
Trastuzumab, induces only 20% growth inhibition [84].  
It has been previously reported that TNF-α resistance caused by the amplified 
ERBB2 expression [83, 280] was significantly decreased by anti-ERBB2 treatment 
[84]. In the experimental setting where 5 µg/ml anti-ERBB2 antibodies were 
combined with 1000 U/ml TNF-α, BH-antibodies caused a substantial decrease in 
relative SK-BR-3 cell growth. BH2, BH5, BH6 and BH7 had a response rate similar 
to Trastuzumab in the presence of TNF-α (Figure 4.23). With ~85 % growth 
inhibition in the presence of TNF-α, BH1 was far stronger than other BH-antibodies, 
Trastuzumab or their paired combinations (Figure 4.23, Figure 4.27, Figure 4.28). 
In addition, as little as 0.25 μg/ml BH-antibodies were sufficient to significantly 
enhance TNF-α-mediated growth inhibition (p<0.005). TNF-α is one of the most 
potent anti-tumor factors when used at high concentrations, but its systematic 
toxicity hampers its clinical applications [323]. The sensitization of SK-BR-3 cells to 
TNF-α with anti-ERBB2 antibodies strongly suggests that combination with 
antibody treatment may help to achieve strong growth inhibition at TNF-α doses as 
low as 62.5 U/ml (Figure 4.24). 
Biological activities of BH-antibodies were also tested on other breast cancer 
cell lines. When used alone, all BH-antibodies tested at 5 µg/ml displayed significant 
growth inhibition on MDA-MB-361 cells, while trastuzumab was ineffective as a 
single agent. On the other hand, only BH1 performed a significant growth inhibition 
on BT-474 cells in comparison to isotype control antibody. As expected, MCF-7 and 
T47D cell lines with low level ERBB2 expression were irresponsive to anti-ERBB2 
treatment under tested conditions (Figure 4.22). Initial experiments where 5 µg/ml 
anti-ERBB2 antibodies were combined with 1000 U/ml TNF-α indicated that, BT-
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474 cells displayed a response opposite to SK-BR-3 cells, where addition of BH-
antibodies suppressed TNF-α-induced BT-474 growth inhibition (Figure 4.26). 
TNF-α was almost totally toxic for MDA-MB-361 and MCF-7 cells at 1000 U/ml, 
and addition of BH-antibodies did not alter this toxicity significantly under these 
conditions (Figure 4.26). Growth of T47D cells were unaffected by anti-ERBB2 
treatment, TNF-α and their combinations (Figure 4.26).  
Growth assays where BH-antibodies and TNF-α were tested in single dose 
combinations suggested that they had opposite modes of interaction on different 
cellular backgrounds; strongly synergic on SK-BR-3 and antagonistic on BT-474 
(Figure 4.29). Trastuzumab on the other hand, significantly increased the growth 
inhibitory effect of TNF-α on both cell lines (Figure 4.29). The sensitization of SK-
BR-3 cells to TNF-α cytotoxicity by mouse monoclonal antibody 4D5 (from which 
Trastuzumab has been humanized) was reported previously [84]. Though the Bliss 
analysis provided scores of 0.92 and 1.21 for their interaction on SK-BR-3 and BT-
474 backgrounds respectively, since their combined effect were significantly 
stronger than either Trastuzumab or TNF-α alone on both cell lines, their mode of 
interaction were accepted as additive if not synergistic on both cell lines.. 
While 2% more growth inhibiton than the most effective agent is enough to 
receive a significantly “synergistic” Bliss score when the cell is almost irresponsive 
to one of the agents (i.e 5 µg/ml Trastuzumab + 1000 Unit/ml TNF-α on MDA-MB-
361 cells; Figure 4.29), even 17% more growth inhibition than both of the agents 
may still yield an “antagonistic” Bliss score when the individual growth inhibitions 
of both agents are around 60% (i.e 5 µg/ml Trastuzumab + 1000 Unit/ml TNF-α on 
BT-474 cells; Figure 4.29). In addition, Bliss analysis does not consider “additivity” 
which is a very important phenomenon of drug interactions [296]. In a review where 
different methods used for the determination of the drug interactions were compared, 
Lee et. al. highlighted the major differences between the Loewe additivity model and 
Bliss independence model; while the former was suggested to be used in mutually 
exclusive drug settings, the latter was suggested to be used in mutually nonexclusive 
drug settings [296]. Therefore, we used both Loewe additivity model and Bliss 
independence model in order to drive conclusions regarding the drug interactions 
between BH-antibodies and TNF-α on checkerboard assays. 
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Being the most potent of all five novel anti-ERBB2 antibodies, BH1 was 
selected to further investigate the drug interactions between BH-antibodies and TNF-
α on different breast cancer cell lines in more details. The checkerboard assay results 
where growth of each cell line was examined on a 7x8 grid of BH1 antibody and 
TNF-α combinations were analysed by two separate drug interaction analysis 
methods; Bliss model of independence and Loewe model of additivity (Figure 4.30).  
According to checkerboard analyses, synergy between BH1 and TNF-α on SK-
BR-3 cells was confirmed by both methods. On the contrary, BH1 concentrations as 
low as 0.16 µg/ml strongly suppressed TNF-α induced growth inhibition of BT-474 
cells, confirming their antagonistic interaction on BT-474 background (Figure 4.30).  
Since both of the cell lines had high degree of ERBB2 amplification and 
ERBB2 expression, it was interesting to observe opposing drug interactions on SK-
BR-3 and BT-474. Gijsen et. al demonstrated opposing effects between anti-ERBB2 
treatment and TNF-α on BT-474 model; Trastuzumab mediated decrease of 
phosphorylated Akt was shown to induce ADAM-mediated activation of TNF-α, 
creating a negative feedback loop and resulting in anti-ERBB2 resistance [202]. In 
addition, multiple other pathways participate in the effects observed downstream of 
ERBB2 receptor and TNF-α (Sections 1.2 and 1.5); and various articles comparing 
the molecular signatures of breast cancer cell lines displayed numerous differences 
between the expression profiles of SK-BR-3 and BT-474 [286–289] (Table 3.4). 
Detailed molecular analysis is requied to identify the exact players responsible for 
the opposing modes of interaction observed on SK-BR-3 and BT-474. 
While it was not possible to calculate Loewe interaction scores on MCF-7 and 
T47D backgrounds due to their BH1-insensitivity, Bliss scores indicated 
independence and antagonism for MCF-7 and T47D respectively (Figure 4.30). 
Although Bliss scores implied modest antagonism on MDA-MB-361 cells, Loewe 
analysis indicated a synergic interaction. Linear analysis of the effect of BH1 and 
TNF-α combinations indicated a more complicated interaction; BH1 decreased TNF-
α toxicity above IC50 concentration of TNF-α (125 Unit/ml), while increasing its 
toxicity below IC50 (Figure 4.31). 
As a conclusion, BH-antibodies induced selective growth inhibition of breast 
cancer cell lines depending on their level of ERBB2 expression and cellular 
background. When used alone, novel anti-ERBB2 antibodies significantly inhibited 
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the growth of SK-BR-3, BT-474 and MDA-MB-361 cells with ERBB2 
overexpression; while no detectable effect was observed on MCF-7 and T47D cells 
lacking ERBB2 amplification. When the antibodies were tested in combination with 
TNF-α, they acted synergistically on SK-BR-3 cells, while they had antagonistic 
effects on growth of BT-474 cells. 
 
5.3 BH-antibodies Induce G0/G1 Arrest on ERBB2-overexpressing 
SK-BR-3 Cells 
BH-antibodies had a substantial therapeutic effect on ERBB2-overexpressing 
SK-BR-3 cells ex-vivo, significantly decreasing the total number of cells upon 6 day 
treatment ±TNF-α. In order to understand whether they modulate proliferation, 
senescence and/or apoptosis mechanisms, we have analysed BrdU-incorporation 
(Figure 4.32), SAβ-gal positivity (Figure 4.33) and cell-cycle distribution of the 
treated cells (Figure 4.34).  
When BrdU incorporation was assessed, a modest yet significant inhibition 
was observed starting from the second day of anti-ERBB2 treatment; strongest 
response was obtained by BH1 antibody. When BH-antibodies were used in 
combination with TNF-α, BrdU incorporation was decreased down to 25 % starting 
from the first day, which was not present in IgG control samples (Figure 4.32).  
The significance of the combined treatments started to decrease on the 
following days due to decelerating BrdU incorporation observed by TNF-α alone. In 
addition, expansion of the resistant clones survived from the devastating initial effect 
of the combined treatment caused a modest increase in the BrdU incorporation index 
of combined treatments on later time points. Despite these, inhibitory effect of BH1 
+ TNF-α was still significantly higher than TNF-α alone until the sixth day of 
treatment; suggesting limited resistance to BH1 in the presence of TNF-α (Figure 
4.32). Indeed, microscopic analysis revealed that colony size was dramatically 
decreased after 6 days BH1 + TNF-α treatment, and the surviving cells were almost 
totally SAβ-gal positive; suggestive of senescence induction (Figure 4.33). To 
summarize, BH1 was the strongest anti-proliferative agent among all BH-antibodies 
both in the presence and absence of TNF-α. 
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Anti-ERBB2 treatments were shown to have substantial effects on cell cycle 
distribution of SK-BR-3 and BT-474 cells. Significant decrease in BrdU 
incorporation after Trastuzumab and Pertuzumab treatments were accompanied with 
reduced percentage of S phase cells and increased percentage of G0/G1 cells [324, 
325]. Anti-ERBB2 antibodies were also shown to induce G2-arrest [257]. 
In order to determine the cell cycle phases affected by BH1 treatments and to 
investigate whether the proliferation inhibition was also accompanied by apoptosis, 
the cell cycle distribution of the treated SK-BR-3 cells were analysed (Figure 4.34). 
In addition, expression of some of the effector proteins downstream ERBB2 were 
examined by western blotting (Figure 4.36).  
BH1 treatment caused a modest decrease in S-phase cells on the first day of 
treatment; an effect more significant starting from day 2. While the decrease in S-
phase was accompanied with an increase in G2/M-phase cells on the initial days of 
treatment; a significant G0/G1-arrest as well as increase in SubG1 cells was observed 
on the later days (Figure 4.35). In addition to these changes, phospho-Erk1/phospho-
Erk2 levels were elevated as early as 1 hour. Although their phosphorylation was 
slightly decreased between 4 and 24 hours, it still remained higher than the pre-
treatment levels. While phospho-Akt levels decreased starting from 8
th
 hour, Cyclin 
D1 started to accumulate as early as 4 hour (Figure 4.36).  
TNF-α signaling generates both cell survival and apoptosis signals, depending 
on the activation of NFB transcription factor [326]. Under tested conditions, TNF-α 
treatment caused a decrease in the fraction of S-phase cells throughtout the analysis, 
together with an increase in G0/G1 fraction. The further increase observed in the 
fraction of cells at G0/G1-phase on day 6 was accompanied with strong inhibition of 
BrdU incorporation. No significant apoptosis induction was observed by TNF-α 
treatment alone (Figure 4.35). Of all the molecular effectors analyzed, only 
phospho-Akt levels were affected by TNF-α treatment; a delayed inhibition of Akt 
phosphorylation was observed at 24 hours (Figure 4.36).  
The decrease in the fraction of S-phase cells obtained by BH1 or TNF-α alone 
was coupled with strong increase in G0/G1 fraction starting from day 1 when the two 
agents were combined, and accompanied with a drastic inhibition of BrdU 
incorporation. In addition, strong SAβ-gal positivity was obtained on day 6, 
suggesting induction of senescence. Yet, proliferation inhibition coupled to 
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senescence induction was not the only route by which they led to decrease in colony 
size of ERBB2 overexpressing cancer cells. Cell cycle analysis also revealed that 
BH1-induced apoptosis was significantly substantiated by the addition of TNF-α. 
Since apoptotic cells do not remain intact in the culture media for long periods, the 
observed subG1-peaks represent the recent apoptosis instead of reflecting the total 
amount of cells that has entered apoptosis over time. Therefore samples collected on 
each day should be evaluated individually and the total apoptotic response should be 
envisioned additively. Apoptotic response upon BH-antibody ±TNFα treatment 
started to get stronger second day onwards, reaching highest levels on the sixth day 
(Figure 4.35). Complementation of TNF-α cytotoxicity suggests BH-antibodies as 
potential therapeutic agents for TNF-α resistant, ERBB2 overexpressing breast 
cancer cases. On the other hand, TNF-α did not modify the effects of the BH1 
antibody on phospho-Akt, phospho-ERK1/2 and Cyclin D1 in SK-BR-3 cell line, 
suggesting involvement of other molecular effectors and/or pathways (Figure 4.36).   
Information gathered on cell cycle distribution of cells analysed by PI-staining 
depends on the DNA-content of the cells. Since it is technically not feasible to 
distinguish regular G1-phase cells from the cells arrested at G0 (senescent) and G1 
(quiescent), proliferation inhibition and senescence induction effects of a treatment 
maybe underestimated if only judged by cell cycle analysis. In order to overcome 
this limitation, both the fraction of non-proliferating cells and the extent of 
senescence-induction were considered in addition to the cell cycle distribution of the 
treated cells. Therefore, when accompanied with SAβ-gal positivity, inhibition of 
DNA synthesis (decrease of S-phase cells and BrdU-incorporation) and G0/G1-
accumulation strongly suggested senescence instead of a regular G1-arrest. 
Signal transduction downstream ERBB2 proceeds mainly through PI3K and 
MAPK pathways and involves PI3K-dependent activation of Akt and Ras-dependent 
activation of Erk1/2; leading to cell survival and proliferation. Therapeutically 
relevant Anti-ERBB2 antibodies were previously shown to exert their effect through 
inhibition of Akt and Erk1/2 phosphorylations [102, 113, 206, 253]. In addition, 
Cyclin D1 levels were demonstrated to be elevated throughout the cell cycle except 
S-phase indicating that its degradation was required for the initiation of DNA 
synthesis. Therefore, Cyclin D1 accumulation was suggested to block DNA-
synthesis and G1-S transfer; inducing G1-arrest [307]. Here we show Cyclin D1 
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accumulation was coupled to Akt deactivation when SK-BR-3 cells were treated with 
BH1 antibody either in the presence or absence of TNF-α; suggesting accumulation 
of cells at G1 and G2/M phases. 
The observations summarized on Table 5.1 suggest that, the early influence of 
BH1 treatment was induction of G2/M-arrest, whereas its later effect was more 
pronounced as G0/G1-arrest and senescence induction. TNF-α on the other hand, 
appears to cause G0/G1-arrest throughout the treatment period without a significant 
apoptosis induction; and was accompanied with a modest senescence induction on 
day 6. Combination of BH1 with TNF-α induced stronger outcomes both 
macroscopically and on a molecular basis. BH1+TNF-α led to a dramatic G0/G1-
arrest as early as day 1; this strong proliferation inhibition was significantly 
associated with a senescent phenotype and accompanied with apoptosis induction at 
later time points; suggesting profound multifunctional effects on elimination of 
ERBB2-overexpressing cells. Further molecular analyses of additional effectors will 
enable us understand the exact mechanism of these treatments and suggest alternative 
adjuvant settings in treatment of ERBB2-overexpressing breast cancers. 
It should be noted that, stabilization of Cyclin D1 protein through Akt-
mediated inhibition of GSK-3β is extensively documented in literature [312], and on 
the contrary to our results, Trastuzumab-induced decrease of Akt phosphorylation 
was suggested to decrease Cyclin D1 levels through GSK-3β stabilization [113]. In 
addition, anti-ERBB2 treatment was also documented to increase p27 stability [113] 
inhibit CDK2 [39] and decrease Cyclin E levels [327]. Examination of these 
additional molecular effectors will aid in the detailed verification of changes 
occurring on PI3K and MAPK pathways upon BH-antibody treatment.  
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BH1 TNF- BH1+TNF-
Apoptosis ~ ~ ~
G1             
S          ~        
G2/M                 
         ~                  
p-Akt (t:8hr) (t:24hr) (t:8hr)
p-Erk (t:1hr)  (t:4hr) ~ (t:1hr)  (t:4hr)
Cyclin D1 (t:4hr) ~ (t:4hr)
BH1 TNF- BH1+TNF-
Apoptosis            ~   
G1           
S          
G2/M            
                         
++ + +++
~  Colony size
BrdU Incorporation
SA -gal positivity
Late Effects (6 days)
Cell Cycle 
Analysis
Early Effects (24 hr)
Cell Cycle 
Analysis
BrdU Incorporation
Downstream 
Effectors
 
Table 5.1 Summary of biological activities of BH1, TNF-α and their 
combination on SK-BR-3 cells. SK-BR-3 cells were treated with BH1 antibody, TNF-α 
or their combination. Macroscopic and molecular changes observed 24 hours (early effects) 
or 6 days (late effects) after each treatment are listed.  
 
 
Besides PI3K and MAPK pathways, multiple other pathways either acting 
interactively or independently were documented to perform anti-ERBB2 and TNF-α 
responses of ERBB2-overexpressing cells. While NFB induced c-FLIP was shown 
to inhibit caspase-8-mediated ERBB2 cleavage decreasing TNF-α induced apoptosis 
[272], Akt inhibition was documented to sensitize these cells to TNF-α induced 
apoptosis through deactivation of NFB [280]. Treatment with anti-ERBB2 agents 
together with TNF-α was shown to down-regulate Akt-phosphorylation and induce 
apoptosis through cleavage of caspase-8, caspase-3 and poly(ADP)ribose polymerase 
(PARP) [328]. The advances in molecular biology rapidly unravel the resistance 
mechanisms faced in clinics during cancer therapy. Therefore, analysis of signalling 
pathways other than PI3K and MAPK pathways are also necessary to derive a more 
definitive conclusion regarding the exact mechanism of individual and combined 
treatments. 
As a conclusion, we have developed five novel anti-ERBB2 antibodies, all 
reacting with conformational epitopes formed by the intact extracellular region of 
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native human ERBB2 protein. Although we do not yet know whether our antibodies 
recognize identical, overlapping or independent epitopes on the intact ECD domain, 
it is evident that their epitope(s) is different from those recognized by Trastuzumab 
and Pertuzumab. Antibodies directed to ECD epitope(s) different from other anti-
ERBB2 therapeutic antibodies may serve as new analytical tools to study the 
structural organization of ERBB2 at the cell surface that may be present as 
monomers, homodimers and heterodimers depending on cell type and extracellular 
environment such as the availability of ligands that activate heterodimer partners of 
ERBB2. Dynamic changes at the receptor ECD in relation with transcriptional, 
translational and post-translational modifications can be monitored with these 
antibodies, both biochemically and biologically. In addition, regarding their growth 
inhibitory, senescence and apoptosis inducing effects, the novel antibodies may be 
potent anti-cancer agents. BH1, followed by BH6 stood out being the strongest anti-
proliferative agents. Although BH2, BH5 and BH7 were weaker anti-proliferative 
agents, they reacted with ERBB2 epitopes selectively present on ERBB2-
overexpressing cells which would be quite useful in clinic where there is increasing 
need to limit side-effects on healthy cells. Cell-dependent synergy and antagonism 
between anti-ERBB2 antibodies and TNF-α provide evidence for a complex 
interplay between ERBB2 and TNF-α signaling pathways. Such complexity may 
drastically affect the outcome of ERBB2-directed therapeutic interventions. 
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6 FUTURE PERSPECTIVES 
 
Anti-proliferative effects of BH-antibodies suggest that it would be feasible to 
investigate these antibodies further as potential alternative therapeutics for ERBB2-
overexpressing cancer therapy. Yet their efficiency should be validated in vivo; their 
exact action mechanism and individual epitopes preferred by each novel anti-ERBB2 
antibody should be revealed through additional investigations; and any possible 
resistance should be determined. 
As preliminary results suggest that some of these novel antibodies may be 
interacting with ERBB2 epitopes selectively present on dimerized receptors, it is 
judicious to investigate the affinities of each antibody for monomeric, homo- and 
heterodimeric ERBB2 molecules and complexes. Chemical cross-linkers such as 
bis(sulfosuccinimidyl) suberate selectively stabilize oligomeric complexes present in  
the cellular milieu, especially on the cell membrane. Analysis of the interaction 
between the antibodies and the dimerized receptor complexes stabilized by chemical 
crosslinking would enable detection of the preferred conformations by each antibody. 
A thorough MALDI-TOF mass spectrometric analysis may further be used for 
detailed epitope mapping [329]. It is suggested that antireceptor therapy by some 
monoclonal antibodies may affect oligomerization status [330], and internalization of 
ERRB receptors [258]. In this regard, exploration of the changes in cellular ERBB2 
dimerization and membrane localization statuses upon treatment would provide 
invaluable information on therapeutic activity of these novel anti-ERBB2 antibodies. 
Novel antibodies demonstrated cell-dependent synergy and antagonism 
between with TNF-α. Therapeutic potentials and selective targeting efficiencies of 
the BH-antibody treatments in presence and absence of TNF-α need to be validated 
on heterogeneous cell populations both in vitro and in vivo. Co-cultures of 
differentially labelled normal human mammary epithelial cells (HMECs) and 
ERBB2-overexpressing breast cancer cell lines would be useful to mimic the 
tumorigenic breast tissue. In addition, the anti-proliferative effects, effective dose 
ranges, potential side-effects and the tissue disposition need to be verified in vivo 
using mice xenografts. Furthermore, it will be useful to examine whether ADCC 
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induction is one of the mechanisms by which the novel anti-ERBB2 antibodies 
eliminate tumor cells in vivo. 
The detailed analysis of downstream pathways activated by BH-antibodies will 
unveil the precise mechanism of their action and enable us to place them in the 
correct therapeutic combination according to the molecular signature of the tumor to 
be treated. Therefore, the changes in expression and phosphorylation levels and the 
localization of effector proteins in PI3K and MAPK pathways such as PI3K, Src, 
PTEN, GSK3β, p70S6K, p27, CDK2, Cyclin E; and effector proteins in NFB 
pathway such as NFB, c-FLIP, caspase-8, caspase-3, PARP should be examined 
upon BH-antibody treatment both in the presence and absence of TNF-α.  
Examination of downstream effectors on different cell lines will also reveal the 
mechanism of the opposite responses observed on SK-BR-3 and BT-474 cells upon 
BH-antibody treatment in combination with TNF-α. 
It is long been known that, upto 88 % of the patients developed resistance to 
Trastuzumab therapy depending on the stage of the disease and the treatment regime. 
Numerous mechanisms participating in resistance development were revealed as 
explained above. Some of the resistance was due to the mutations or deletions of the 
effector molecules downstream of antibody binding; such as activating PI3K 
mutations, Cyclin E overexpression and PTEN deletion. However, other mechanisms 
inducing resistance could be by-passed through targeting different ERBB2 epitopes. 
For instance, it is possible to evade destructive effects caused by overexpression of 
other Her-family receptors (i.e. EGFR) and/or their ligands (i.e. EGF, TGF-α, 
heregulins) or other receptors types (i.e. IGF-1R) by preventing heterodimerization 
of ERBB2. Therefore growth inhibitory effects of BH-antibodies both in the 
presence and absence of TNF-α should be validated on cells overexpressing these 
additional factors. Part of the Trastuzumab resistance was documented to be caused 
by prevention of antibody binding either through blockage by MUC4 or by receptor 
shedding. Therefore, the effect of BH-antibody binding on prevention of receptor 
shedding should be studied. In addition, efficiency of BH-antibody antibody 
treatment should be examined on MUC4-overexpressing JIMT-1 cell line. It is also 
necessary to perform long-term BH-antibody treatments in vitro; in order to 
investigate potential resistance development. 
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Abstract 
Background 
One-third of breast cancers display amplifications of the ERBB2 gene encoding the 
HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an 
epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of 
HER2-overexpressiong mammary tumors. However, many tumors are either natively 
resistant or acquire resistance against Trastuzumab. Antibodies directed to different 
epitopes on the extracellular domain of HER2 are promising candidates for 
replacement or combinatorial therapy. For example, Pertuzumab that binds to 
202 
 
subdomain II of HER2 extracellular domain and inhibits receptor dimerization is 
under clinical trial. Alternative antibodies directed to novel HER2 epitopes may 
serve as additional tools for breast cancer therapy. Our aim was to generate novel 
anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, either 
alone or in combination with tumor necrosis factor-α (TNF-α). 
Methods 
Mice were immunized against SK-BR-3 cells and recombinant HER2 extracellular 
domain protein to produce monoclonal antibodies. Anti-HER2 antibodies were 
characterized with breast cancer cell lines using immunofluorescence, flow 
cytometry, immunoprecipitation, western blot techniques. Antibody epitopes were 
localized using plasmids encoding recombinant HER2 protein variants. Antibodies, 
either alone or in combination with TNF-α, were tested for their effects on breast 
cancer cell proliferation. 
Results 
We produced five new anti-HER2 monoclonal antibodies, all directed against 
conformational epitope or epitopes restricted to the native form of the extracellular 
domain. When tested alone, some antibodies inhibited modestly but significantly the 
growth of SK-BR-3, BT-474 and MDA-MB-361 cells displaying ERBB2 
amplification. They had no detectable effect on MCF-7 and T47D cells lacking 
ERBB2 amplification. When tested in combination with TNF-α, antibodies acted 
synergistically on SK-BR-3 cells, but antagonistically on BT-474 cells. A 
representative anti-HER2 antibody inhibited Akt and ERK1/2 phosphorylation 
leading to cyclin D1 accumulation and growth arrest in SK-BR-3 cells, 
independently from TNF-α. 
Conclusions 
Novel antibodies against extracellular domain of HER2 may serve as potent anti-
cancer bioactive molecules. Cell-dependent synergy and antagonism between anti-
HER2 antibodies and TNF-α provide evidence for a complex interplay between 
HER2 and TNF-α signaling pathways. Such complexity may drastically affect the 
outcome of HER2-directed therapeutic interventions. 
Keywords 
HER2, ERBB2, TNF-α, Monoclonal Antibodies, Epitope Mapping, Growth 
Inhibition, Breast Cancer, Synergy, Antagonism 
Background 
With a lifetime risk of ~12%, breast cancer is the most common cancer in women 
[1]. Although the survival rates of breast cancer patients are increasing due to the 
recently developed therapeutic approaches, breast cancer remains the most frequent 
cause of cancer-related death in women [2]. More than 225,000 new cases of female-
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breast cancer are estimated to occur in 2012, in the United States alone, and 40,000 
female deaths are expected as a result [3]. 25-30% of breast cancers display HER2 
overexpression [4]. ERBB2 gene amplification that was discovered in the early 1980s 
is the main cause of HER2 overexpression [5]. HER2 is a tyrosine kinase receptor 
belonging to the ErbB/HER family that also includes epidermal growth factor 
receptor (EGFR/HER1), ErbB3/HER3 and ErbB4/HER4. HER2 displays tyrosine 
kinase activity, but has no known ligand. ErbB family receptors are activated by 
homodimerization or heterodimerization. HER2 is activated either by ligand-
independent homodimerization when it is overexpressed, or by heterodimerization 
with a ligand-dependent ErbB/HER member, in particular with ErbB3/HER3 [6]. 
Following the discovery of ERBB2 gene amplifications in breast cancer, the HER2 
receptor became an attractive target for monoclonal antibody-based therapies. 
Trastuzumab is the first clinically approved humanized monoclonal antibody 
targeting HER2. It produced 11-26% overall response rates as monotherapy for 
metastatic breast cancer. In addition, as adjuvant to chemotherapy, Trastuzumab 
significantly increased disease-free and overall survival in both early stage and 
metastatic breast cancers. Trastuzumab is effective only in HER2-
amplified/overexpressing tumors and primary resistance to therapy is a challenge [7]. 
Moreover, the majority of metastatic breast cancer patients who initially respond to 
Trastuzumab begin to demonstrate disease progression again within 1 year [8]. 
Trastuzumab resistance was linked to many factors, including the overexpression of 
other ErbB/HER family receptors and/or their ligands [9,10], insulin-like growth 
factor receptors [11,12], MUC4 [13] and soluble extracellular domain (ECD) of 
HER2 circulating in the blood [14,15], activating PI3K mutations [16], PTEN 
deletions [17], downregulation of cyclin-dependent kinase inhibitor p27 [18] and 
increased Akt activity [19,20]. 
HER2-HER3 heterodimer is known to be the most potent activated form of HER2 in 
terms of strength of interaction, ligand-induced tyrosine phosphorylation and down-
stream signaling. Indeed, HER3 might be a necessary partner for HER2-mediated 
oncogenic activity in HER2-overexpressing tumors [6]. The ECD of HER2 is 
composed of four subdomains and Trastuzumab is directed to its subdomain IV [21]. 
The antibody inhibits HER2 activation [6], but cannot prevent HER2-HER3 
heterodimerization [22]. Pertuzumab is another antibody directed to another epitope 
that is located at subdomain II, which is involved in receptor dimerization [23]. It 
appears to be more effective than Trastuzumab, in particular in low HER2-
expressing tumor cells because of its ability to interfere with HER2-HER3 
heterodimerization [23]. Pertuzumab and Trastuzumab were shown to act 
synergistically against breast cancer cell survival [24], suggesting that antibodies 
against different epitopes of the ECD are able to generate not only additive but also 
synergistic cellular responses. The limited efficacy of Trastuzumab for cancer 
therapy, problems of acquired resistance and the potential impact of novel anti-HER2 
antibodies as therapeutic partners or alternative therapeutics justify more investment 
on HER2 targeting with novel monoclonal antibodies. Here, we describe five novel 
monoclonal antibodies directed against an epitope (or epitopes) restricted to the 
native conformation of HER2 ECD. In vitro studies provide evidence for anti-cancer 
activity of these antibodies. More interestingly, these novel antibodies appear to 
interact with tumor necrosis factor-α (TNF-α) in a cell-dependent manner, generating 
both synergistic and antagonistic growth responses. 
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Methods 
Reagents 
A disulfide-linked homodimer of histidine-tagged extracellular domain of HER2 
fused to human IgG1 Fc domain (HER2 ECD), a similar construct based on EGFR 
extracellular domain (EGFR ECD), and IgG1 isotype control antibody were from 
R&D Systems (MN, USA). Alkaline phosphatase (AP)- and horseradish peroxidase 
(HRP)-conjugated secondary antibodies to mouse and human IgGs, propidium 
iodide, trichloroacetic acid (TCA), Sulforhodamine B (SRB), Incomplete Freund’s 
Adjuvant, anti-calnexin antibody (#C4731), p-nitrophenyl phosphate, disodium salt 
(PNPP), 4', 6-diamidino-2-phenylindole (DAPI), insulin and Bromodeoxyuridine 
(BrdU) were from Sigma Aldrich (MO, USA). Anti-HER2 CB11antibody (#ab8054) 
was from Abcam (MA, USA). Anti-BrdU antibody (#M0744) was from Dako 
(Glostrup, Denmark). Anti-Akt (#9272), anti-phospho-Akt (#9271), anti-Erk 1/2 
(#9107), anti-phospho-Erk 1/2 (#9106) antibodies were from Cell Signaling (MA, 
USA). Anti-phospho-HER2 (#sc-1011694) and anti-Cyclin D1 (#sc-246) antibodies 
were from Santa Cruz (California, USA). Alexa Fluor 488-conjugated secondary 
antibodies to mouse and human IgGs and Lipofectamine 2000 were from Invitrogen 
(CA, USA). HiTrap Protein G HP columns and ECL plus western blot detection kit 
were from GE-Healthcare (WI, USA). Recombinant human TNF-α was from 
PeproTech (NJ, USA). RNAse A and all restriction enzymes were from Fermentas 
(Vilnius, Lithuania). Trastuzumab (Herceptin), EDTA-free protease inhibitor 
cocktail tablets and phosSTOP (phosphatase inhibitor cocktail) tablets were from 
Roche Ltd (Basel, Switzerland). Antibody isotyping kit was from Thermo Fisher 
Scientific Inc (IL, USA). Protein G coupled Sepharose gel slurry was from East 
Coast Biologics (ME, USA). 
Cell culture 
SK-BR-3, MDA-MB-361, T47D, MCF-7 and BT-474 cell lines were obtained from 
ATCC. Huh-7 cell line is used in lab since 1995 and was last tested for authenticity 
in 2010 (originally from Jack Wands Lab at Massachusetts General Hospital, Boston, 
MA). All breast cancer cell lines have been tested and authenticated by short tandem 
repeat profiling in September 2009 and February 2012, as described previously [25]. 
SK-BR-3 cells were grown in McCoy’s 5A medium. MDA-MB-361, T47D, MCF-7, 
BT-474 and Huh-7 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM), as described [25,26]. Hybridomas were grown in RPMI 1640, DMEM or 
Serum Free Media (SFM) from Hyclone (IL, USA). Cell culture media were 
purchased from GIBCO (CA, USA), Sigma or Hyclone, and were supplemented with 
10% fetal calf serum (FCS), 1% penicillin/streptomycin (P/S), 1% non-essential 
amino acids and 1% L-glutamine, unless otherwise stated. BT-474 cell growth 
medium was supplemented additionally with 10 μg/ml insulin. 
Florescent in situ hybridization analysis of ERBB2 copy numbers 
MCF-7, T47D, MDA-MB-361, SK-BR-3 and BT-474 cells were harvested at 
confluence and fixed in Carnoy’s fixative (3:1 methanol/glacial acetic acid). A dual-
color FISH was performed with Texas Red-labeled ERBB2 and FITC-labeled 
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chromosome 17 α-satellite (D17Z1) DNA probes mix (LPS 001; Cytocell Ltd, 
Cambridge, UK), as described by supplier with minor modifications. The slides were 
treated at 72°C for 2 min in denaturation solution containing 70% formamide, 
2XSSC (3 M NaCl, 0.3 M sodium citrate, pH 7.0). The probe mixture was applied 
onto slides; the area was covered with a 22X22 mm glass coverslip, sealed with 
rubber cement. Slides were placed on a hot plate and heated at 75°C for 5 min. The 
hybridization was done overnight at 37°C in humidified chambers. Post-
hybridization washes were done once with 0.4XSSC at 72°C for 2 min and once with 
2XSSC containing 0.05% Tween 20, at room temperature for 30 s. After post-
hybridization washes, the slides were dehydrated in a series of 70%, 85%, and 97% 
ethanol. Air-dried sides were counterstained with 4,6-diamidino-2-phenylindole 
(DAPI) in an anti-fade solution. Copy numbers in >100 nuclei of each cell line were 
counted under a Nikon Eclipse E600 epifluorescence microscope (Nikon Corp., 
Tokyo, Japan) equipped with filter sets appropriate for DAPI, FITC, and rhodamine. 
Individual single-color images of DAPI, FITC, and rhodamine were acquired 
through a high-sensitivity monochrome charge-coupled device (CCD) camera 
integrated to a Power Macintosh. Digitally acquired individual images were overlaid 
and operated with MacProbe image analysis software (PCI Scientific Systems 
League City, TX, USA). ERBB2 copy numbers and ploidy level based on average 
counts of centromere 17 in interphase and metaphase FISH were evaluated according 
to international standard cytogenetic nomenclature [27]. 
Generation of anti-HER2 monoclonal antibodies 
Animal experiments described here have been pre-approved by the Bilkent 
University Animal Experiments Ethical Review Panel, and conducted at Bilkent 
Animal House, which is certified by the Ministry of Agriculture of Turkey. All 
procedures complied with the guidelines of the Ministry of Agriculture (Official 
Gazette. No. 25464). BALB/c mice were immunized five times with live SK-BR-3 
cells (5–10 × 106 cells in PBS) by intra-peritoneal injection at three-week intervals. 
As a final booster, each mouse received 20 μg recombinant HER2 ECD protein 
injected with incomplete Freund’s adjuvant. On the third day of last immunization, 
mice were sacrificed and their splenocytes were fused with SP2/O myeloma cells to 
produce hybridomas as previously described [28]. 
HER2 ECD ELISA assay 
96-well Polysorb (NUNC, Roskilde, Denmark) microtiter plates were coated 
overnight at 4°C with HER2-ECD (25–50 ng/well) in carbonate buffer. Following 
saturation with 1% BSA for one hour, plates were incubated with hybridoma 
supernatants or purified primary antibodies for 2–4 h, and bound antibodies were 
detected by further incubation with AP-conjugated anti-mouse IgG antibodies. 
Trastuzumab binding was tested using AP-conjugated anti-human IgG antibodies. 
Phosphatase activity was measured using PNPP substrate with absorbance (OD) 
reading at 405 nm using μQuant ELISA reader (BioTek, VT USA). The cross-
reactivity tests with EGFR ECD were performed under the same conditions, except 
that ELISA plates were coated with EGFR ECD. 
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Antibody isotyping and affinity purification 
The isotypes of monoclonal antibodies were determined using a commercial kit. 
Selected hybridoma clones were expanded and the antibodies were purified from the 
culture supernatants by FPLC using HiTrap Protein G HP columns (GE Healthcare, 
WI, USA). 
Immunofluorescence 
Cells were seeded on coverslips in 6-well plates. After 36 h of cell culture, they were 
fixed with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100. 
Following saturation with 10% FCS, the fixed cells were incubated with anti-HER2 
antibodies for 90 min. Primary antibody binding was detected using Alexa Fluor 488 
conjugated goat anti-mouse IgG or Alexa Fluor 488 conjugated goat anti-human IgG 
antibodies, depending on the type of the primary antibody. Nuclei were 
counterstained with DAPI and cells were observed using Zeiss Axio Imager.A1 
microscope (Jena, Germany). 
Flow Cytometry 
Cells (3-4×105) were fixed with 2% paraformaldehyde and incubated 1 h with 5 
μg/ml anti-HER2 antibodies or IgG1 isotype control antibody (in 1% BSA and 0.5 
mg/ml NaN3 in PBS). Cells were then incubated 1 h with Alexa-488-conjugated anti-
mouse IgG antibody and the percentage of positively stained cells were counted on 
FACSCalibur (BD Biosciences). 
Immunoprecipitation 
For detection of endogenous HER2 protein, cells were lysed in RIPA buffer (150 
mM NaCl, 50 mM Tris–HCl pH; 7.4, 1 mM EDTA, 1% Triton X-100, 1% Na-
deoxycholate, 0.1% SDS, 1X Protease Inhibitors) [29,30], 2 mg protein were diluted 
with milder NP40 buffer (150 mM NaCl, 50 mM Tris–HCl pH: 8, 1% NP40, 1X 
Protease Inhibitors) and incubated with 20 μg antibody for 2 h on a rotator at 4°C. 
Then, 200 μl Protein G-coupled Sepharose gel slurry was added, and the mixture was 
incubated 4 h at 4°C. 
Western blot 
Following immunoprecipitation experiments, antigen-antibody bound Protein G 
beads were boiled in SDS-loading buffer; solubilized proteins were run on 8% or 4-
12% gradient SDS-PAGE. Proteins subjected to SDS-PAGE were transferred to 
PVDF membrane using XCell II Blot Module (Invitrogen, CA, USA). Unoccupied 
protein binding sites on the PVDF membrane were saturated by incubating with 5% 
dried milk (in TBS-T) for 1 h. Full length and truncated forms of HER2 protein were 
detected using CB11 antibody directed against intracellular domain. Briefly, 
membranes were incubated overnight with CB11 antibody (1/500 dilution), followed 
by 1 h incubation with HRP-conjugated secondary antibodies to mouse IgGs and 
bound antibody was detected using ECL plus western blot detection kit. 
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Epitope mapping 
The experiment was based on testing of antibody binding to HER2 proteins that have 
been modified by deletion of different subdomains of its ECD. Mammalian 
expression plasmids were constructed and transiently transfected into Huh-7 cells. 
Antibody binding was tested by combined immunoprecipitation-western blot and 
indirect immunofluorescence assays. A pDEST26-derived plasmid vector expressing 
full-length human HER2 protein (OCABo5050G0219D; shortly called p219D here) 
was obtained from Source BioScience LifeSciences (Nottingham, UK). HER2 
extracellular domain was extracted from p219D by Sac I/Eco RI digestion leaving 
the coding sequence for the N-terminal 22 amino acid signal peptide intact. pCC2001 
was produced by inserting Not I and Xho I sites between this sequence and the 
sequence encoding the rest of HER2 protein starting from the transmembrane 
domain. DNA sequences allowing the inclusion of domains I, II, III and IV of ECD 
under different combinations were amplified by PCR and inserted into pCC2001 
plasmid using the Not I and Xho I sites. The integrity of cloned sequences has been 
verified by DNA sequencing. Huh-7 cells (6×105) were transfected in 6-well plates 
with different HER2 plasmid constructs (5 μg each) using Lipofectamine 2000, 
following a protocol provided by the manufacturer. Following 8-h Lipofectamine 
incubation, cells were washed with PBS and incubated overnight with fresh complete 
media (without P/S). Next day, the cells were trypsinized and replated. On the 
second day of cell-expansion, the cells were collected, lysed in RIPA buffer and 
subjected to immunoprecipitation and western blot analyses as described above, 
except that 150 μg proteins were immunoprecipitated using 15 μg antibody. 
Cell growth assay 
These assay was performed as described previously [31]. Briefly, cells (10
3
) were 
seeded in 96-well plates in triplicate and allowed to attach by 2 h of preincubation. 
Antibodies were diluted in cell culture medium and added to preincubated cells to 
obtain 0–20 μg/ml concentrations under a final volume of 200 μl medium/well. Cells 
were then incubated up to 6 days. TNF-α treatment was performed similarly except 
that cells were preincubated for 6 h. For antibody and TNF-α co-treatment 
experiments and checkerboard assays, cells were preincubated for 2 h for attachment, 
followed by 4-h incubation with antibodies prior to TNF-α addition. At the end of 
each time point, culture supernatants were discarded. Attached cells were washed 
twice with PBS, fixed with ice-cold 10% TCA for one hour, followed by 
Sulforhodamine B-based reading, as described [32]. 
Drug interaction modeling 
Drug interaction scores for pairwise combinations of TNF-α with individual 
antibodies at fixed concentrations were calculated as follows. Growth level in a drug 
condition was defined as the growth measurement in the drug condition normalized 
by growth measurement under no drug. To understand the interaction between an 
antibody and TNF-α at certain concentrations, growth levels under single antibody, 
TNF-α, antibody + TNF-α were compared. Expected growth level under no drug 
interaction was defined for each pairwise drug combination as the multiplication of 
the growth levels under each individual drug, following the Bliss Independence 
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Model for drug interactions [33]. The observed growth level for each combination 
was divided by the expected growth level to find an interaction score. According to 
this analysis, a score of 1 means no interaction, or independence, a score smaller than 
1 means synergy, and a score larger than 1 means antagonism. For the drug 
interaction experiments where more than one concentration combination was 
experimentally tested, a single interaction score between two drugs was computed. 
For this, a modified version of the above algorithm and the data from all 
concentration combinations was used, as described previously [34]. The scores and 
the scale of these scores are equivalent to the single combination drug interaction 
experiment and are interpreted in the same way (<1 = synergy; >1 = antagonism). 
Each interaction experiment was done in triplicate, and the average growth levels 
were used for interaction score calculation. 
Bromodeoxyuridine incorporation assay 
Cells (10
4
) were plated on coverslips in 12-well plates, and treated as described for 
cell growth assays. At 48
th
 hour, BrdU (10 μg/ml) was added into cell culture media 
and cells were further incubated for 24 h. The detection of BrdU incorporation was 
performed as described previously [35], except that Alexa Fluor 488-conjugated anti-
mouse IgG antibody was used for visualization. Cell nuclei were counterstained with 
DAPI, examined using Zeiss Axio Imager.A1 microscope and representative 
photographs (3–5 frames per coverslip) were acquired. Percent BrdU incorporation 
was calculated after manual counting of BrdU-positive (BrdU
+
) and BrdU-negative 
(BrdU
-
) nuclei. 
Cell cycle analysis 
Analyses were performed as described previously [36]. Briefly, 2.5×104 (for 6-day 
samples) or 10
5
 (for 1 and 3-day samples) SK-BR-3 cells were seeded in 6-well 
dishes in McCoy’s 5A medium. After 36 h incubation, the medium was replaced 
with fresh McCoy’s 5A medium including BH1 or IgG1 isotype control antibody 
(final 5 μg/ml) ± 1000Unit/ml TNF-α. On days 1, 3 and 6 after the addition of 
antibodies, both suspended and adherent cells were collected, fixed and stained with 
propidium iodide (PI). PI-stained cells were measured and analysed by flow 
cytometry. 
Analysis of the downstream protein expression 
In order to analyze the effect of BH1 treatment on the downstream pathway, SK-BR-
3 cells were treated for 1–24 h with 10 μg/ml BH1, 1000 Unit/ml TNF-α alone or 
their combination. Cells collected at each time point (1
st
, 2
nd
, 4
th
, 8
th
, 12
th
, 24
th
 hour) 
were lysed with RIPA buffer (containing 1X PhosSTOP). Solubilized proteins were 
resolved by SDS-PAGE and analyzed by immunoblotting. PVDF membranes 
initially used for detection of phospho-Akt, phospho-Erk 1/2 and phospho-HER2 
proteins were stripped once (62.5 mM Tris-Cl pH: 6.7, 2% SDS, 100 mM β-
mercaptoethanol), washed thoroughly with TBS-T and re-blotted with anti-Akt, anti-
Erk 1/2, anti-cyclin D1 and anti-calnexin antibodies. Following incubation with 
HRP-conjugated secondary antibodies to mouse or rabbit IgGs, bound antibodies 
were detected using ECL plus western blot detection kit. 
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Statistical analysis 
Experimental data were presented as mean ± SD. Statistical analysis of experiments 
that have been performed at least in triplicate was done using Student’s t test. 
Results 
Novel monoclonal antibodies directed to extracellular domain of HER2 
We used a combined immunization protocol with repeated injections of live SK-BR-
3 cells to BALB/c mice, followed by a single injection of recombinant HER2 ECD 
protein. Hybridoma clones were screened by HER2 ECD ELISA assay. Five 
hybridoma clones (namely BH1, BH2, BH5, BH6 and BH7) were selected for further 
analyses, based on their reactivity with HER2 ECD, but not EGFR ECD (Additional 
File 1). All monoclonal antibodies were isotyped as IgG1 with κ-light chains. 
Antibodies were purified from hybridoma supernatants using Protein G affinity 
chromatography and used for further studies. 
Antibody reactivities against breast cancer cell lines 
Anti-HER2 antibodies were tested using five breast cancer cell lines with different 
ERBB2 copy numbers. Fluorescence in situ hybridization (FISH) using probes 
against ERBB2 gene and chromosome 17 centromere showed that MCF-7 had three 
chromosome 17 and two ERBB2 signals. MDA-MB-361 provided 4–8 chromosome 
17, and 8–12 ERBB2 signals. Both SK-BR-3 and BT-474 displayed 5–6 chromosome 
17 signals and highly amplified ERBB2 signals (Figure 1, left panel). Most of T47D 
cells displayed three chromosome 17 and three ERBB2 copies (data not shown). 
These findings were in perfect agreement with a previous study reporting 47, 43, 11 
and 2.5 copies of the ERBB2 gene in BT-474, SK-BR-3, MDA-MB-361 and MCF-7, 
respectively [37]. When tested by indirect immunfluorescence assay, all five anti-
HER2 antibodies displayed strong fluorescence intensities with both BT-474 and 
SK-BR-3 cells. The signals obtained with MDA-MB-361 were positive but not 
strong, but those provided by MCF-7 were negative or barely detectable (Figure 1, 
BH1, BH2, BH5, BH6, BH7 panels). 
Figure 1 Strong binding of anti-HER2 antibodies to ERBB2-amplified breast 
cancer cell lines. ERRB2 amplification was analyzed by FISH analysis. Cells were 
harvested at confluence, fixed and subjected to dual-color FISH using Texas Red-
labeled ERBB2 (red) and FITC-labeled chromosome 17 α-satellite CEP17 (green) 
DNA probes (left panel). For generation of anti-HER2 monoclonal antibodies, mice 
were immunized with SK-BR-3 cells, followed by a recombinant protein composed 
of extracellular domain of HER2 fused to human IgG1 Fc domain (HER2 ECD). 
Antibodies were purified from conditioned hybridoma cell culture media by affinity 
chromatography. For immunofluorescence assay, cells were seeded on coverslips in 
6-well plates, incubated 36 h in cell culture medium, fixed, and permeabilized. Fixed 
cells were incubated with anti-HER2 antibodies, and the primary antibody binding 
was detected using Alexa 488- conjugated anti-mouse IgG (BH1, BH2, BH5, BH6, 
BH7 panels; green). Nuclei were counterstained with DAPI (blue) and pictures were 
acquired using Zeiss Axio Imager.A1 microscope 
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The binding strengths of antibodies were compared using HER2 ECD ELISA and 
flow cytometry. ELISA test provided evidence of strong binding capacity for BH1, 
BH6 and BH7 antibodies. BH5 antibody displayed lowest binding capacity, whereas 
BH2 had intermediate activity. These observations strongly suggested that we 
produced three anti-HER2 antibodies with high affinity, one with low and one with 
intermediate affinities (Figure 2A). Flow cytometric analyses provided similar 
findings. When tested with T47D breast cancer cell line expressing low levels of 
HER2 [38], BH1 and BH6 displayed highest shifts in staining intensity as compared 
to isotype control antibody. The binding of BH5 was not detectable, whereas BH2 
displayed a weak binding (Figure 2B). However, when tested with BT-474 that has 
ERBB2 gene amplification (Figure 1, left panel), all antibodies displayed strong 
intensity shifts, BH1 producing the best shift (Figure 2C). 
Figure 2 Binding affinities of anti-HER2 antibodies. (A) HER2 ECD ELISA assay 
showing the binding strengths of five monoclonal antibodies. HER2 ECD-coated 
plates were incubated with increasing concentrations of anti-HER2 antibodies, 
followed by alkaline phosphatase-conjugated anti-mouse IgG antibodies. Y axis 
shows the absorbance (OD) reading at 405 nm following incubation with alkaline 
phosphatase substrate. T-bars: SD. (B) and (C), Flow cytometric analysis of antibody 
binding to low HER2-expressing T47D (B) and high HER2-expressing BT-474 (C) 
breast cancer cells. Fixed single-cell suspensions were incubated with anti-HER2 
antibodies, followed by Alexa-488-conjugated secondary antibodies and 
fluorescence intensities were measured using flow cytometry 
Newly generated anti-HER2 antibodies recognize conformation-
dependent epitopes 
Bioactive antibodies that are most effective against HER2-overexpressing tumors 
recognize conformational epitopes located at ECD subdomains involved in either 
receptor activation [21] or receptor dimerization [23]. Thus, the bioactivity of anti-
HER2 antibodies may be strongly dependent on how they occupy the critical regions 
on their target. We performed a series of analyses to identify epitopes recognized by 
newly raised monoclonal antibodies. In these studies, Mouse IgG1 isotype antibody 
and humanized Trastuzumab were used as negative and positive controls, 
respectively. NCL-CB11 (CB11 in short) antibody against intracellular domain of 
HER2 was also used. Initially performed western blot assays using different breast 
cancer cell line lysates provided positive signals with CB11 antibody, but not with 
others (data not shown). Based on these findings, we hypothesized that the epitope(s) 
recognized by our antibodies were unstable under denaturing conditions of SDS-
PAGE, although they remained stable after paraformaldehyde fixation used in 
indirect immunofluorescence and flow cytometry experiments (Figures 1, 2). Next, 
we tested whether our antibodies were able to immunoprecipitate HER2 from cell 
lysates made in RIPA buffer. Cell lysates made from T47D cells were subjected to 
immunoprecipitation with our antibodies and antibody-bound proteins were tested by 
western blot assay using CB11 antibody. All antibodies tested were able to 
immunoprecipitate HER2 under these conditions. The signal obtained with BH5 
antibody was weak, as expected (Additional File 2). These findings provided 
evidence that newly generated antibodies recognized conformation-dependent 
epitope(s) on endogenously expressed HER2 protein. 
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Discovery of a new epitope(s) restricted to the intact form of the 
extracellular domain of HER2 
In order to delineate the epitope(s) recognized by the antibodies, we constructed a 
series of plasmids to express truncated forms of HER2 at its ECD (Figure 3). Huh-7 
cells that express low levels of endogenous HER2 protein [39] were transiently 
transfected with plasmids to express different forms of HER2, and immunoreactivity 
of each antibody was tested by indirect immunofluorescence and western blotting 
following immunoprecipitation. In immunofluorescence assay, CB11 antibody that 
was used as a positive control for expression of full length and truncated forms of 
HER2 transgene identified strongly positive transfected cells with all plasmids tested 
(Figure 4, right panel). Another control was Trastuzumab that is directed against an 
epitope located at domain IV of the extracellular region of HER2 [21]. All truncated 
forms of HER2 protein containing domain IV provided strongly positive signals with 
Trastuzumab (Figure 4, Tzm panel). Surprisingly, all five of our antibodies 
recognized only full-length HER2. They did not react with recombinant HER2 
protein forms lacking any one of the ECD subdomains (Figure 4, panels BH1, BH2, 
BH5, BH6, BH7). Immunoprecipitation-western blotting assays following transient 
expression of full length and four truncated forms of HER2 confirmed 
immunofluorescence findings (Additional File 3). We deduced that newly generated 
antibodies are directed to an epitope, or closely related epitopes present only on 
structurally intact ECD of HER2. In other words, the reactivity of antibodies was lost 
when any of the four subdomains of the HER2 ECD was deleted. Thus, all five 
antibodies described in the report required the structural integrity of ECD for 
recognition of HER2 receptor (Figure 3). 
Figure 3 Schematic representation of antibody epitope mapping studies. 
Mammalian expression plasmids expressing full-length HER2 (p219D) or partially 
deleted HER2 were transfected into Huh7 cells. Anti-HER2 antibody reactivity was 
tested by indirect immunofluorescence (Figure 4) and immunoprecipitation-western 
blotting (Additional File 3) techniques. The boxes named as I, II, III, IV represent 
four subdomains of ECD. Grey box: transmembrane domain, TK: tyrosine kinase 
domain, CT: carboxyl-terminal domain. Tzm: Trastuzumab.+: antibody reactivity, -: 
no antibody reactivity. Stars (*) near plasmid names indicate that 
immunofluorescence data were confirmed with immunoprecipitation-western blot 
assay 
Figure 4 Epitope mapping of anti-HER2 antibodies using indirect 
immunofluorescence assay. Huh7 cells were transfected in 6-well plates using a set 
of mammalian expression plasmids encoding full-length or N-terminally truncated 
HER2 protein. Transfected cells were cultivated for 48 h, and subjected to indirect 
immunofluorescence assay. Transfected cells that were recognized by specific 
antibodies displayed strong green fluorescence. The letters from (a) to (k) indicate 
the plasmids in the following order: pDEST26 (empty vector), p219D, pCC2001, 
pCC2005, pCC2004, pCC2003, pCC2002, pCC2008, pCC2007, pCC2006, pCC2012 
(see Figure 3 for description of HER2-expression plasmids). (−) No primary 
antibody, Tzm: Trastuzumab, CB11: a monoclonal antibody recognizing an epitope 
at intracellular domain of HER2 that was used as a positive control for expression of 
transfected plasmids 
212 
 
Effect of anti-HER2 antibodies on cell growth 
The bioactivity of antibodies was first tested against SK-BR-3 cells. Affinity purified 
anti-HER2 antibodies were added at increasing concentrations into the culture media 
and relative cell growth was tested following 6 days of cell culture. Only BH6 and 
BH1 antibodies displayed modest but significant inhibitory effect on target cells, by 
lowering relative cell growth to 65% and 73% respectively, as compared to isotype 
control antibody (Figure 5A; p < 0. 006 at 10 μg/ml antibody concentration). In 
contrast, BH2, BH5 and BH7 antibodies did not affect the growth of SK-BR-3 cells. 
Figure 5 Anti-HER2 antibodies exhibit enhanced anti-growth effect in the 
presence of tumor necrosis factor-α in SK-BR-3 cells. (A) SK-BR-3 cells were 
plated onto 96-well plates and incubated at 37°C with 5% CO2. After 2 h of 
incubation, antibodies (0–10 μg/ml) were added, and cells were incubated for 6 days. 
(B) Antibodies (0–10 μg/ml) were added as described in (A), and cells were 
incubated for 4 h prior to TNF-α (1000 U/ml) addition to the culture medium. Cells 
amount was determined by Sulforhodamine B assay after 6 days of treatment. T 
Bars, SD; * p < 0.006, ** p < 0.0005, (A, B) 
Effects of anti-HER2 antibodies in combination with tumor necrosis 
factor-α 
It has been previously reported that amplified expression of HER2 in breast cancer 
cells induces resistance to TNF-α cytotoxicity [40,41] that can be sensitized by 
Trastuzumab [42]. Therefore, we asked whether our anti-HER2 antibodies were able 
to sensitize SK-BR-3 cells to TNF-α. We performed antibody treatment experiments 
in the presence of 1000 U/ml of TNF-α (Figure 5B). In the absence of antibody, 
TNF-α alone induced nearly 50% growth inhibition. This effect was not modified 
significantly in the presence of increasing concentrations of IgG1 isotype control 
antibody (up to 10 μg/ml tested). In sharp contrast, all five anti-HER2 antibodies 
strongly enhanced TNF-α-induced growth inhibition (p < 0.0005 at 10 μg/ml 
antibody concentration). As little as 0.25 μg/ml anti-HER2 antibody was sufficient to 
significantly enhance TNF-α-mediated growth inhibition, as compared to IgG1 
isotype control antibody at the same concentration (p < 0.005). Only one antibody, 
namely BH7, displayed a slightly weaker enhancer activity, reaching significance at 
1.25 μg/ml concentration (p <0.02). Enhancer effects of anti-HER2 antibodies were 
nearly saturated at 2.5 μg/ml concentration, reaching to 80-90% growth inhibition 
depending on antibody (Figure 5B). 
Cell-dependent interactions between anti-HER2 antibodies and tumor 
necrosis factor-α creating both synergistic and antagonistic growth 
effects 
Based on observations with SK-BR-3 cells, we analyzed interactions between anti-
HER2 antibodies and TNF-α, using five different breast cancer cell lines. We 
compared growth responses to (i) 5 μg/ml of each individual antibody, (ii) 1000 U/ml 
of TNF-α, and (iii) 5 μg/ml antibody and 1000 U/ml of TNF-α in combination. An 
interaction score for each combination was calculated as described in the Methods, 
where a score of 1 means no interaction, or independence; a score smaller than 1 
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means synergy, and a score larger than 1 means antagonism [32]. In Figure 6, we 
analyzed TNF-α and anti-HER2 antibody interactions as compared to IgG1 isotype 
control antibody. IgG1 control antibody interactions with TNF-α provided scores 
between 0.81-0.88. Therefore, we considered values between 0.8-1.2 as an indication 
of non-interaction. When tested with SK-BR-3 cell line, interaction scores obtained 
for TNF-α and new anti-HER2 antibody combinations ranged between 0.26 and 0.48 
(Figure 6, top). Synergy scores obtained with BH1, BH2 and BH5 were particularly 
strong (scores: 0.35, 0.30 and 0.26, respectively). In contrast, there was no 
interaction between Trastuzumab and TNF-α (score = 0.95). Thus, all five new anti-
HER2 antibodies acted synergistically with TNF-α to inhibit the growth of SK-BR-3 
cells. 
Figure 6 Synergy and antagonism between anti-HER2 antibodies and tumor 
necrosis factor-α. Anti-Her2 antibodies and TNF-α acted synergistically in SK-BR-
3 cells (top), but antagonistically in BT-474 cells (bottom). Growth effects observed 
under antibody (white columns), TNF-α (striped columns), and antibody + 1000 
TNF-α (black columns) were obtained as follows. Cells were plated onto 96-well 
plates and incubated at 37°C with 5% CO2. After 2 h of pre-incubation, antibodies (5 
μg/ml) were added, and cells were incubated for 6 days to study the effects of 
antibodies alone (white columns). The effects TNF-α (1000 U/ml) alone (dark 
columns) were studied by adding this cytokine into cell culture medium after 4 h of 
pre-incubation. For combined treatments, antibodies (5 μg/ml) and TNF-α (1000 
U/ml) were added after 2 h and 4 h of pre-incubations, respectively. Cells amount 
was determined by Sulforhodamine B assay after 6 days of treatment. Growth level 
under a drug condition was defined as the growth under that condition normalized by 
growth under no drug condition. Expected growth level under no interaction (gray 
columns) was calculated by multiplying the growth levels under each individual 
drug. The observed growth level for each combination was divided by the expected 
growth level to find an interaction score according to Bliss Independence Model for 
drug interactions (displayed under each antibody label). The combination of TNF-α 
with isotype control antibody (IgG1) or Trastuzumab (Tzm) provided scores near 1, 
meaning no interaction or independence in both cell lines. New anti-HER2 
antibodies provided scores less than 0.57 in SK-BR-3 cells, meaning synergy. In 
contrast their interaction scores were more than 1.40 in BT-474 cells, meaning 
antagonism 
Further studies indicated that the interaction between anti-HER2 antibodies and 
TNF-α was cell-dependent. Indeed, we observed a completely opposite response with 
another breast cancer cell line, namely BT-474 (Figure 6, bottom). This cell line 
responded to a few anti-HER2 antibodies modestly albeit significantly (BH1, 
p < 0.05; Tzm, p < 0.003). The response to TNF-α alone was about 50% growth 
inhibition, as observed with SK-BR-3 cells. Novel anti-HER2 antibodies abolished 
TNF-α-induced growth inhibition either completely (BH1, BH2, BH5, BH7) or 
partially (BH6) in BT-474 cells. Interactions scores of novel anti-HER2 antibodies 
ranged between 1.40 and 3.08, all indicative of an antagonistic interaction with TNF-
α. Again, Trastuzumab had no major interaction with TNF-α (score = 1.21). Data on 
interaction analyses performed with MDA-MB-361, MCF-7 and T47D were shown 
in Additional File 4. When tested alone with MDA-MB-361 cells, some antibodies 
(BH1, BH2, BH7) displayed significant growth inhibition (>50% inhibition, 
p < 0.0003). Traztuzumab had no detectable anti-growth effect, but BH5 and BH6 
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displayed only modest activity (27% and 35% growth inhibition, respectively; 
p < 0.02). TNF-α was highly toxic to this cell line causing >95% growth inhibition. 
Antibody co-treatments rescued TNF-α induced growth inhibition only slightly. 
Thus, drug interaction analysis was not conclusive. The growth of MCF-7 cells did 
not appear to be affected by antibody treatment. In contrast, these cells were the most 
sensitive ones to TNF-α with nearly 100% growth inhibition. Antibody co-treatments 
did not change their response to TNF-α. T47D cells were resistant to both anti-HER2 
antibody and TNF-α treatments, either alone or in combination. 
Detailed analysis of interaction between BH1 antibody and tumor 
necrosis factor-α 
Drug interaction analyses described above were performed using fixed amounts of 
antibodies and TNF-α. We obtained clear-cut results with only SK-BR-3 and BT-474 
cells. Therefore, we decided to test the effects of combined treatment of anti-HER2 
antibody BH1 and TNF-α on four breast cancer cell lines using a checkerboard assay. 
BH1 was selected as a representative of newly generated anti-HER2 antibodies. Each 
cell line was grown on a 7×8 grid of BH1 antibody and TNF-α combinations. The 
concentration of TNF-α was increased on the x-axis (0, 8, 16, 32, 62.5, 125, 250 and 
500 U/ml) and the concentration of BH1 antibody was increased on the y axis (0, 
0.16, 0.312, 0.625, 1.25, 2.5 and 5 μg/ml). Such an experimental setting allowed us 
to measure the growth of each cell type in 42 concentration combinations of BH1 
antibody and TNF- α, in addition to the growth of cells under each ‘drug’ alone. This 
experiment was done in triplicate for each cell type. The average growth measures 
are shown in Figure 7. We analyzed the growth measures using the same definition 
of drug synergy based on Bliss Independence Model as described above. We found 
concentration combinations where BH1 and TNF-α are significantly synergistic or 
antagonistic, which are indicated as green or blue dots on Figure 7, respectively. For 
each of the drug interaction experiments, we next computed a single interaction score 
as described previously [33]. These scores, which are interpreted as described above, 
are shown in Figure 7. According to this, BH1 and TNF-α exhibited synergy in SK-
BR-3 cells, while they were antagonistic in BT-474 and MDA-MB-361 cell types, 
when all concentration combinations are considered. Interestingly, BH1 antibody, 
even at a very low dose (0.16 μg/ml), strongly suppressed the growth inhibition 
triggered by TNF-α in BT-474 cells. These observations confirm strong synergistic 
and antagonistic interactions of TNF-α and anti-HER2 antibodies in SK-BR-3 and 
BT-474, respectively (Figure 6). The interaction score for MCF-7 was very close to 
1, suggesting independence. 
Figure 7 Anti-HER2 antibody and tumor necrosis factor-α interaction is cell 
type-specific. The growth of breast cancer cell lines under various combinations of 
BH1 antibody (0, 0.161, 0.312, 0.625, 1.25, 2.5, 5.0 μg/ml) and TNF-α (0, 8, 16, 32, 
62.5, 125, 250, 500 U/ml) treatments was experimentally tested in triplicate and the 
average relative growth levels were calculated. Heatmap represents the cell growth 
(as measured by OD) under different conditions. Synergistic and antagonistic 
interactions are indicated by green and blue dots, respectively. Numbers associated 
with cell line names indicate interaction scores. According to this checkerboard 
assay, BH1 and TNF-α show synergy in SK-BR-3 cells, but antagonism in BT-474 
and MDA-MB-361 cells. There is no interaction in MCF-7 cells 
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Mechanisms of growth inhibition by anti-HER2 antibodies and tumor 
necrosis factor-α 
In cancer cells, overexpressed HER2 is believed to be constitutively active as 
homodimers and/or as heterodimers with ligand-dependent HER3 [6]. Downstream 
signaling from HER2 involves PI3K-dependent activation of Akt and Ras-dependent 
activation of ERK1/ERK2 proteins by phosphorylation, mediating cell survival and 
proliferation activities of HER2 [6]. Therapeutically relevant Trastuzumab and 
Pertuzumab antibodies inhibit both Akt and ERK1/ERK2 phosphorylation, leading to 
growth inhibition [24,43-45]. TNF-α signaling generates both cell survival and 
apoptosis signals, depending on the activation of NFκB transcription factor [46]. We 
further investigated the mechanisms of growth inhibition in responsive SK-BR-3 
cells. As shown in Figure 8 left panel, untreated SK-BR-3 cells displayed relatively 
stable expression of phospho-HER2, phospho-Akt, total Akt, phospho-Erk1/2 and 
total Erk1/2. Cyclin D1 levels were undetectable under this experimental condition. 
Cells treated with 10 μg/ml BH1 antibody inhibited Akt phosphorylation that was 
clearly detectable between 8 h and 24 h of treatment. There was also a partial 
inhibition of Erk1/2 phosphorylation between 4 h and 24 h of treatment. In parallel 
with these changes, we also observed progressive accumulation of cyclin D1 levels 
detected as early as 4 h of treatment. In contrast, HER2 phosphorylation was not 
affected by antibody treatment (Figure 8 middle panel). Cells co-treated with 10 
μg/ml BH1 and 1000 U/ml TNF-α displayed essentially the same type of alterations 
(Figure 8 right panel). Thus, TNF-α appeared not to modify the effects of the anti-
HER2 antibody on phospho-Akt, phospho-ERK1/2 and Cyclin D1 in SK-BR-3 cell 
line. Indeed, treatment of cells with 1000 U/ml TNF-α alone did not affect any of the 
parameters studied, except a delayed inhibition of Akt phosphorylation at 24 h 
(Additional File 5). 
Figure 8 In vitro molecular responses of SK-BR-3 cell to anti-HER2 antibody 
BH1 and tumor necrosis factor-α. SK-BR-3 cells were treated up to 24 h with BH1 
antibody (10 μg/ml), TNF-α (1000 U/ml) or the combination of both agents. Cell 
lysates were prepared from cells harvested at indicated times (hr, hours) and the 
expressions of phospho-HER2 (pHER2), phospho-Akt (pAkt), total Akt (Akt), 
phospho-ERK1/phospho-Erk2 (pErk1/2), total Erk1/Erk2 (Erk 1/2) and Cyclin D1 
were analyzed by western blotting. Calnexin was used as a loading control. 
Untreated cells were incubated in a parallel experiment in the absence of any 
treatment 
Cyclin D1 accumulates in G1 and G2 phases of cycling cells with a loss of 
expression in S phase cells [47]. Accordingly, Cyclin D1 accumulation could 
indicate progressive accumulation of cells at G1 and G2/M phases under anti-HER2 
antibody treatment. We tested this hypothesis by exposing BH1 and/or TNF-α-
treated cells to BrdU labeling and cell cycle analysis experiments during 6 days of 
treatment. Tests were performed at days 1, 3 and 6 (Figure 9A). SK-BR-3 cells have 
doubling times varying between 15 h and 36 h [48,49]. In order to detect the ratio of 
cells at G1/G0 phase, we used a modified DNA labeling protocol by exposing cells 
to BrdU for 24 h prior to each experimental time. As compared to IgG1 isotype 
control antibody, BH1 induced a significant decrease in the number of BrdU
+
 cells at 
days 3 and 6 (p ≤ 0.05). Treatment of cells with IgG1 and TNF-α resulted in a more 
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pronounced decrease of BrdU
+
 cells that dropped progressively to 35% at day 6. 
When compared to IgG1 + TNF-α-treated cells, BH1 + TNF-α-treated cells 
responded immediately by a radical decrease of BrdU incorporation rates to 25% and 
26% at days 1 and 3, respectively (p ≤ 0.05). However, this inhibition was not stable 
and reversed to 37% at day 6 (Figure 9A). These findings indicated that both BH1 
and TNF-α significantly increased the number of cells at G1/G0 phase, although this 
effect was delayed in BH1-only treatment. Sharp and immediate decrease in BrdU 
(+) cells with BH1 + TNF-α co-treatment confirmed the synergy between BH1 and 
TNF-α in these cells. Cell cycle analyses confirmed these findings (Figure 9B-D). As 
compared to IgG1 isotype control antibody-treated cells, BH1-treated cells first 
showed an increase in G2 cells at day 1, followed by a progressive increase of G1 
cells at days 3 and 6. This was accompanied with a decrease in S phase cells. TNF-α 
treatment resulted in an immediate and stable response with an increase in G1 cells, 
concomitant with a decrease of S phase cells at all time points tested. BH1 + TNF-α 
treatment exaggerated this response, leading to a stronger accumulation of G1 phase 
cells, associated with a depletion of G2 phase cells. We concluded that both BH1 
antibody and TNF-α were able to induce sustained accumulation of SK-BR-3 cells at 
G1/G0 phase, and their combination amplified this response particularly in early 
times of co-treatment. 
Figure 9 Effects of anti-HER2 antibody BH1 and tumor necrosis factor-α on 
DNA synthesis and cell cycle in SK-BR-3 cells. (A) Effects on DNA synthesis were 
tested by 24-h BrdU incorporation assay. Cells were plated on coverslips in 12-well 
plates, treated as described in Figure 5, and were exposed to BrdU during 24 h prior 
to indicated days. Nuclear BrdU was detected by indirect immunofluorescence assay. 
Nuclei were counterstained with DAPI, examined using Zeiss Axio Imager.A1 
microscope. Representative photographs (3–5 frames per coverslip) were acquired. 
Percent BrdU incorporation was calculated after manual counting of BrdU
+
 and 
BrdU
-
 nuclei. * Denotes p-values ≤ 0.05 (BH1 vs. IgG1, BH1 + TNF-α vs.IgG1 + 
TNF-α). T-bars: SD. (B-D). Effects on cell cycle were analyzed by flow cytometry. 
SK-BR-3 cells were treated with 20 μg/ml BH1 or IgG isotype control antibody in 
the presence or absence of 1000 U/ml TNF-α. Cells were fixed on day 1 (B), day 3 
(C) and day 6 (D), stained with propidium iodide and the cell cycle distribution was 
analysed with flow cytometry. Fraction of cells present in G2/M-phase (G2/M), S-
phase (S) and G1-phase (G1) are shown in purple, green and orange respectively. 
Fraction of apoptotic cells observed as a SubG1 peak is shown in black 
Discussion 
This report describes five novel anti-HER2 monoclonal antibodies that have been 
produced by immunizing mice with HER2-overexpressing whole cells, followed by a 
boost with recombinant HER2 ECD homodimer protein. Immunoprecipitation and 
western immunoblotting studies indicated that all five antibodies were directed 
against conformation-dependent epitope(s) present on the endogenous HER2 protein. 
Epitope mapping with recombinant HER2 protein forms that have been truncated at 
ECD domain indicated that all five antibodies react only with the native form of 
cellular HER2, being unable to recognize truncated proteins lacking any of the four 
subdomains. Although we do not yet know whether our antibodies recognize 
identical, overlapping or independent epitopes on the intact ECD domain, it is 
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evident that their epitope(s) is different from those recognized by Trastuzumab and 
Pertuzumab. Trastuzumab, a therapeutic antibody already approved for clinical use, 
recognizes an epitope restricted to subdomain IV, involved in receptor activation 
[21]. Pertuzumab, a therapeutic antibody tested in different clinical trials, recognizes 
a distinct epitope located on subdomain II, involved in receptor dimerization [23]. 
Antibodies directed to ECD epitope(s) different from other anti-HER2 therapeutic 
antibodies may serve as new analytical tools to study the structural organization of 
HER2 at the cell surface that may be present as monomers, homodimers and 
heterodimers depending on cell type and extracellular environment such as the 
availability of ligands that activate heterodimer partners of HER2. Dynamic changes 
at the receptor ECD in relation with transcriptional, translational and post-
translational modifications can be monitored with these antibodies, both 
biochemically and biologically. 
In vitro effects of novel anti-HER2 antibodies were tested against five different 
breast cancer cell lines displaying different degrees of ERBB2 amplification and 
HER2 expression. Individually tested novel anti-HER2 antibodies were weakly 
effective as growth inhibitors (Figure 6). This was not surprising. Indeed, 
Trastuzumab (4D5) has a modest growth inhibitory effect (56%), and Pertuzumab 
(2C4), the best therapeutic alterative to Trastuzumab, induces only 20% growth 
inhibition [42]. Based on the synergy between Trastuzumab and Pertuzumab directed 
to different epitopes of HER2 [24], we performed studies to test combinatory anti-
growth effects of our anti-HER2 antibodies with Trastuzumab on SK-BR-3 cells. 
Preliminary data suggested a synergy between them, raising the possibility that our 
antibodies may be combined with Trastuzumab or Pertuzumab to enhance anti-
cancer activity. This will be the focus of further work. 
The most striking feature of novel anti-HER2 antibodies was their differential 
interaction with TNF- α depending on cell type. They synergized with TNF-α on SK-
BR-3 cells by raising growth inhibition from 50% to nearly 90%. In sharp contrast, 
the same antibodies displayed strong antagonism with TNF-α on BT-474 cells and 
MDA-MB-361 cells by abolishing TNF-α-induced growth inhibition either 
completely (BT-474 cells) or partially (MDA-MB-361 cells). Trastuzumab did not 
have any synergistic or antagonistic effects on TNF-α-mediated growth inhibition in 
these cell lines (Figure 6). The sensitization of SK-BR-3 cells to TNF-α cytotoxicity 
by mouse monoclonal antibody 4D5 (from which Trastuzumab has been humanized) 
has been reported [41], but there is no previous data on synergy or antagonism 
between anti-HER2 antibodies and TNF-α, to our best knowledge. 
TNF-α is one of the most potent anti-tumor factors when used at high concentrations, 
but its systematic toxicity hampers its clinical applications [50]. The sensitization of 
SK-BR-3 cells to TNF-α with anti-HER2 antibodies provides experimental evidence 
for combination of low TNF-α doses with anti-HER2 antibody treatment to achieve 
effective anti-growth effects. Based on checkerboard analyses reported in Figure 7, a 
synergistic anti-growth response could be obtained from SK-BR-3 cells with as low 
as 32 U/ml TNF-α under in vitro conditions. But, one caveat is that the same 
antibody-TNF-α combination could produce completely opposite responses in other 
cells, as reported here for BT-474 and MDA-MB-361 cells. For example, as little as 
0.1 mg/ml BH1 antibody was able to abolish TNF-α cytotoxicity in BT-474 cells. 
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The mechanisms of differential responses of breast cancer cell lines to combined 
treatment with anti-HER2 antibody and TNF-α merit further investigation. Here, we 
investigated the mechanisms of growth response of SK-BR-3 cells to combined 
treatment. The analysis of several downstream targets of HER2 signaling indicated 
that BH1 antibody did not inhibit HER2 phosphorylation, yet it was able to inhibit 
the phosphorylation of Akt and ERK1/2 kinases. These changes resulted in a 
progressive increase of cyclin D1 protein levels. DNA synthesis was inhibited and 
cells accumulated progressively at G1 phase of the cell cycle. The addition of TNF-α 
to BH1 treatment dramatically enhanced these responses leading to an immediate and 
stable growth arrest. 
Conclusions 
Newly generated anti-HER2 monoclonal antibodies allowed the identification of a 
novel epitope on HER2 receptor that is restricted to the intact form of its ECD. These 
antibodies displayed cell type-dependent interactions with TNF-α, resulting in 
synergistic, antagonistic or independent anti-growth effects. The synergistic activity 
was associated with inhibition of Akt and ERK1/2 phosphorylation leading to 
immediate and stable cell cycle arrest. 
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Additional files 
Additional_file_1 as PDF 
Additional File 1 Anti-HER2 antibodies did not react with EGFR. Mice were 
immunized with SK-BR-3 cells, followed by a recombinant protein composed of 
extracellular domain of HER2 fused to human IgG1 Fc domain (HER2 ECD). 
ELISA plates that have been coated with either HER2 ECD or EGFR ECD were 
incubated with antibody-containing hybridoma supernatants, followed by alkaline 
phosphatase-conjugated anti-mouse IgG antibodies. The Y axis shows the 
absorbance (OD) reading at 405 nm following incubation with alkaline phosphatase 
substrate (assays in duplicate). 
Additional_file_2 as PDF 
Additional File 2 Antibody binding to endogenously expressed HER2 protein as 
tested by immunoprecipitation-western blot assay. T47D-derived lysates were 
subjected to immunoprecipitation with different anti-HER2 antibodies. Antigen-
antibody complexes were captured onto Protein G-conjugated beads, eluted and 
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subjected to western blot assay using CB11 antibody. Blots were overexposed to 
visualize the weakly positive HER2 immunoprecipitated by BH5 antibody. Tzm: 
Trastuzumab used as a positive control antibody. (−): No primary antibody. 
Additional_file_3 as PDF 
Additional File 3 Epitope mapping of anti-HER2 antibodies using combined 
immunoprecipitation-western blot assay. Huh7 cells were transfected in 6-well 
plates using a set of mammalian expression plasmids encoding full-length or N-
terminally truncated HER2 protein. Transfected cells were cultivated for 48 h; cell 
lysates were subjected to immunoprecipitation with different anti-HER2 antibodies. 
Antigen-antibody complexes were captured onto Protein G-conjugated beads, eluted 
and subjected to western blot assay using CB11 antibody. . Arrows: immunoreactive 
bands specific for full-length and truncated HER2 protein forms. IP: 
immunoprecipitation; *: non-specific bands originating from antibodies used for 
immunoprecipitation. 
Additional_file_4 as PDF 
Additional File 4 Interaction between anti-HER2 antibodies and tumor necrosis 
factor-α. MDA-MB-361 cells were partially sensitive to anti-HER2 antibodies, but 
highly sensitive to TNF-α (top). MCF-7 cells were resistant to anti-HER2 antibodies, 
but highly sensitive to TNF-α (middle). T47D cells were resistant to both anti-HER2 
antibodies and TNF-α (bottom). Growth measurements observed under 5μg/ml 
antibody (white columns), 1000 U/ml TNF-α (striped columns), and 5 μg/ml 
antibody + 1000 U/ml TNF-α (black columns) were obtained experimentally, as 
described in Figure 6. Growth level under a drug condition was defined as the growth 
under that condition normalized by growth under no drug condition. Expected 
growth level under no interaction (gray columns) was calculated by multiplying the 
growth levels under each individual drug. The observed growth level for each 
combination was divided by the expected growth level to find an interaction score 
according to Bliss Independence Model for drug interactions Interaction scores were 
not calculated for these cell lines. 
Additional_file_5 as PDF 
Additional File 5 In vitro molecular responses of SK-BR-3 cells to tumor 
necrosis factor-α. SK-BR-3 cells were treated up to 24 h with TNF-α (1000 U/ml). 
Cell lysates were prepared from cells harvested at indicated times (hr, hours) and the 
expressions of phospho-HER2 (pHER2), phospho-Akt (pAkt), total Akt (Akt), 
phospho-ERK1/phospho-Erk2 (pErk1/2), total Erk1/Erk2 (Erk 1/2) and Cyclin D1 
were analyzed by western blotting. Calnexin was used as a loading control. 
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